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abstract
Protein-protein interactions (PPI) mediate numerous biological processes, 
but inhibiting these interactions with small molecules has been difficult to achieve 
in drug discovery. A small number of successes have shown that some PPIs are 
amenable to inhibition. Computational algorithms designed to measure the drug-
gability of PPIs have been developed based on these successes. These algorithms 
have identified the interaction between the NF-κB essential modulator (NEMO) 
and IκB kinase β (IKKβ) as a candidate for inhibition. Furthermore, in vivo pep-
tide-based inhibition of the NEMO-IKKβ interface has shown benefits in attenuat-
ing the NF-κB response in cellular and animal models. In addition to its intrinsic 
vii
interest as a drug target, developing inhibitors against the NEMO/IKKβ interac-
tion may help in the development of improved methods for PPI inhibition. 
In this thesis, the production of full-length, recombinant forms of soluble 
NEMO is described. This protein was used in a variety of biochemical assays to 
advance our understanding of NEMO structure and function. Furthermore, a fluo-
rescence anisotropy (FA) assay was developed to screen for compounds inhibiting 
the NEMO/IKKβ PPI. Hits from the FA assay were tested by several methods to 
confirm true inhibition. Additionally, the FA assay was used to accurately measure 
the affinity of NEMO for IKKβ, and to assess the degree of cooperativity in IKKβ 
binding. The oligomeric state of NEMO has been characterized through the devel-
opment of a panel of NEMO cysteine to alanine mutants, using polyacrylamide gel 
electrophoresis analysis, analytical ultracentrifugation, and fluorescence anisotro-
py. These data represent the first comprehensive characterization of full-length 
human NEMO, and may provide a path toward development of drug-like inhibi-
tors of the NEMO/IKKβ interaction. 
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1Chapter 1: inhibiting Protein-Protein interactions
1.1 General Introduction to the Importance of Protein-Protein Interactions in 
Biology
Protein-protein interactions (PPI) are important for mediating a multitude 
of biological functions.1 Current models estimate that there are up to 650,000 PPIs 
in human biology2 – underscoring their importance throughout nearly all cellular 
processes.3 Many of these PPIs contribute to disease states. Therapeutics targeting 
PPIs have not been plentiful due to initial struggles in developing drug-like inhib-
itors, and therefore, PPIs were classified by many researchers as “undruggable”. 
However, as the field of PPI inhibition progresses, there have been significant ad-
vances in understanding which types of PPIs can be inhibited,3–21 what kinds of 
molecules can disrupt PPIs,6–8,17,22–31 and specific cases where PPI inhibition has 
been achieved with drug-like inhibitors.4,5,12,13,17,23,31–37
1.2 Targeting Protein-Protein Interactions with Orally Available Small Mole-
cules
The inhibition of PPIs was once seen as an immensely challenging and po-
tentially unsolvable prospect in drug-discovery.5,6 This challenge was based on the 
bias of drug-discovery methods and chemical libraries toward those that favored 
classically druggable protein types. Furthermore, there are significant differenc-
es in the way that a protein interacts with another protein compared to how it 
2interacts with a natural small ligand. Despite initial challenges, there have been 
numerous successful attempts to develop small-molecule inhibitors of PPIs, and 
some PPI inhibitors have entered into clinical trials.17,20,21,38 Thus, in recent years, 
more PPIs have been successfully targeted for therapeutic intervention.
Traditionally, small-molecule inhibitors were discovered through 
high-throughput screening (HTS) of large chemical libraries. These libraries were 
refined based on the analysis of the chemical properties of successful drugs,7 pri-
marily from the prominent and influential drug-likeness classification called Lip-
inski’s Rule of Five (Table 1.1).39 The Rule of Five was developed to map out drug-
like chemical space based on the molecular properties of drugs that lead to good 
cell permeability and aqueous solubility (herein referred to as oral availability).39 
However, successes in small-molecule drug discovery have been dominated by 
drugs that inhibit proteins that naturally bind small molecules - enzymes, G-pro-
tein coupled receptors, and nuclear hormone receptors.7,40 Thus, the Rule of Five 
and chemical screening libraries that were based on the Rule of Five were biased 
toward molecules that innately bind to these protein classes.7 
Table 1.1: Common rules for drug-likeness. Lipinski derived features that were common to orally 
bioavailable drug candidates to predict drug-likeness in small molecules.39 A separate rule set, de-
rived by Veber, suggests that few rotatable bonds and a low polar surface area are better indicators 
of druglikeness.70
Veber’s Rules
Rotatable Bonds ≤10
Polar Surface Area ≤140 Å2
Lipinski’s Rule of Five
Hydrogen bond donors ≤5
Hydrogen bond acceptors ≤10
Molecular Mass ≤500 Da
cLogP ≤5
3To circumvent the limitations of classical HTS, many research groups use al-
ternate techniques in order to discover inhibitors of PPIs.6–8,17,22–31. Fragment-based 
screening involves a high-throughput screen of small chemicals in order to identi-
fy weak hits that can then be modified and expanded into stronger, more drug-like 
inhibitors.41–43 The idea behind fragment-based screening is that testing very small 
molecules allows for a more comprehensive scan of chemical space than HTS.42 
Another technique involves rational design of inhibitors based on the three-di-
mensional structure of the PPI.6 Finally, using the same idea as structure-based 
Figure 1.1: Binding hot-spots of four PPIs.46 In each PPI, the interaction residues were mutated to 
alanine and the change in binding energy (ΔΔG) was measured. The ΔΔG magnitude was used 
to color code the residues in order to visualize the hot spots. In all cases, only a small number of 
residues contribute to the interaction, leading to the hypothesis that inhibitors targeting this area 
should be able to fully disrupt the interaction. 
4design, in silico HTS can be performed virtually in order to reduce the amount of 
synthetic and manual labor prior to the identification of inhibitors.16 Furthermore, 
in silico techniques can be tailored to identify sites in the PPI that can accommodate 
inhibitors, beyond simply the identification of compounds.16,44 These techniques, 
along with traditional HTS, have identified a wealth of small-molecule PPI inhib-
itors.31 Therefore there are now several drug-like PPI inhibitors that show some 
clinical efficacy. 
The challenges discussed thus far are primarily methodological issues. 
However, PPI inhibition with small molecules is inherently challenging aim apart 
from the chemotype biases. Compared with a protein binding to a small-molecule 
ligand, PPIs interact with a much larger interface that buries on average 1600 ± 400 
Å2 of solvent accessible surface area.45 However, there are concentrated regions of 
binding energy within the large interaction area, referred to as hot-spots. Alanine 
scanning mutagenesis has been performed on very many PPIs to map out these 
A) B)
Figure 1.2: Binding of a small molecule to two surfaces with varying concavity. (A) A theoretical 
small-molecule does not make complete contact with all of the points of binding energy in a flat 
interface (arrows). (B) In contrast, the same small molecule can interact with all of the interaction 
sites in a deep cleft. 
5hot-spot areas (Figure 1.1). This method involves mutating a non-alanine residue 
to alanine and measuring the change in binding energy from the wild-type inter-
action.46 The success of a small-molecule inhibitor is directly related to its ability to 
disrupt the interactions at the hot-spot to effectively block the interaction between 
the binding partners. This can be achieved both orthosterically and allosterically, 
and there are numerous cases that elaborate on this effect.  
In addition to possessing a larger interface than traditional druggable pro-
teins, PPI interfaces are also often flatter than the deep cleft or pocket that compris-
es the binding site of a typical enzyme.1 Flat interfaces are difficult to target with 
an inhibitor because a small molecule is only able to make a small number of in-
teractions (Figure 1.2a). In contrast, when a small-molecule binds in a pronounced 
cavity or cleft, the surface area of contact with the protein is much greater, allowing 
more interactions to be made between the protein and small-molecule and thereby 
Figure 1.3: Structures of IL-2 with a small-molecule inhibitor.32 (A) The co-crystal structure of IL-2 
and a small-molecule inhibitor shows that the protein makes many contacts with the small-mole-
cule. (B) The same small-molecule superimposed over an apo crystal structure of IL-2 shows that 
the surface of the protein adopts a different conformation when the small-molecule is not present. 
6generating more binding affinity with the ligand (Figure 1.2b). Some PPI interfaces 
can experience a degree of adaptivity – the interface has a high degree of plasticity 
allowing for local changes to the interface to accommodate various binding inter-
actions (Figure 1.3).47,48 A classic example of PPI interface adaptivity is provided 
by the region of interleukin 2 (IL-2) that interacts with the IL-2 receptor α chain 
(IL-2Rα).32 A small-molecule inhibitor of this interaction was found to function 
by inducing a cleft in IL-2 (Figure 1.3a).32 The conformation of the protein at this 
interface was significantly different in the absence of the small molecule, so much 
so that the small molecule would not fit (Figure 1.3b).32 Adaptivity is a feature seen 
in many proteins that bind to multiple binding partners and may be an intrinsic 
property of some PPIs that can be exploited for inhibitor development.48–50
As more PPI inhibitors have been identified, the druggability of various 
classes of PPIs has been assessed to better understand the properties of PPIs that 
lead to successful inhibition by small molecules. One recent analysis of current 
PPIs that have been inhibited classified the structural properties and affinities of 
the interaction into four categories.19 These PPI categories are grouped by whether 
they have a wide or narrow interface and whether the interaction is weak or strong. 
Generally, researchers have found that narrow interfaces with strong affinities, 
like the IL-2/IL-2Rα interaction, are the most represented in these databases.19 An-
other noteworthy success in PPI inhibiton is the development of small molecules 
that can inhibit interactions of members in the Bcl family of apoptosis-modulating 
7proteins.36 The Bcl family includes many structurally similar proteins that are criti-
cal in controlling apoptosis. They function by forming heterodimers with other Bcl 
family members through a recognition domain present on many Bcl-family pro-
teins called BH3.51 Upregulation of certain Bcl family proteins has been implicated 
in various kinds of cancer, and consequently these PPI targets have been studied 
extensively with a view to the development of therapeutic inhibitors.52 One of the 
most heavily studied PPIs in this family is the interaction of Bcl-xL with the rec-
ognition domain of its binding partner BAK (Figure 1.4).53 Several groups have re-
ported small molecules that target this interface on Bcl-xL,35,36,54–61 and at least one 
of these molecules, ABT-263, has progressed as far as clinical trials.60
Within this class of narrow PPIs are those that interact by burying an α-helix 
within a deep groove in the binding partner.62–64 An analysis of all PPI structures 
Figure 1.4: Structure of Bcl-xL and a peptide derived from the BH3 domain from Bcl-family mem-
bers.53 The BH3 peptide (red) binds in a deep cleft on the surface of Bcl-xL (blue). 
8within the PDB revealed that this type of interaction is quite common among PPI 
structures.63 The success of inhibiting these PPIs is due to their inherent similarity 
to small-molecule binding proteins – the interface forms a groove and there are 
small hot-spot regions.63 Furthermore, it is clear that if a PPI falls into this category, 
it will have a good chance of being inhibited by a small molecule. 
Inhibition of PPIs that interact with strong affinities but over a larger inter-
face have had equal success.19 Interestingly, inhibitors in this class have not been 
identified through conventional assays designed to measure simple disruption of 
the PPI.19 In many cases, the inhibition is achieved allosterically.65,66 One interest-
ing example of this is the identification of an inhibitor of the inducible isoform of 
nitric oxide synthase (iNOS). In an in vitro assay designed to detect disruption of 
the iNOS dimer, no compounds were identified.67 However, when a cell-based 
assay was used, the iNOS protein was able to exchange between monomer and 
dimer. 67 Using this assay, a molecule was identified that was able to bind to the 
monomeric form of iNOS and allosterically prevent dimerization.67 This type of 
interaction is significantly different from how a narrow PPI or a small molecule 
binding protein interacts with its respective binding partners, and exemplifies the 
need for new types of compounds and alternate screening formats. Additionally, 
inhibitors targeting the class of PPIs tend to be structurally complex and clearly do 
not obey the Rule of Five. These examples explain why it has been hard to identify 
inhibitors of PPIs using classical HTS strategies.13 
9The final two categories of PPIs are those that interact weakly with their 
binding partners over a wide or narrow interface. Weak PPIs can be indicative 
of interaction with multiple binding partners,48 or of a need for multivalency, as 
with some cell-surface receptors.68 There are few inhibitors of these types of PPIs, 
underscoring the need for either new chemotypes or new methods for identifying 
inhibitors, like those developed that identified allosteric inhibitors. 
It is clear from the iPPI database of known PPI inhibitors31 that some PPIs 
require a large, complex inhibitor to achieve adequate disruption of the complex. 
According to the Rule of Five and other conventional concepts of drug-likeness, 
many of the current PPI inhibitors would fail as drugs. A comparison of the molec-
ular properties of the iPPI database compounds with orally available drugs shows 
that 40% of PPI inhibitors fail at least two parameters of the Rule of Five.31 Only 
10% of oral drugs are uncompliant.31 PPIs fail because they tend to be very large, 
contain many hydrophobic aromatic groups, and have many hydrogen bonding 
elements. However, the Bcl-xL inhibitor ABT-263 violates the Rule of Five but re-
tains oral availability.60 Futhermore, the ligand efficiency of PPI inhibitors, which 
describes the averaged contribution of non-hydrogen atoms to the binding ener-
gy,69 is 0.24 kcal/mol for PPI inhibitors.13 Thus, for potent PPI inhibitors that ap-
proach low nM affinity, the molecular weight is expected to exceed 500 Da. There 
has been much speculation that the types of molecules that are able to inhibit a 
PPI and are orally available are not described by the chemical space defined by 
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the Rule of Five. Another drug-likeness classification was developed by Veber and 
coworkers, and this classification describes alternate but complementary molecu-
lar features that allow for oral availability (Table 1.1).70 Veber’s rules suggest that a 
molecule can achieve drug-likeness simply by the number of rotatable bonds and 
the solvent exposed surface area (Table 1.1).70 Consequently, the failure rate be-
tween PPI inhibitors and orally available drugs is lower if Veber’s rules are applied 
(18% for the Rule of Five versus 13% for Veber’s rules).31 It is likely that Veber’s 
rules can better assess the drug-likeness of PPI inhibitors. 
In summary, the prospects for inhibiting PPIs with orally available small 
molecules is challenging, but recent successes prove that it is achievable. Certain 
types of PPIs may be more amenable to inhibition than others, and the likelihood 
of inhibition seems to be linked to an ability to encapsulate a small molecule in or-
der to disrupt the hot-spot. Furthermore, an expansion of drug-like chemical space 
is bound to increase the number of orally available PPI inhibitors. 
1.3 The Use of Macrocycles in Drug Discovery
Macrocycles are large organic molecules that contain a central scaffolding 
ring of 12 or more atoms and substituent groups that project from the scaffold.71 
Macrocycles are common among natural products, and frequently act by bind-
ing to proteins to modulate their function.71,72 Due to this natural predilection for 
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binding to proteins, there is growing interest in utilizing this class of molecules in 
drug discovery.38,71,73–75 In inhibitor design, macrocyclization of organic molecules 
can be beneficial for increasing the affinity, selectivity, solubility, and cell perme-
ability of an inhibitor.73,76 Macrocycles achieve these properties by their semi-rigid 
structure. A rigid molecule, compared to an uncyclized variant, has fewer con-
formational states and lower configurational entropy.71,73,77 Conversely, the lim-
ited flexibility that cyclization imparts on a macrocycle allows for changes in the 
three dimensional structure that can enhance aqueous soluble and hydrophobic 
cell-membrane permeability.71
Cyclization imparts rigidity upon a molecule, which reduces the number of 
accessible conformations.71,73,77 If the compound is cyclized in such a way that it can 
sample conformations that allow for binding to a protein, there is a lower entropic 
penalty upon binding compared to an uncyclized version of the molecule. Conse-
quently, the affinity of the interaction may increase by virtue of this entropic ad-
vantage, following the Gibbs free energy equation (Equation 1.1). As the number 
of conformational states decrease, the loss of entropy (ΔS) is smaller, effectively 
making the free energy (ΔG) larger, and increasing the affinity. 
Some macrocycles can drastically change their conformation depending on 
the solvent.71 One example of this is the peptide-based natural product cyclospo-
Equation 1.1∆ ∆ ∆G H T S RTlnKD= − = −
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rin A. In polar solvents, this macrocycle adopts a structure in which the amide 
backbone is solvent exposed, allowing for hydrogen bonding with the solvent. 
Conversely, in non-polar solvents, the molecule adopts a different conformation 
in which many of the hydrogen bonds are satisfied internally.71,78 Conformational 
adaptability of this kind can enhance the solubility and cell permeability of macro-
cyclic-based inhibitors, as it allows for environmental adaptability. 
Some have hypothesized that macrocycles represent a privileged chemo-
type for binding to proteins.71,72 Nature uses natural products (including macro-
cycles) to bind to and modulate the function of proteins.72,77 Natural product mac-
rocycles tend to be larger and more structurally complex than synthetic drugs.71,77 
This suggests that these molecules occupy a different area of drug-like chemical 
space. The question arises of what structural properties of natural product-based 
macrocycles lend themselves to good pharmacokinetics and protein binding.
There are many orally available macrocycles that have progressed through 
clinical trials (Table 1.2). By the classification of the Rule of Five (Table 1.1), these 
macrocyclic drugs would be classified as non-druglike.39 First, they tend to be 
much larger than 500 Da. They also contain a large number of hydrogen bonding 
elements, which according to the Rule of Five is a poor predictor of drug-likeness. 
However, as with cyclosporin A, many hydrogen bonding elements may allow for 
the formation of intermolecular hydrogen bonds.71 Because only a small fraction 
of advanced drug candidates are macrocycles, and many of the approved macro-
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cyclic drugs post-date Lipinski’s study, they were poorly represented in the devel-
opment of the Rule of Five.39,73,75 Thus the Rule of Five is biased toward non-mac-
rocycles and is likely only descriptive of a certain area of drug-like chemical space. 
Conversely, Vebers’s rules suggest that the polar surface area and number of ro-
tatable bonds are better predictors of oral bioavailability (Table 1.1).70 These are 
features that macrocycles are able to achieve and possibly are intrinsically better 
at than small molecules.73,74 While macrocycles are rigidified by their ring, they 
still have a degree of flexibility that can alter the polar surface area depending on 
whether the molecule is in a polar environment (extra- or intraceullar matrix) or a 
Molecular Weight Hydrogen Bond 
Acceptors
Hydrogen Bond 
Donors
Rotatable Bonds
Rifaximin 785.4 11 5 3
Amphotericin B 923.5 17 12 3
Rifabutin 846.4 13 5 5
Rifampin 822.4 14 6 5
Sirolimus 913.6 12 3 6
Rifapentine 876.5 14 6 6
Tacrolimus 803.5 11 3 7
Azithromycin 748.5 13 5 7
Abamectin 874.5 13 3 8
Clarithromycin 747.5 13 4 8
Everolimus 957.6 13 3 9
Troleandomycin 813.5 12 0 12
roxithromycin 836.5 16 5 13
vancomycin 1447.4 24 19 13
Erythromycin 861.5 14 4 14
Cyclosporin A 1201.8 12 5 15
Fidaxomicin 1056.4 15 7 15
Desmopressin 1068.4 15 14 19
AVERAGE 921.4 14 6.1 9.3
Table 1.2: Orally available natural product macrocyclic drugs. The 18 approved macrocyclic drugs 
all violate the Rule of Five due to their high molecular weight, and numerous hydrogen bonding 
elements yet retain oral availability. 
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non-polar environment (cell membrane).71,78,79 Furthermore, the cyclic scaffold and 
intramolecular hydrogen bonding can both drastically constrain bond rotation. 
It appears, therefore, that Veber’s rules are more informative for evaluating the 
drug-likeness of macrocycles. 
All orally available macrocyclic drugs are derived from natural products. 
However, the area of chemical space explored by natural-product based macrocy-
cles is biased toward what was beneficial for the evolution of the organism rath-
er than a thorough exploration of drug-like macrocyclic space for the benefit of 
drug-discovery. Thus the use of synthetic chemistry is essential for the develop-
ment of new classes of drugs.80 To that end, many groups are focusing on the de-
velopment of novel synthetic methods to support the development of macrocyclic 
based drugs.73,80 The ability to develop synthetic methods for the efficient synthesis 
of macrocyclic molecules would allow for more diverse exploration of macrocyclic 
druggable chemical space. 
Overall, the use of macrocycles may represent a widely applicable chemo-
type for drug discovery. The rigidity coupled with limited flexibility that many 
macrocycles achieve seems to be key for achieving high potency and good oral 
availability. While many larger macrocycles fail the classical molecular definitions 
of drug-likeness, as synthetic methods advance we will more fully understand the 
how to apply macrocycles in drug discovery. 
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1.4 Biology of NF-κB Essential Modulator
Nuclear factor κB (NF-κB) is a family of transcription factors that control 
genes responsible for cellular responses to extracellular stress, and cell prolifer-
ation and differentiation.81,82 There are five proteins in this family – NF-κB1, NF-
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Figure 1.5: Schematic of the NF-κB canonical pathway. The IKK complex is recruited to a large, 
multi-protein complex upon extracellular stimuli. Next, IKKβ is activated by phosphorylation. 
Subsequently, IκB is phosphorylated by the activated IKK complex, leading to its proteosomal 
degradation. Finally, the NF-κB transcription factors are free to translocate into the nucleus, allow-
ing for upregulation of genes.
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κB2, RelA, RelB, and c-Rel.81 NF-κB functions as a heterodimer consisting of these 
proteins in up to at least 15 combinations.81,82 Activation of these transcription fac-
tors is controlled by extracellular stimuli signaling through one at least three dif-
ferent branches of this pathway.81,83 NF-κB is usually held in an inactive form in the 
cytoplasm through interactions with one of the four inhibitor κB proteins (IκBα, 
IκBβ, IκBε, and IκBδ).82 Upon pathway stimulation, IκB becomes phosphorylated 
by the multicomponent IκB kinase (IKK complex), and the phospho-IκB molecule 
is degraded by the proteasome.81,82 The unbound NF-κB is then released into the 
nucleus to upregulate genes in response to the original stress. 
The NF-κB essential modulator (NEMO) is involved in one branch of the 
NF-κB pathway, referred to as the canonical pathway. NF-κB activation occurs 
through two pathways referred to as the canonical and non-canonical pathways.83 
The defining difference between these two pathways is that the canonical pathway 
is requires NEMO, whereas the non-canonical pathway does not.83 Furthermore, 
the canonical pathway tends to be associated with the immune functions of NF-
κB, whereas the non-canonical pathway is involved with organism development.83 
In the canonical pathway, NEMO functions as part of the IKK complex along with 
the catalytic subunit inhibitor of κB kinase β (IKKβ).84,85 This complex is likely 
composed of a 2:2 ratio of NEMO and IKKβ,86 though other stoichiometries have 
also been proposed.84,87–90 Some work has suggested that a close homolog of IKKβ, 
IKKα, can also participate as a catalytic subunit in the IKK complex.83,91,92 Howev-
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er, IKKα functions in the non-canonical pathway, and it has only been shown to 
function in the IKK complex in IKKβ-knockout models.93,94 
Activation of the canonical NF-κB pathway is complex, and there are many 
features that are not fully understood.83 This pathway is known to be activated 
by extracellular stimuli targeting the TNF-receptor I, the IL-1R receptor, or TLRs 
(Figure 1.5).83 These stimuli signal the recruitment of the IKK complex to the tar-
geted receptor and an associated multi-protein complex in order to activate the 
IKK complex.83 To date, there are three described mechanisms by which the IKK 
complex is activated. The first involves the recruitment of an E2/E3 ligase complex 
consisting of the proteins UbcH5 and cIAP1 to the TNFR1.95,96 The E2/E3 ligase 
complex forms various types of linked ubiquitin chains on the kinase RIP1.96 The 
IKK complex, along with the kinase TAK1, bind to these ubiquitin chains and be-
come phosphorylated both by TAK1 and through trans-autophosphorylation.96,97 
The second mechanism involves the association of LUBAC with the TNFR1 re-
ceptor.98,99 LUBAC then directly conjugates ubiquitin chains to NEMO within the 
IKK complex, and the IKK complex is activated by trans-autophosphorylation of 
IKKβ.100 The third activation mechanism is dependent on association of proteins 
with the IL-1R and TLR receptors. The E2/E3 ligase complex consisting of Ubc13 
and TRAF6 is recruited to these receptors and conjugates K63-linked ubiquitin 
chains to IRAK1.96,101 As with the first mechanism, both TAK and the IKK complex 
can bind to the ubiquitin chains to initiate phosphorylation.96
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Once activated, the IKK complex binds and phosphorylates IκB.100,102 This 
triggers IκB’s ubiquitination by the E3 ubiquitin ligase SCF/βTRCP, and degrada-
tion by the 26S proteasome.103 The NF-κB transcription factors that were bound 
to IκB are thus released into the cytoplasm and traverse the nucleus to enhance 
transcription of specific target genes. 
NEMO is essential for proper functioning of the canonical NF-κB pathway. 
Knockout of NEMO in a mouse model causes fatal liver damage stemming from 
uncontrolled apoptosis due to the lack of NF-κB mediated survival signaling in he-
patocytes.104 Furthermore, even minor mutations in NEMO can give rise to human 
diseases causing immune impairment.105 NF-κB signaling is responsible for cell 
proliferation and differentiation, and due to these important biological functions, 
this pathway is upregulated in certain cancers.106–109 Because NEMO is at the crux 
of proper functioning of this pathway, it has been studied as a point of therapeutic 
intervention for diseases related to NF-κB function.86,110 Direct disruption of the 
IKK complex could be one way to inhibit hyper-activation of the NF-κB pathway. 
It has been shown that an 11-residue peptide derived from the NEMO associating 
region of IKKβ, named the NEMO binding domain (NBD), is the minimal-associa-
tion region of IKKβ.111 Further studies using a cell-penetrating variant of the NBD 
peptide showed that disrupting the NEMO/IKKβ complex in vivo can elicit a spe-
cific and selective biological outcome that attenuates activation of NF-κB but does 
not affect basal NF-κB function.110 This contrasts with the phenotypes observed for 
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NEMO or IKKβ-deficient mice. In the absence of NEMO, mouse embryos die due 
to liver degeneration caused by apoptosis.104 The results from an IKKβ-knockout 
mouse model were the same, except that degeneration of the liver occurred slight-
ly later in the embryos.112 Thus, disrupting the PPI between NEMO and IKKβ has 
shown to be an effective route toward NF-κB attenuation. 
1.5 Structure and Oligomerization of NEMO
The full three-dimensional structure of NEMO and the IKK complex is still 
unsolved. Most fragments of NEMO for which three-dimensional structures have 
been reported show a NEMO dimer formed into an α-helix coiled-coil (Figure 
Figure 1.6: Structures of NEMO to date. Seven unique structures have been solved for various 
domains of NEMO. (A) NEMO N-terminus bound to IKKβ.86 (B) NEMO bound to v-Flip.115 (C) 
NEMO interaction with di-ubiquitin.116 (D) NEMO bound to di-ubiquitin.118 (E) NEMO bound to 
DARPin.119 (F) NEMO CC2/LZ domain.117 (G) NEMO zinc finger domain.120
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1.6a).86 However, other non-crystallographic or NMR-based work has shown that 
NEMO can form monomers,84,87,89,113 dimers,84,86,87,89,90,113–119 trimers,84,87,89,90,113 tetram-
ers,88,114 and pentamers113. The extent that oligomers other than dimers are biolog-
ically relevant, even outside of the IKK complex, has yet to be conclusively deter-
mined. 
No crystal structure has been reported for full-length NEMO, but seven 
unique structures are available for various fragments and domains of NEMO that 
collectively encompass the entire length of the protein except for the N-terminal 
44 residues and the region extending from residues 111-195.86,115–120 With the ex-
ception of the C-terminal zinc finger domain,120 each of the structures shows a 
highly helical, dimeric protein (Figure 1.6).86,115,117–119 Of note is the structure of the 
N-terminal domain of NEMO (residues 44-111) complexed with a 45-mer peptide 
comprising the NEMO-interacting region of IKKβ.86 This structure is the only one 
Table 1.3: Energetic contribution of IKKβ residues to NEMO binding.123 Select residues in the NE-
MO-binding region of IKKβ were mutated to alanine. Most residues contribute very little binding 
energy to the interaction (-1 to 1 kcal/mol). However, a few residues do contribute more favorably 
to binding (>1 kcal/mol). 
Mutation Calculated ΔΔG
L708A 2.8
V709A 1.7
N714A -0.8
L715A -0.4
L719A 4
I723A 1.9
D725A -0.6
T726A -0.5
V727A -0.3
E729A -0.7
Mutation Calculated ΔΔG
Q730A -0.8
S733A -0.5
F734A 1.5
T735A -0.1
L737A 1.6
D738A 3.6
W739A 4.3
S740A 1.0
W741A 3.5
L742A 3.2
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that shows NEMO associating with IKKβ, and confirms that the stoichiometry of 
the IKK complex is 2:2 (Figure 1.6a). Another structure shows a complex between 
NEMO (193-251) and the viral FLICE inhibitory protein (vFLIP, Figure 1.6b).115 
vFLIP is a viral protein that is produced in order to activate the NF-κB pathway 
through its interaction with NEMO. This structure thus presumably represents 
what this region of NEMO looks like in an active state. The four structures of 
NEMO that encompass the residues ~250-340 all show dimeric NEMO (Figure 
1.6d-f).116–119 Co-crystallization of this region of NEMO with di-ubiquitin (Figure 
1.6c, d), with the engineered antibody mimetic protein DARPin (Figure 1.6e), or 
alone (Figure 1.6f) show NEMO structures similar to that seen in the complex 
with vFLIP. Finally, the zinc finger domain structure was solved by NMR (Figure 
1.6g).120 The fold of this zinc finger is typical of most zinc finger domains.121 This 
region serves as a docking site for IκB – NEMO bridges activated IKKβ and IκB for 
Figure 1.7: Structure of the NEMO/IKKβ interaction showing the relative contribution of IKKβ res-
idue to binding. Several IKKβ residues were mutated to alanine and the change in binding energy 
was measured. The residues are classified as either contributing a large amount (red), a moderate 
amount (yellow) or little (green) binding energy. The important residues are clustered into three 
hot spots that may be amenable to inhibitor design.
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the initial step in NF-κB activation.122 
Inhibition of any of these endogenous interactions could be targeted with 
an inhibitor to attenuate NF-κB signaling. However, as discussed, there is strong 
evidence that inhibiting the NEMO/IKKβ interaction is biologically tractable.110 In 
comparison, there is not as much work showing the biological utility of inhibiting 
NEMO’s other interactions. However, the biological tractability of NEMO/IKKβ 
interaction says nothing about the druggability of this interaction. Like many oth-
er PPI inhibitors, developing a NEMO inhibitor will likely require some degree 
structure-based design.13 The minimal region of IKKβ that has been shown to bind 
to and inhibit NEMO is an 11-residue region referred to as the NEMO binding do-
main (NBD), comprising IKKβ residues 737-742.111 A longer peptide encompass-
ing IKKβ residues 701-745 was shown to bind with much higher affinity, due to 
its more extensive contact with NEMO.86 Alanine scanning mutagenesis of many 
of the residues within this 45 residue region that directly contact NEMO shows 
that a few residues contribute most of the binding energy to this interaction (Table 
1.3),111,123 consistent with the notion that PPIs contain binding energy hot-spots (Fig-
ure 1.1).46 The hot-spot residues on IKKβ are clustered into three regions (Figure 
1.7). The first and strongest hot-spot includes residues in the region of D738-L742 
(Figure 1.7). The fact that this hot-spot is the most essential to IKKβ binding agrees 
with previous reports identifying the minimal NBD peptide.111 A second hot spot 
involves the region around L708 and V709 and is located distal to the first hot 
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spot, while the third involves residues L719, I723, and T276, located in between the 
first two hot-spots (Figure 1.7). Computational analysis of the druggability of the 
IKKβ binding site on NEMO confirms that the hot spot region corresponding to 
the NBD binding site is the position most likely to accommodate a small, organic 
inhibitor.44,123 Taken together, these data indicate that the NEMO/IKKβ interface is 
likely to be druggable. There is biological evidence for the usefulness of disrupting 
this PPI and structural data to guide the development of inhibitors. Furthermore, 
the use of novel chemical tools – namely macrocycles – increases the potential for 
successfully inhibiting this PPI. 
1.6 Overview of Thesis
The ultimate goal of this research project is to develop inhibitors of the 
NEMO/IKKβ interaction in order to (1) develop new methodologies to inhibit 
PPIs, and (2) determine properties of synthetic macrocycles that might advance 
their use as orally available drugs, especially against PPI targets.  The work dis-
cussed in this thesis involves the characterization of NEMO and its interaction 
with IKKβ and screening for inhibitors. Chapter 2 focuses on the development of 
a recombinant form of full-length NEMO. This work provides insight into the oxi-
dation state of NEMO’s many cysteine residues and how these cysteines affect the 
structure and activity of the protein. Furthermore, the NEMO protein developed 
in this chapter supports the aims of the subsequent chapters.
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In chapter 3, the development of a set of bio-assays is presented. Fluores-
cence anisotropy (FA) was chosen as the primary assay for measuring association 
of NEMO with IKKβ due to its ease and simplicity. An ELISA was also developed 
to confirm the results from the FA assay. These assays were developed to support 
the screening and validation of compounds as inhibitors of the NEMO/IKKβ PPI. 
Chapter 4 describes the use of the reagents and assays developed in Chapters 2 
and 3 to screen two different compound collections and validate the resulting hits. 
These were (1) computationally designed macrocycles and (2) a large library of 
traditional small molecules. 
Finally, Chapter 5 describes more advanced biophysical characterization of 
NEMO and of the NEMO/IKKβ complex. The molecular weight and distribution 
of species from a sample of NEMO was analyzed by analytical ultracentrifugation, 
extending the results from Chapter 2. A labeled form of NEMO was developed to 
probe the propensity of the protein to form higher-order oligomers. Finally, the 
degree of cooperativity in the binding of IKKβ to NEMO was assessed by FRET 
homoquenching. The work described herein is distinct from previously published 
characterizations of NEMO structure and biochemistry in vitro, in that previous 
studies have focused on specific domains of NEMO, rather than using full-length 
NEMO protein as do here.
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Chapter 2: NEMO Purification and Expression
2.1  Introduction
NEMO has been studied extensively in vivo. However, attempts at study-
ing the protein in vitro have been hampered by a number of factors. Some studies 
have reported low yields of recombinant NEMO,86,124 hindering the application of 
biophysical methods that require high concentrations of protein. This hindrance 
is likely due, at least in part, to complications arising from the different codon bi-
ases between prokaryotes and eukaryotes.125 To overcome this issue, recombinant 
NEMO can be expressed along with tRNA molecules that are uncommon in the 
host strain, as has been done in a few studies.102,114,118 Another study reported what 
they concluded to be extensive partial proteolysis of purified full-length NEMO.87 
However, the proteolysis seen was likely due to the presence of one or more rare 
codons, leading to formation of a heterogeneous population of NEMO truncations 
through incomplete translation which was incorrectly interpreted as proteolysis. 
In addition to these expression issues, the propensity of NEMO to form aggre-
gates87,119,126 also makes it difficult to achieve good yields. Due to these difficulties, 
many researchers have simply used truncations of the protein to study individual 
domains rather than the whole protein.86,87,89,90,113–115,117–119,122,126,127 
A variety of mutations have been made to full-length or shorter NEMO 
constructs. In one study, mutation of Cys54 was used to prevent disulfide bond 
formation in a NEMO 1-355 construct.114 It has been residues Cys54 and Cys347 
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can contribute to intermolecular disulfide bond formation in cells.128 If a NEMO 
dimer crosslinked with these residues is a biologically relevant form of the protein, 
it is unclear why they would mutate Cys54 and why they would leave Cys347 in-
tact. A mutation of Lys285 to Asn has also been reported as a beneficial mutation 
to allow for the formation of NEMO crystals for structural studies, in the context of 
a variety of NEMO constructs.114,119,129 It is unclear why this mutation was beneficial 
for either the structural or biophysical studies in which this protein was used, as it 
was incorporated without a clear explanation for its purpose. 
As discussed, the biological form of NEMO that functions within the IKK 
complex is most likely a dimer.84,86,87,89,90,113–119 However, whether the formation and 
stability of the dimer is dependent on the presence of intermolecular disulfide 
bonds has not been conclusively determined. It has been shown that in vivo, NEMO 
can form homotypic crosslinks with Cys54 and Cys347 when cells are treated with 
5% H2O2,128 though it was not clear whether the a Cys54/347 cross-linked dimer is 
a biologically relevant species. A NEMO mutant in which both Cys54 and Cys347 
were mutated to Ala showed slightly delayed kinetics and lower levels of in vivo 
Figure 2.1: Structure of the NEMO N-terminus bound to the IKKβ C-terminus.86 The structure of 
NEMO’s N-terminus shows that only Cys54 is positioned close enough to allow for disulfide bond 
formation, whereas Cys76 and 95 are not.
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TNF-α-induced NF-κB DNA binding,128 but it was not clear whether this was due 
to an inability of NEMO to form a covalently dimeric species. Furthermore, the 
study did not determine whether the mutations affected NEMO’s ability to form a 
non-covalent dimer, which is another possibility for the biologically relevant form 
of the protein. One structure of the N-terminal 44-111 residues of NEMO shows 
the location of Cys54, and showed that this residue did not form a disulfide bond 
between the NEMO monomers.86 However, the structure was solved under reduc-
ing conditions, and both Cys54 residues are positioned in a way that could allow 
for disulfide bond formation (Figure 2.1).
This chapter focuses on the development of a recombinant form of NEMO 
to support detailed biochemical characterization of the NEMO/IKKβ binding in-
teraction as well as the development of assays for inhibitor identification. To min-
imize any complications arising from working with NEMO truncations, a full-
length construct is used. Many of the questions regarding the oligomeric state and 
oxidation of the Cys resides are addressed. 
2.2 Materials and Methods
2.2.1 Plasmids and Site-directed Mutagenesis
The genes for wild-type and 7xAla NEMO were generously provided by 
Dr. Tom Gilmore. The 5xAla NEMO gene was synthesized with codon optimi-
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zation to increase protein yield for E. coli expression (Genscript, Piscataway, NJ). 
The genes for WT, 5xAla, and 7xAla were inserted into the NdeI and XhoI into the 
NdeI and XhoI sites of the pET24b(+) vector (Novagen). The NEMO addback mu-
tants were created using the QuickChange mutagenesis method130 or a modified 
QuickChange protocol, using the 7xAla NEMO gene as the base construct. The 
modified QuickChange protocol involves first making a large primer and then 
performing the QuickChange method with this “mega-primer.” The mega-primer 
is created by first incorporating the mutation into a ~20 bp primer. This primer is 
designed as either a forward or reverse primer depending on the terminus that the 
mutation is closest to. The list of primers used to generate these constructs is listed 
in Appendix I. All constructs were confirmed by DNA sequencing. 
2.2.2	 E.	coli	Expression	and	Purification
Wild-type, 5xAla, and 7xAla were initially transformed into the T7 Express 
Iq Competent E. coli (New England Biolabs, Ipswich, MA). In later experiments, 
the NEMO constructs were transformed into Rosetta 2(DE3)pLysS competent cells 
(Novagen), which allows for the expression of additional tRNAs and helps to alle-
viate any issues with rare codons. 
To produce the protein, NEMO-transfected E. coli were grown overnight in 
LB broth at 37 °C. A new culture was seeded from the overnight culture at a 1:200 
dilution, and grown to OD600 ~0.4. Protein expression was induced by 1 mM iso-
propyl β-D-thiogalactoside (IPTG), and the cells were grown for an additional 4 h. 
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Cells were pelleted and stored at -80 °C. 
The majority of the proteins used in this study was prepared using the stan-
dard protein purification protocol. In this protocol, cells were lysed by adding 
Bacterial Permeabilization Reagent (B-PER, Pierce, Rockford, IL) at 4 mL/g of cell 
pellet together with 2.5 mg/mL lysosome (Pierce), 5 mg/mL streptomycin sulfate 
(Gold Bio, St. Louis, MO), 10 μL/mL Halt Protease Inhibitor Cocktail (Thermo Sci-
entific, Rockford, IL), and 0.2% w/v DNase I (Pierce, Rockford, IL). The lysate was 
incubated for 20 min at room temperature, 8 M urea was added to solubilize inclu-
sion bodies and denature the protein, and the lysate was incubated for a further 
1 h at 37 °C. The lysate was clarified by centrifugation at 38,000 RPM for 30 min, 
and was then filtered through a 0.8 μm filter. The prepared lysate was applied to 
a 5 mL HisTrap FF crude column (GE Healthcare, Piscataway, NJ), followed by 5 
column volumes of 20 mM sodium phosphate, 500 mM NaCl, 40 mM imidazole, 
6 M urea at pH 7.4. The bound protein was refolded on the column using a 20 
column volume urea gradient from 6 M to zero. The refolded protein was eluted 
using a step gradient of increasing concentration of 20 mM sodium phosphate 500 
mM NaCl, 500 mM imidazole at pH 7.4. 
Three alternate protocols were developed based on the standard protocol. 
(1) Prior to the discovery of an associated bacterial heat-shock protein, DnaK, the 
cells were lysed without adding urea and thus was a non-denaturing protocol. Ad-
ditionally, the purification was performed with buffers that did not contain urea, 
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and the refolding step from buffer containing 6 M urea to no urea was omitted. 
(2) Due to severe problems in purifying wild-type NEMO, a modified protocol 
was developed in which the lysate and nickel-NTA buffers were supplemented 
with 5 mM TCEP to reduce disulfide-mediated misfolding and aggregation. (3) 
For the NEMO addback mutants, the lysate was prepared in the same way and 
was instead applied to a gravity column containing 1 mL HisTrap HP resin (GE 
Healthcare, Piscataway, NJ). The column was washed with by 5 column volumes 
of 20 mM sodium phosphate, 500 mM NaCl, 40 mM imidazole, 6 M urea at pH 7.4, 
followed by 10 column volumes of the same buffer lacking urea. The protein was 
eluted using 3 column volumes of 20 mM sodium phosphate 500 mM NaCl, 500 
mM imidazole at pH 7.4. 
In the standard and modified protocols except for the NEMO addback pro-
tocol, the NEMO eluate was concentrated and applied to a HiPrep 26/60 Sephacryl 
S-300 HR column (GE Healthcare) equilibrated with 20 mM sodium phosphate, 
500 mM NaCl at pH 7.4. Purified NEMO was concentrated from the fractions elut-
ing between the void volume and 160 min, aliquotted, and stored at -80 °C. Protein 
concentrations were calculated from the absorbance at 280 nm (NanoDrop, Ther-
mo Scientific) using an extinction coefficient of 14,815 M-1cm-1 calculated from the 
protein sequence.
2.2.3 SDS-PAGE Analysis
All SDS-PAGE experiments were performed using 12% polyacrylamide 
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Tris-HEPES gels (Thermo Scientific). Gels were stained using either GelCode Blue 
Safe Protein Stain (Thermo Scientific) or coomassie G-250 in 40% methanol, 10% 
acetic acid. To oxidize or reduce the protein, NEMO constructs were pre-treated 
with 5% H2O2 or 10 mM DTT for 1 h. After pre-treatment, the protein was incubat-
ed in SDS sample buffer (4% w/v SDS, 20% v/v glycerol, 0.01% w/v Bromophenol 
Blue, 125 mM Tris, pH 6.8) for 5 min or boiled in SDS sample buffer with 100 mM 
DTT prior to analysis. 
2.2.4 Analytical Gel Filtration Chromatography
The oligomeric state of recombinant NEMO preparations was determined 
using analytical gel filtration. To measure the degree of aggregation, a sample of 
wild-type NEMO was purified using the standard protocol. Instead of purification 
on the S-300 gel-filtration column, the NEMO eluate was loaded directly onto a 
Superose 6 10/30 GL analytical gel filtration column. The protein was eluted over 
1.5 column volumes using 20 mM sodium phosphate, 500 mM NaCl at pH 7.4 with 
a flow rate of 0.4 mL/min.
To assess the level of aggregation of fully purified NEMO, a 40 μM sample 
of wild-type NEMO purified using the reducing protocol, 5xAla, and 7xAla was 
pre-incubated for 1 h in 20 mM sodium phosphate, 500 mM NaCl at pH 7.4 con-
taining 0, 1, or 10 mM DTT. A 100 μL sample of the treated protein was then load-
ed onto a Superose 6 10/300 GL analytical gel-filtration column (GE Healthcare), 
and eluted over 1.5 column volumes of 20 mM sodium phosphate, 500 mM NaCl 
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at pH 7.4 run at 0.4 mL/min. 
2.2.5 Fluorescence Anisotropy Binding Studies
FITC-labeled IKKβ(701-745) peptide (referred to as IKKβ-fluorescein) was 
synthesized commercially (Genscript) and then further purified on a RESOURCE 
RPC 3 mL reversed phase FPLC column (GE Healthcare), using a buffer system 
of 0.125% ammonium hydroxide in water and 0.125% ammonium hydroxide in 
100% methanol. The concentration of purified IKKβ-fluorescein was determined 
from its UV absorbance at 280 and 493 nm, by Nanodrop using the Equation 2.1 131:
To determine whether the fluorescein label had an effect on the affinity of IKKβ 
for NEMO, a titration with an unlabeled IKKβ-(45-mer) peptide was performed. 
The IKKβ-(45-mer) was generously donated by Biogen-Idec. In this assay format, 
IKKβ-fluorescein and NEMO were held constant at 15 nM and the concentration 
of IKKβ-(45-mer) was varied. 
A direct binding experiment was performed to measure the affinity of IK-
Kβ-fluorescein for NEMO. In this assay format, the tracer peptide (either IKKβ-flu-
orescein or IKKβ(C-S)-fluorescein) was held constant at 15 nM. Each NEMO con-
struct was varied from 0-10 μM and, depending on the experiment, was pre-treated 
for 1 h at 4 °C with 10 mM DTT or 5% v/v H2O2. One column in the assay plate was 
reserved for a control in which only the tracer peptide was present, and another 
Equation 2.1Concentration
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for a control that contained only assay buffer. 
A binding-site titration was performed for 5xAla to determine the relative 
percent activity of the recombinant protein. The experiment was performed identi-
cally to the direct-biding experiment, except IKKβ-fluorescein was added at vary-
ing concentration (500, 250, 125, 62.5, and 31.25 nM). 
Assays were performed in 96-well polypropylene black plates (Corning, 
Corning, NY) in triplicate, using an assay volume of 200 μL and a buffer of 50 
mM tris pH 7.4, 200 mM NaCl, 0.01% v/v Triton X-100, 1 mM DTT. Each NEMO 
concentration was measured in triplicate, and each assay was run at least three 
times. Assays were incubated for 1 h at 25°C unless otherwise noted. Assay plates 
were read using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, 
CA), using excitation and emission wavelengths of 488 and 520 nm, respectively. 
A more thorough description of the assay and data workup is described in sec-
tion 3.2.2. The anisotropy dose-response curves for the direct binding experiments 
were fitted to a quadratic binding equation, modified to include an offset value to 
account for the non-zero anisotropy observed in the absence of NEMO, and also 
a linear term to account for the upward slope seen at high protein concentrations 
(Equation 3.11).
To measure the effect of the Cys residue of IKKβ on dimerization and assay 
interference, the assay was performed by measuring the anisotropy of 15 nM IK-
Kβ-fluorescein constant in assay buffer with and without 1 mM DTT. 
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2.2.6 Circular Dichroism Spectroscopy
A 2 mL sample of WT, 5xAla, and 7xAla NEMO was dialyzed overnight 
against 2 L of 20 mM sodium phosphate pH 7.4, 150 mM NaCl, 2.5 mM TCEP (CD 
Buffer). For 11xAla, the same procedure was performed omitting TCEP in the as-
say buffer. After dialysis, the protein was diluted to ~10 μM in CD buffer. The CD 
spectrum of a 300 μL sample of each variant was taken in a 0.1 cm cuvette at 20 °C 
from 195 nm to 260 nm. For all CD experiments, the circular dichroism signals (in 
millidegrees) was normalized to the mean molar residue ellipticity using Equation 
2.2.132
The thermal stability of each variant was measured using the same protein 
preparation and was monitored by the increase in the CD signal at 222 nm from 
10-70 °C using a 1 °C min-1 ramping rate. To determine that thermal unfolding was 
independent of the ramping rate, thermal unfolding was measured for 5xAla at 0.5 
°C min-1 and 0.33 °C min-1. The melting temperature was determined by the major 
peak in the first derivative plot of the melting curve. 
2.3 Results and Discussion
2.3.1 Initial Design and Purification of NEMO Cysteine Mutants
To develop high quality recombinant full-length NEMO protein for de-
tailed biophysical and structural characterization, we initially generated recom-
Equation 2.2θ[ ]( ) = ( )
−deg cm dmol
millidegrees
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35
binant constructs of wild-type NEMO and two mutants in which either five or 
seven of the protein’s 11 Cys residues were changed to Ala (Figure 2.2).133 Previ-
ous studies have used variations of NEMO to avoid issues of low yield and poor 
solubility.86,87,89,100,102,111,113,114,117–119,122,124,126,127,129  To overcome these issues, two Cys to 
Ala mutants were developed. In the 7xAla construct, all of NEMO’s Cys residues 
except for the four in the C-terminal zinc finger domain are substituted.120 In the 
5xAla construct, Cys54 and Cys347, which have been shown to be capable of in-
ter-chain disulfide bond formation,128 were also retained to test whether these two 
residues contribute to the stability of the protein or are important for achieving 
full IKKβ binding activity. The published structure of NEMO(44-111) bound to 
IKKβ(701-745) suggests that formation of a covalent NEMO dimer through di-
sulfide bonding at Cys54 is compatible with the active conformation of the pro-
tein (Figure 2.1), though the structure shows the protein in a reduced state.86 The 
potential for inter-chain disulfide bonding at Cys54 to affect IKKβ binding was 
therefore of particular interest. 
CC1 CC2 LZ ZF
11 54 3471671319576
396, 397
400, 417Wild-Type
5xAla 11 54 3471671319576
396, 397
400, 417
7xAla 11 54 3471671319576
396, 397
400, 417
Figure 2.2: Domain structure of NEMO with recombinant NEMO sequences.133 The domain assign-
ment of full-length NEMO is shown along with the eleven Cys residues. The Cys residues colored 
in red have been mutated to alanine in that construct. 
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When initially developing the purification protocol we found that a ~70 
kDa protein co-eluted with NEMO nickel column (Figure 2.3a). We were able to 
eliminate this contaminant by loading the crude protein onto the nickel-NTA col-
umn in 8 M urea, and then refolding the bound NEMO directly on the column by 
applying a urea gradient. This protein was likely the bacterial chaperone protein 
DnaK, which has been reported to associate with NEMO.87 
It was found that wild-type NEMO, purified using the standard protocol 
(section 2.2.2), aggregated extensively (Figure 2.3). However, boiling with 100 
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Figure 2.3: Wild-type NEMO aggregates in the absence of a reducing agent. (A) Wild-type NEMO 
aggregated severely when purified in buffers lacking a reducing agent, as seen by the presence 
of large molecular weight bands. The aggregates were reducible upon boiling with 100 mM DTT, 
suggesting that they result from the many cysteine residues in the protein. (B) Wild-type NEMO 
purified only by nickel-NTA resin was analyzed by analytical gel-filtration. A significant fraction 
of the protein eluted with the void volume, suggesting that the aggregate seen in (A) is a very large 
species. 
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mM DTT in SDS sample buffer reduced the protein to a monomeric species (Fig-
ure 2.3a). Incubation of purified wild-type NEMO for 1 h with up to 10 mM DTT 
failed to fully eliminate the aggregated forms (data not shown). Aggregation is 
likely due to the numerous cysteine residues present in the protein sequence (Fig-
ure 2.2). Any surface exposed cysteine residues that do not contribute to disul-
fide bonds and are otherwise solvent exposed would likely be reduced since the 
cytosol is a reducing environment. However, in vitro, wild-type NEMO may be 
able to form detrimental random crosslinks between solvent exposed cysteines. 
Analysis of crude E. coli lysates by standard reducing SDS-PAGE showed that the 
expression levels of the three forms of NEMO (wild-type, 5xAla and 7xAla) were 
200
150
120
100
85
70
60
50
40
100 mM DTT
WT 5xAla 7xAlaWT 5xAla
No DTT
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Figure 2.4: Reducing and non-reducing SDS-PAGE of NEMO variants. Purified wild-type NEMO, 
5xAla, and 7xAla were analyzed by SDS-PAGE. Wild-type NEMO, even when purified under re-
ducing conditions, showed a moderate degree of aggregation. 5xAla NEMO was predominantly 
dimeric, and there were at least two distinct monomeric species. 7xAla migrated as a mixture of 
monomer and dimer. It is likely that Cys396, which is in the zinc finger but does not contribute 
directly to zinc binding, can mediate a disulfide interaction, which explains some of the higher-or-
der oligomeric states. Each construct can be reduced to a monomeric species when boiled in SDS 
sample buffer containing 100 mM DTT.
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roughly equal (data not shown), indicating that the poor yield obtained with wild-
type NEMO was due to loss of material during purification, presumably resulting 
from oxidation and aggregation during or after cell lysis. To overcome these issues 
and also to probe the structure/function relationship of proposed disulfide-medi-
ating residues Cys54 and Cys347, two NEMO cysteine mutants were developed in 
which either five or seven of the 11 Cys residues were mutated to Ala (Figure 2.2). 
Analysis of the three purified NEMO proteins by SDS-PAGE (Figure 2.4) showed 
that, even after boiling with SDS, under non-reducing conditions wild-type NEMO 
was a mixture of unresolved dimer and higher-order oligomer. In contrast, under 
non-reducing conditions the 5xAla NEMO gave two major bands, likely corre-
sponding to two forms of NEMO dimer, which may be due to two differently oxi-
dized forms. 7xAla NEMO predominantly migrated as a mixture of NEMO dimer 
and monomer. Western blotting with anti-NEMO and anti-6xHis-tag antibodies 
showed that all visible bands contained 6xHis-tagged NEMO (data not shown). 
Boiling with DTT and SDS reduced all three preparations to the molecular weight 
expected for monomeric NEMO, showing that the NEMO dimers and oligomers 
observed under non-reducing conditions were covalently joined through disulfide 
bonds (Figure 2.4).
2.3.2 Comparison of NEMO Cysteine Mutants to Wild-Type NEMO
The homogeneity and oligomerization state of wild-type NEMO purified 
in the presence of 5 mM TCEP was compared to those of 5xAla and 7xAla NEMO, 
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both of which were purified under the standard non-reducing (no TCEP) condi-
tions. Freshly prepared protein was analyzed by analytical gel-filtration after incu-
bation for 1 h with 0, 1, or 10 mM DTT. In the absence of DTT, wild-type and 5xAla 
NEMO both showed a major peak eluting at about 11 mL, plus a smaller peak that 
eluted with the void volume of the column and corresponds to aggregated protein 
(Figure 2.5a, b, blue lines). The slower migrating peak corresponds to an apparent 
molecular weight of >450 kDa, as compared to the elution times of globular molec-
ular weight standards. However, as previously reported, NEMO migrates anoma-
lously on gel-filtration columns,114 which has been attributed to the protein having 
an elongated rather than a globular structure, and so the true size of the species 
eluting at 11 mL cannot be inferred from its gel filtration retention time alone. 
The anomalous migration seen by gel-filtration can explain the notion that 
the IKK complex is a high-molecular weight complex.85,134 Both NEMO113,114 and 
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Figure 2.5: Analytical gel-filtration of NEMO variants. To measure the degree of aggregation, (A) 
wild-type, (B) 5xAla, and (C) 7xAla NEMO were treated with varying amounts of DTT and ana-
lyzed by analytical gel-filtration. Both wild-type and 5xAla (A, B) showed some degree of aggre-
gation in the absence of a reducing agent (first peak, blue lines), however the protein was reduced 
down to a monodispersed species with a minimal amount of reducing agent. 7xAla NEMO be-
haves much better, showing very little aggregation at all conditions tested. 
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IKKβ135–137 are known to adopt relatively elongated structures, which would be 
expected to migrate slower than a similarly sized globular protein. It is therefore 
likely that what was interpreted to be a large multimeric complex consisting of 
many molecules of NEMO and IKKβ was instead incorrect interpretation of the 
anomalous migration of an elongated 2:2 NEMO:IKKβ complex. 
For both wild-type and 5xAla NEMO, the aggregated component present 
in these preparations was largely eliminated by treatment with 1 mM DTT (Figure 
2.5a, b, red lines). In contrast to the other two constructs, 7xAla NEMO appeared 
relatively homogeneous by gel filtration, with only small amounts of higher mo-
lecular weight material that was not eliminated by inclusion of DTT. These results 
Figure 2.6: Binding groove in NEMO formed by the interaction with IKKβ.86 Three residues in the 
NEMO-binding domain of IKKβ, F734, W739, and W741, induce a pronounced groove into the 
surface of NEMO. 
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suggest that, even when wild-type NEMO is purified under stringently reducing 
conditions, it retains a propensity to form disulfide-linked aggregates. Moreover, 
these aggregates appear to be substantially mediated by Cys54 and/or Cys347, in 
that replacement of the five Cys residues at positions 11, 76, 95, 131 and 167 with 
Ala in the 5xAla mutant did not reduce the extent of aggregation.
2.3.3	 The	IKKβ	Binding	Activity	of	NEMO	Cys	Mutants	is	Equivalent
To assess whether the multiple Cys mutations in the 5xAla and 7xAla 
constructs affected the biochemical properties of NEMO, we tested the ability of 
each protein construct to bind to a peptide derived from the C-terminal domain 
of IKKβ.86 IKKβ(701-745) binds to the N-terminal domain of NEMO, occupying 
the groove that is formed when two NEMO molecules associate into a dimer to 
form an α-helical coiled-coil at the IKKβ-binding region. The NEMO dimer con-
tains two IKKβ binding sites, one on each face of the CC1 domain, leading to a 2:2 
binding stoichiometry with IKKβ (Figure 2.1).86 As shown in Figure 2.1, each IKKβ 
molecule makes extensive contact with the region of NEMO extending roughly 
between residues 44 and 111. This region of NEMO contains three Cys residues, 
at positions 54, 76 and 95, with additional Cys residues flanking the IKKβ binding 
region in both the N-terminal (Cys11) and C-terminal (Cys131, Cys167) directions 
(Figure 2.2). Comparison of the 5xAla and 7xAla forms of NEMO, which in the vi-
cinity of the IKKβ binding region differ only by the presence or absence of Cys54, 
provides a means to assess whether formation of a disulfide bond at this position 
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is important for IKKβ binding.
The binding of NEMO to IKKβ(701-745) was tested using a fluorescence 
anisotropy (FA) binding assay (see section 3.3.1 for a more thorough discussion of 
this method). A synthetic IKKβ(701-745) peptide labeled at the N-terminus with 
fluorescein isothiocyanate (IKKβ-fluorescein) was used as the tracer probe. FA 
works on the principle that when a fluorescently labeled ligand of low molecular 
weight is excited with plane polarized light, due to the ligand’s rapid tumbling in 
solution, the polarization observed in the emitted light is small. However, if the 
tracer probe binds to a large protein, the bound probe tumbles more slowly, lead-
ing to retention of more polarization in the emitted light. Thus, the degree of po-
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Figure 2.7: Confirmation that the NEMO anisotropy assay can measure binding to IKKβ. (A) The 
IKKβ-fluorescein peptide, when incubated in assay buffer, gave a low anisotropy signal in an un-
bound state. When the peptide was incubated with an excess of NEMO, the anisotropy increased, 
indicating that the peptide was bound by NEMO. (B) An unlabeled IKKβ-(45-mer) peptide com-
pletely inhibited the interaction between NEMO and IKKβ-fluorescein, showing that the interac-
tion of the IKKβ-fluorescein peptide and NEMO is specific and that inhibition can be measured 
and quantified under the assay conditions used for the experiment. 
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larization in the emitted fluorescence provides a measure of the fraction of tracer 
probe that is bound to the protein receptor.138,139 The theory and details of this as-
say are described in more detail in chapter 3. Figure 2.7a shows that inclusion of a 
molar excess of NEMO substantially increased the degree of anisotropy observed 
with 15 nM IKKβ-fluorescein. Moreover, the anisotropy could be returned to base-
line in a dose-dependent fashion upon addition of unlabeled IKKβ(45-mer) as a 
competitive inhibitor (Figure 2.7b). Fitting the data from inhibition experiments 
such as that shown in Figure 2.7b to a competitive binding model (Appendix IV) 
gave a value for the binding of unlabeled IKKβ-(45-mer) to 5xAla NEMO of 2.2 ± 
0.8 nM (n = 4).
We used the FA binding assay to compare the IKKβ binding affinity of 
wild-type NEMO with that of the 5xAla and 7xAla mutants (Figure 2.8). These 
binding measurements were performed either with or without pre-incubation 
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Figure 2.8: IKKβ binding activity of the NEMO variants measured by fluorescence anisotropy. The 
IKKβ-fluorescein peptide was incubated with various concentrations of NEMO in order to mea-
sure the affinity of recombinant NEMO for IKKβ. The affinity of IKKβ for wild-type (circles), 5xAla 
(squares), and 7xAla (triangles) was in the low nM range for all constructs with either (A) no DTT 
treatment or (B) with a 1 h treatment with 10 mM DTT, which is consistent with literature values 
for this interaction.
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with 10 mM DTT for 1 h. This concentration of DTT eliminated most high molecu-
lar weight aggregates from the 5xAla and 7xAla mutants (Figure 2.9), thereby en-
suring that these proteins were not covalently crosslinked monomeric under these 
assay conditions. In contrast, without pre-treatment with DTT the 5xAla NEMO 
exists primarily as a covalent dimer (Figure 2.9). As shown in Figure 2.8, incuba-
tion of 15 nM IKKβ-fluorescein with various concentrations of NEMO for 1 h gave 
a dose-dependent increase in anisotropy. Fitting the data for each NEMO con-
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Figure 2.9: SDS-PAGE of 5xAla (left) and 7xAla (right) under varying oxidation states. 5xAla NEMO 
was reduced to a mostly monomeric species when boiled with 100 mM DTT. When incubated with 
H2O2 (without boiling prior to separation), the protein predominately oxidized into a dimer. This 
dimer migrated slower than the expected molecular weight for a dimer (100 kDa), suggesting that 
this form of NEMO may be structurally different than the faster migrating dimer. 7xAla NEMO 
shows the expected bands upon similar treatment. It does not appear as though 7xAla NEMO can 
form the slow migrating dimeric structure, indicating that oxidation is primarily dependent on 
Cys54 and/or Cys347.
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struct to a quadratic binding equation (Equation 3.11) gave essentially identical 
values for the binding affinity of IKKβ-fluorescein, of KD = 7.4 ± 2.1 nM (n = 3) for 
wild-type NEMO, 2.8 ± 1.1 nM (n = 3) for 5xAla and 4.9 ± 0.6 nM (n = 3) for 7xAla, 
where the uncertainty limits represent one standard deviation. Under non-reduc-
ing conditions the binding data were essentially identical (Figure 2.8a), giving af-
finity values of KD = 9.5 ± 2.1 nM (n = 3) for wild-type NEMO, 6.8 ± 1.5 nM (n = 3) 
for 5xAla and 4.9 ± 1.9 nM (n = 3) for 7xAla. Comparison of the affinity of 5xAla 
NEMO for binding to IKKβ-fluorescein versus the unlabeled IKKβ(45-mer) pep-
tide as competitor (Figure 2.7b) showed that the presence of the FITC label does 
not greatly affect the binding affinity (full analysis in section 3.3.1). More impor-
tantly, our results show that the binding affinity of NEMO for IKKβ is unaffected 
by the presence or absence of Cys54, Cys347 or the five other cysteines outside the 
C-terminal zinc finger domain of NEMO. Moreover, when Cys54 and Cys347 are 
present, the binding affinity for IKKβ is unaffected by whether these two cysteines 
form inter-chain disulfide bonds to give a covalent NEMO dimer. 
The binding affinity of IKKβ peptides encompassing residues 701-745 for 
various truncated forms of NEMO has previously been reported as ranging from 
single digit nanomolar to ~1 μM, depending on the protein construct and mea-
surement method used.86,110,113 Binding of the same IKKβ peptide to a NEMO(2-
200) truncation via SPR gave an affinity of 75 nM, while inhibition assays using 
NEMO(2-200), GST-NEMO(1-196), and GST-NEMO(2-200) gave IC50 values of 15-
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30 nM, 1-7 nM and 47 nM, respectively.86,110 The affinity of a longer IKKβ peptide 
(residues 680-756) for NEMO(38-196) was measured to be 3.4 nM by SPR and 1 μM 
by ITC.113 The discrepancy seen between these two methods is likely due to the 
limitation of measurable affinities for ITC, which is only accurate at determining 
KD values from ~100 nM to 100 μM.
140 Taken together, our results show that our 
recombinant full-length NEMO constructs give IKKβ binding affinities compara-
ble to the highest affinities previously reported for various fragments or truncated 
forms of NEMO. Our results also show that the binding of NEMO to IKKβ is inde-
pendent of the presence of any cysteines in the region of NEMO extending from 
residues 1-395, and in particular is not affected by inter-chain disulfide bonding 
involving Cys54, in the IKKβ binding region of NEMO. 
It is important to note that the maximum anisotropy signal seen for wild-
type NEMO was 15-20% higher than that for the Cys variants. Anisotropy is a 
method that is based on molecular motion – a higher anisotropy signal means the 
labeled molecule or complex tumbles slower in solution, generally either because 
it is larger or differently shaped. In our experiments, the increased signal seen 
for wild-type NEMO suggests that there is a fraction of NEMO that is active in 
binding IKKβ but is present in a high-molecular weight aggregated complex. This 
result provides additional evidence of the high propensity of wild-type NEMO to 
aggregate, discouraging its use for detailed biochemical, biophysical, or structural 
study. 
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2.3.4 Active Site Titration Shows that NEMO Preparation is Fully Active
To further validate the quality of the Cys-mutant NEMO preparations, we 
used the FA binding assay to perform a binding site titration of the 5xAla protein, 
to determine what fraction of the protein in the preparation is active with respect 
to its ability to bind IKKβ. Active site titrations are a well-established approach for 
quantifying the amount of active protein present in enzyme preparations, but the 
use of equivalent methods to characterize non-catalytic proteins is less common.141 
By performing a binding titration under conditions where the fixed concentration 
component is present at levels well above the interaction KD, the resulting binding 
curve becomes quadratic rather than hyperbolic in form, and can be analyzed to 
determine the stoichiometric end-point of binding. In cases where the concentra-
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Figure 2.10: Binding site titration of 5xAla. The percent activity of the 5xAla preparation was ana-
lyzed by a binding site titration through the quantification of the titration end-point derived from 
five independent experiments in which the IKKβ-fluorescein peptide was added in at different 
concentrations. The calculated concentration of IKKβ-fluorescein fits well to the equivalence point 
derived from the curve fit (inset plot), indicating that the protein is near 100% active.
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tions of active ligand and receptor are accurately known, this approach can be 
used to determine the stoichiometry of complex formation.142–144 Alternatively, if 
the interaction stoichiometry is known, as is the case here for NEMO-IKKβ, the 
method can be used to determine the concentration of active material in a prepa-
ration of one binding component by titrating it against a solution of its binding 
partner of known concentration.86 We performed such a titration for 5xAla NEMO 
by incubating various concentrations of the protein against several fixed high 
concentrations of IKKβ-fluorescein ranging from 31.25-500 nM. IKKβ-fluorescein 
concentrations were standardized based on the absorbance of the labeled peptide 
measured at both 280 nm and 493 nm (section 2.2.5). Figure 2.10 shows that each 
titration gave a well-defined titration end-point, and that the position of the end-
point was more or less proportional to the concentration of IKKβ-fluorescein pres-
ent in the experiment (Figure 2.10 inset plot). The slope of the inset plot in Figure 
2.10, in which the titration end-point is plotted against the nominal concentration 
of IKKβ-fluorescein, has a value close to unity. Given that X-ray crystallography 
has shown that NEMO binds IKKβ in a 2:2 complex, this result indicates that es-
sentially all of the NEMO protein present in the 5xAla preparation is active with 
respect to its ability to bind to IKKβ.86
2.3.5 NEMO Functions as a Dimer as Measured by CD
Circular dichroism spectroscopy was performed on the NEMO variants in 
order to elucidate the relative secondary structure content and to assess whether 
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the absence of intermolecular disulfide bonds changes the global protein structure. 
One study has suggested that residues 44-11 of NEMO is disordered in the absence 
of IKKβ,86 and other studies have shown that many domains tend to form into 
coiled-coil structures.86,115–119 To determine the relative secondary structure content 
of NEMO variants, the CD spectra were measured with enough TCEP to reduce 
any aggregates while maintaining any beneficial disulfide bonds (Figure 2.11). 
While this method gives no information on the quaternary structure of NEMO, it 
is a useful for comparison of the degree of helicity among the three variants. The 
CD spectra contain negative bands at 208 and 222 (Figure 2.11a), which are charac-
teristic of a highly α-helical protein and is consistent with the crystal structures of 
various NEMO fragments and domains.86,118,119 Furthermore, the relative degree of 
helicity – normalized to the concentration - is identical among the three variants, 
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Figure 2.11: Circular dichroism spectra of NEMO variants. (A) The secondary structure content of 
each NEMO variant was analyzed by circular dichroism spectroscopy in order to assess the impor-
tance of the Cys residues on the integrity of the protein. The normalized spectra for each form of 
NEMO show a similar degree of α-helicity, as determined by the magnitude of the minima at 208 
nm and 222 nm. (B) The samples analyzed by CD were also analyzed by SDS-PAGE. Each NEMO 
form looks different by SDS-PAGE, however, the CD spectra indicate that these forms may look 
different when in a buffered solution that does not contain denaturing SDS. 
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confirming that the secondary structures of the proteins are most likely identical. 
One concern about this experiment, however, is that the 5xAla NEMO preparation 
is heterogeneous. As analyzed by a non-reducing and non-boiling gel, the 5xAla 
preparation that was tested by CD shows at least two species (Figure 2.11b). One 
form of the protein is covalently cross-linked, although it is not clear from these 
data which Cys residues are involved. The gel also shows a more intense band for 
a covalently monomeric species. In light of the similar IKKβ binding affinities of 
the three NEMO variants tested, it is likely that the covalently monomeric form is 
a stable non-covalent dimer in solution. When analyzed by SDS-PAGE, the SDS 
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Figure 2.12: Thermal stability of NEMO variants as measured by CD. Each NEMO variant was 
heated from 10-70 °C and unfolding of the protein was measured by monitoring the CD signal at 
222 nm. Each variant showed a similar melting curve and had a transition at approximately the 
same temperature. To determine the melting temperature, the first derivative of the melting curve 
was plotted (inset). The first derivative plot showed a peak at ~39 °C for each variant, signified by 
the gray dotted line, indicating that they are all equally stable. 
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efficiently disrupts the non-covalent dimer. Wild-type and 7xAla NEMO tend to 
appear as either fully dimeric/aggregated or fully monomeric, respectively. The 
thermal stability of the three NEMO variants was measured by heating the protein 
from 10-70 °C and monitoring the loss of helical structure through the CD signal 
at 222 nm (Figure 2.12). Each variant gave a melting temperature of ~39.5 °C, de-
termined from the peak in the first derivative plot of the melting curve (Figure 
2.12, inset), suggesting that the dimeric structure of NEMO is stable regardless of 
the presence of Cys11-347. However, if the protein equilibrates slowly compared 
to the thermal ramping rate, the melting curve will not represent true equilibrium 
melting behavior of the protein. Control experiments showed that thermal unfold-
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Figure 2.13: Comparison of the temperature ramping rate on 5xAla unfolding. 5xAla NEMO was 
heated from 10-70 °C using a thermal ramping rate of 0.33, 0.5, and 1 °C min-1 to assess whether un-
folding measured at these rates represents an equilibrium process. 5xAla NEMO unfolded with the 
same temperature (inset), and the melting curves appeared to be similar for each condition tested. 
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ing of 5xAla NEMO was independent of the thermal ramping rate at least up to 1 
°C min-1 and is therefore representative of the equilibrium thermal stability (Fig-
ure 2.13). Refolding was measured by cooling the melted protein from 70-10 °C. In 
each case, melting was shown to be largely reversible.
These data show that despite their multiple mutations, 5xAla and 7xAla 
NEMO appear to be structurally similar to wild-type NEMO. This result is sur-
prising given that there are numerous point mutations throughout NEMO that 
lead to severe diseases stemming from an inability of NEMO to signal properly in 
the NF-κB pathway, though none of these mutants involves any of the Cys resi-
dues mutated in these constructs.34 
2.3.6	 Dimerization	of	NEMO	is	Dependent	on	Specific	Cys	Residues
An outstanding question from the previous studies is whether Cys54 and 
Cys347 form inter-chain disulfides in the native form of NEMO. Figure 2.9 shows 
that with no treatment or with 10 mM DTT, 5xAla NEMO exists in a mixture be-
tween monomeric and dimeric states. However, when treated with H2O2, the pro-
tein is oxidized to a form that migrates slower by electrophoresis. To assess the 
IKKβ binding activity of the oxidized protein, various forms of 5xAla were tested 
in the FA binding assay. 
In order to adapt the assay to be performed in a non-reducing or oxidizing 
buffer, a variant IKKβ peptide was synthesized. The standard NEMO FA assay 
contains 1 mM DTT to maintain a slightly reducing environment and to inhibit 
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any gross aggregation of the tested protein. However, the IKKβ 45-mer peptide 
contains one cysteine, which may be able to form a disulfide bond. In the absence 
of a reducing agent, the anisotropy values for the peptide measured alone were 
higher than when treated with 1 mM DTT (Figure 2.14b). Furthermore, the raw 
fluorescence of the peptide measured under these conditions show that in the 
presence of DTT, the fluorescence of the peptide increases (Figure 2.14a). Fluores-
cein-based fluorophores have a significant degree of overlap between their emis-
sion and excitation, and fluorophores in close proximity can homoquench.139 The 
lower fluorescence seen when no reducing agent is present is thus likely indicative 
No DTT
1 mM DTT
0
10
20
30
40
Fl
uo
re
sc
en
ce
An
is
ot
ro
py
A) B)
50
60
70
80
90
Figure 2.14: Effect of a reducing agent on the measured anisotropy and fluorescence of the IK-
Kβ-fluorescein peptide. The wild-type IKKβ-fluorescein peptide contains one Cys residue which 
can form a non-native disulfide in an unbound state, potentially inhibiting its usefulness in binding 
assays lacking a reducing agent. (A) In an oxidized state, the fluorescence of the peptide was low 
due to homoquenching of the fluorophore. This homoquenching was relieved by the addition of 1 
mM DTT. (B) Similarly, when IKKβ-fluorescein was disulfide bonded, the fluorescent molecule is 
twice the molecular weight. This is apparent in the higher anisotropy signal seen for the peptide in 
a non-reducing assay buffer. 
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of homoquenching.139 Furthermore, the increased anisotropy under these same 
conditions indicates that the peptide exists in a larger state than when reduced 
(Figure 2.14b). These results indicate that the native IKKβ 45-mer peptide is able to 
form a disulfide bond. In the structure of NEMO bound to IKKβ, Cys716 of IKKβ 
is not positioned to form a disulfide bond, and a disulfide in at this position is like-
ly not biologically relevant (Figure 2.15). Binding of the wild-type IKKβ peptide 
should be performed under reducing conditions to minimize this phenomenon. 
However, this limits the study of the NEMO/IKKβ measured under non-reducing 
or oxidizing conditions. 
Figure 2.9 shows that in the absence of reducing agent or upon treatment 
with H2O2, 5xAla can form a slower-migrating species corresponding to a dimer 
that is cross-linked with more disulfide bonds. All of the FA binding data for 5xAla 
Figure 2.15: Structure of the NEMO/IKKβ interaction showing the presence of the Cys residue in 
IKKβ. Residue Cys716 of IKKβ is not in the appropriate position in the NEMO-bound state to form 
a disulfide bond. 
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shown above was measured under reducing conditions, thus the extent to which 
the fully oxidized dimer contributes to the affinity for IKKβ has not been quan-
tified. Furthermore, the question of whether formation of inter-chain disulfide 
bonds at Cys54 and Cys347 is relevant to the function of NEMO, and to what ex-
tent the oxidation of other Cys residues has on the function of NEMO has not yet 
been addressed due to the limitation that the standard NEMO FA assay needs a 
slightly reducing environment to minimize aggregation of NEMO and to disrupt 
the spurious IKKβ-fluorescein peptide. To study the interaction between 5xAla 
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Figure 2.16: Activity of 5xAla and 7xAla NEMO under reducing and oxidizing conditions. A vari-
ant IKKβ-fluorescein peptide in which Cys716 was mutated to Ser was used as the tracer probe to 
determine the dependence of the oxidation state of 5xAla on the activity. The Cys to Ser mutation 
reduced the affinity by ~10-fold in comparison to the wild-type peptide. Assuming that this weak-
er binding is resultant from the mutation, non-treated and reduced NEMO show no difference in 
binding to IKKβ. However, the affinity of oxidized NEMO by H2O2 was much weaker (~20-fold) 
than non-oxidized forms. 
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NEMO and IKKβ under varying oxidation states of NEMO, a mutant IKKβ-flu-
orescein peptide was developed in which Cys716 was mutated to Ser. The use of 
this mutant peptide avoids that complications of the spurious IKKβ disulfide for-
mation and thereby allows the assay to be performed with non-reducing buffers. 
Binding of 5xAla and 7xAla NEMO to this modified peptide was measured using 
the fluorescence anisotropy assay (Figure 2.16). The assay was performed without 
any DTT in the assay buffer such that the oxidation state of NEMO was unaffect-
ed by the assay buffer. The binding affinity for this variant IKKβ-(C-S) peptide 
measured for 5xAla pre-treated with 10 mM DTT (54 ± 11 nM, n = 3) or with no 
pre-treatment (60 ± 16 nM, n = 3) was similar to that of 7xAla (52 ± 11 nM, n = 3), 
indicating that fully or partially reduced protein is equally active in binding to 
IKKβ. The affinity measured for this interaction was ~20-fold weaker than that of 
the wild-type peptide, suggesting that the IKKβ Cys716 is important in binding to 
NEMO. Despite the weaker binding of this variant IKKβ peptide, these measure-
ments allow direct comparison of the effects of oxidation on IKKβ binding. When 
5xAla NEMO pre-treated with 5% H2O2 was tested in this assay, the affinity for 
IKKβ was ~5-fold weaker than any other condition (260 ± 30 nM, n = 3), indicating 
that this form of the protein is structurally different from the non-oxidized forms 
tested. It is not clear whether the oxidized form of the protein results from two 
disulfides at Cys54 and 347 or the Cys residues in the C-terminal zinc finger do-
main. The structure of the zinc-finger domain of NEMO shows that Cys396 is not 
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involved with zinc chelation and is solvent exposed (Figure 2.17). 
It is important to note that none of these assays were performed in assay 
buffers containing zinc. The NEMO zinc finger does bind zinc as part of the do-
main’s function,120 and a mutation of one of the zinc finger Cys residues to Phe 
is associated with a disease resulting from altered NEMO function, highlighting 
the biological importance of the domain.105 Furthermore, the Cys residues in the 
zinc finger are strictly conserved in all NEMO variants for which the sequence is 
available (Table 2.1). Two additional mutants were developed to probe the effect of 
mutating the zinc-finger Cys residues on the structure and IKKβ-binding function 
of NEMO (Figure 2.18). The 8xAla construct contains Cys to Ala mutations up to 
Figure 2.17: NEMO zinc finger structure.120 The zinc chelating residues in this domain involve 
Cys397, 400, and 417 and His413. Cys396, while close to the zinc-interacting residues, is oriented 
away from the zinc ion and may be pointing into solvent. 
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residue 396, leaving the zinc finger Cys residues intact. Additionally, an 11xAla 
construct was also developed in which every Cys residue, including the zinc finger 
domain residues, was mutated to Ala. These additional mutations involve cyste-
ines near the C-terminus of NEMO and were not expected to affect IKKβ binding. 
Furthermore, the zinc finger domain does not dimerize, and it is likely that the 
mutation of these Cys residues would have only a small effect on the structure of 
the protein. The ability of these two mutants to bind to IKKβ was tested (Figure 
2.19). The FA assay was performed identically to the measurements shown in Fig-
ure 2.8a – that is, the standard IKKβ-fluorescein tracer probe was used, in a buffer 
containing 1 mM DTT, and the NEMO protein was not pre-treated with DTT prior 
to testing. The measured affinity of 8xAla (5.3 ± 0.6 n = 2), and 11xAla (1.8 ± 0.7 n 
= 2) for IKKβ-fluorescein was similar to that observed previously for wild-type, 
5xAla, or 7xAla NEMO (Figure 2.8), showing that binding of IKKβ to NEMO is not 
8xAla 11 54 3471671319576 396, 397, 400, 417
7xAla 11 54 3471671319576 396, 397, 400, 417
396, 397, 400, 41711xAla 11 54 3471671319576
396, 397, 400, 4176xAla(11) 11 54 3471671319576
396, 397, 400, 4176xAla(54) 11 54 3471671319576
396, 397, 400, 4176xAla(76) 11 54 3471671319576
396, 397, 400, 4176xAla(95) 11 54 3471671319576
396, 397, 400, 4176xAla(131) 11 54 3471671319576
396, 397, 400, 4176xAla(167) 11 54 3471671319576
396, 397, 400, 4176xAla(347) 11 54 3471671319576
CC1 CC2 LZ ZF
Figure 2.18: Additional NEMO Cys mutant constructs. To probe the structure/function relationship 
of the Cys residues, a larger set of Cys to Ala mutants was developed. Cys residues are numbered 
in black text, and Cys to Ala mutants are indicated in red. 
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dependent on any of the 11 Cys residues. 
To probe the structural and stability of the 11xAla mutant, this protein was 
investigated by CD. Under non-reducing buffer conditions, 11xAla NEMO shows 
the same CD spectra as that of the constructs with fewer Cys mutations (Figure 
2.20a). Thus, the helical content of this construct is equal to that of the wild-type 
protein, and the overall secondary structure is likely unchanged. Furthermore, 
11xAla NEMO had a melting temperature of ~39.5 °C, identical to the other Cys 
mutants tested (Figure 2.20b). 
Taken together, the above results indicate that mutation of all 11 Cys resi-
dues in NEMO does not affect binding to IKKβ and does not affect the structural 
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Figure 2.19: IKKβ binding activity of 8xAla and 11xAla NEMO constructs. Both NEMO Cys mu-
tants were assayed in the NEMO FA assay in order to measure the affinity of these more extensive-
ly mutated constructs for IKKβ. The affinity of either NEMO construct for IKKβ was essentially 
equal to fully active NEMO. 
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integrity of the protein. This result is especially intriguing considering there are 
numerous mutations distributed along virtually the entire length of NEMO that 
cause significant diseases.105 However, it has previously been shown that muta-
tion of two zinc finger Cys residues in the murine NEMO ortholog causes impair-
ment in NF-κB signaling due to an inability of the IKK complex to phosphorylate 
IκB, because in addition to binding IKKβ, NEMO additionally serves to bridge 
IKKβ with IκB via interactions involving N-terminal and C-terminal sequences 
of NEMO, respectively.122 It is therefore likely that, despite the unperturbed IKKβ 
binding affinity of 11xAla NEMO, expression of this protein in NEMO-deficient 
cells would not restore NF-κB function. 
The above results establish that eliminating the seven Cys residues outside 
NEMO’s zinc finger domain greatly reduces the tendency of the protein to form 
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Figure 2.20: Circular dichroism spectra of 11xAla NEMO. (A) The CD spectra of the 11xAla NEMO 
construct was measured to assess the perturbation on secondary structure from eleven Cys to Ala 
mutations. The resulting spectrum contained minima at 208 and 222 nm with the same magnitude 
of the other NEMO variants tested. (B) The thermal stability of 11xAla NEMO was measured by 
heating the protein from 10-70 °C at a rate of 1 °C/min. The magnitude and shape of the curve was 
consistent with the other NEMO variants tested. The melting temperature, calculated from the first 
derivative, was ~39.5 °C (gray dotted line), in agreement with the other NEMO forms tested. 
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disulfide-linked aggregates. To gain more insight into which of these seven Cys 
residues can participate in inter-chain disulfide formation or formation of larger 
aggregates, we created a larger series of NEMO Cys mutants. The 5xAla construct 
was shown above to be able to form two different covalently dimeric species (Fig-
ure 2.9), presumably due to Cy54 and Cys347 oxidizing to different extents. The 
5xAla dimer that migrated with a higher apparent molecular weight on SDS-PAGE 
was not seen with the 7xAla construct, suggesting that the C-terminal Cys residues 
are not responsible for formation of this dimeric species. Starting from the 7xAla 
construct, the seven N-terminal cysteines were each in turn systematically mutat-
ed from alanine back to cysteine to generate seven “addback” 6xAla NEMO con-
structs (Figure 2.18). The addback constructs were analyzed by gel-electrophoresis 
to determine the degree of disulfide-mediated dimerization (Figure 2.21). Each 
variant, when boiled in sample buffer containing DTT, reduced down to a mo-
nomeric species (Figure 2.21, right). When the proteins were allowed to air oxi-
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Figure 2.21: NEMO Ala to Cys addback constructs. A series of addback mutants was created to 
determine the oligomerization state of constructs containing only one Cys residue in the 1-395 
region of NEMO. In the left gel, the proteins were separated by SDS-PAGE after air oxidation. The 
proteins in the right gel were fully reduced by boiling with 100 mM DTT. A dimeric species is seen 
with the Cys11, Cys54, Cys76, Cys167, and Cys347 constructs. 
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dize, the degree of covalent dimerization differed depending on the Cys residue 
present. As expected, a dimer was seen when Cys54 and Cys347 were present. 
The specific dimeric species seen for these two constructs, however, differed. The 
Cys54 addback variant migrated quicker as a dimer and seemed to oxidize to a 
greater extent than the Cys347 construct. Furthermore, the Cys347 dimer looked 
similar to that form seen when 5xAla NEMO is fully oxidized with H2O2.  These re-
Table 2.1: Conservation of the 11 Cys residues present in human NEMO among various NEMO 
orthologs. Nearly all of the Cys residues found in human NEMO are conserved among mammals. 
The Drosophila ortholog of NEMO (named kenny) only contains the orthologous zinc finger resi-
dues and Cys167. 
11 54 76 95 131 167 347 396 397 400 417
C C C C C C C C C C C
C C C C C C C C C C C
C C C C C C C C C C C
C C L - I C C C C C C
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C C C C C C C C C C C
C C C C C C C C C C C
C C C Q C R C C C C C
C C C Q C R C C C C C
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I I Q S T C L R C C C
Homo sapiens
Papio anubis
Pongo abelii
Pan paniscus
Otolemur garnettii
Saimiri boliviensis
Macaca mulatta
Callithrix jacchus
Callicebus moloch
Felis catus
Bos taurus
Canis lupus familiaris
Rhinolophus ferrumequinum
Ailuropoda melanoleuca
Sus scrofa
Mus musculus
Oryctolagus cuniculus
Rattus norvegicus
Cavia porcellus
Sorex areneus
Drosophila melanogaster
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sults suggest that Cys54 is responsible for the predominant dimeric form of 5xAla 
NEMO as seen in Figure 2.4 and Figure 2.9. Thus, the Cys54 residue is more easily 
oxidized than Cys347. Both of these cysteines are strictly conserved among mam-
malian NEMO orthologs (Table 2.1), suggesting that they an importance. Based on 
these results, it is likely that in vitro NEMO dimerization is only dependent on the 
presence of an intramolecular disulfide bond at Cys54. It is not clear whether this 
result has relevance to the functional form of NEMO in vivo. However, it is likely 
that if NEMO does form a disulfide-stabilized dimer in the cell, it would be cross-
linked at Cys54. 
Other Cys residues appear to induce covalent dimerization under air oxi-
dation. Cys11 is able to form a covalent dimer. There is no structural information 
of this region of NEMO, so a definitive conclusion as to the purpose of the pres-
ence of this residue cannot be derived. The structure of NEMO(44-111) (Figure 
2.1) indicates that neither Cys76 nor Cys95 is in a position to form inter-chain 
disulfide bonds in the active (IKKβ-bound) state.86 However, a dimer was seen 
for the Cys76 addback variant under non-reducing SDS-PAGE conditions and also 
when the protein was boiled with 100 mM DTT (Figure 2.21). It may be that in 
the absence of IKKβ binding, Cys76 is solvent exposed and a cross-link can form 
readily via that residue. This variant behaved poorly once purified and aggregated 
into visible particles almost immediately after purification. This is similar to the 
behavior for the wild-type NEMO construct that was purified under non-reducing 
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conditions. It seems that a cross-link at this position is not biologically relevant. 
The intracellular matrix is a reducing environment, and the formation of non-na-
tive disulfides from solvent exposed Cys residues likely does not occur. Therefore, 
a cross-link at Cys76 is probably not biologically relevant. Finally, the Cys167 add-
back mutant showed two bands corresponding to dimer. It is not clear whether 
this residue is positioned toward or away from solvent, as it is not present in any 
of the reported NEMO structures. However, Cys167 is the only Cys residue out-
side of the zinc finger domain that is conserved in the Drosophila NEMO variant, 
though in mammals it is conserved only among primates (Table 2.1). It is likely 
that there is some functional importance to this residue, and structural informa-
tion would shed some light on the importance of a disulfide at this position.
Overall, it seems as though the dimer formed by a disulfide crosslink at 
Cys54 represents a native dimer. Conversely, there is little evidence to suggest 
that the disulfides formed at Cys11, 76, or 347 are biologically relevant. The con-
servation of these residues throughout terrestrial mammals implies that these Cys 
residues are not detrimental to the proper functioning of NEMO in vivo.
2.4 Conclusions and Future Aims
A variety of NEMO Cys mutants has been developed in order to find a vari-
ant of full-length NEMO that is functional and is easily expressed and purified. 
The wild-type NEMO construct aggregated extensively and was purified at low 
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yields. The generation of mutant NEMO Cys to Ala constructs increased the yield 
and stability of the protein without hindering binding to IKKβ. Additionally, a 
construct in which all of the Cys residues were mutated to Ala proved to be equal-
ly stable and equally potent in binding to IKKβ to the other NEMO Cys variants, 
indicating that binding to IKKβ is not dependent on the presence of those Cys res-
idues, and that an intermolecular disulfide bonds are not necessarily important for 
stabilization of NEMO. These results are surprising, given the extensive conserva-
tion of these residues throughout terrestrial mammals (Table 2.1). In this construct, 
the zinc finger Cys residues were not expected to affect binding to IKKβ. However, 
mutation of these residues could hinder NEMO’s interactions with other binding 
partners in the cell.145,146 
Covalent dimerization of NEMO was determined to be primarily depen-
dent on the oxidation of Cys54. However, it is likely that NEMO function via the 
formation of a non-covalent dimer. Future characterization of the oxidation prop-
erties should be performed on a variant of the protein that has this residue mutated 
to Ala to limit the complications of having the extra potentially oxidizable residue. 
Overall, the multiple Cys mutant constructs retained IKKβ binding activity, 
global secondary structure, and thermal stability. The proteins were expressed to 
high yield and were soluble, compared to wild-type NEMO. Thus, these constructs 
are good candidates for development of screening assays to design inhibitors of 
the NEMO/IKKβ interaction. Furthermore, these constructs should be useful for 
further biochemical, biophysical, and structural characterization.  
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Chapter 3: Design of NEMO and Bcl-xL Assays for Inhibitor Screening and 
validation
3.1 Introduction
One of the major goals of this research project is to identify inhibitors of the 
NEMO/IKKβ PPI. Thus, the development of screening assays is a critical step to 
fulfill this aim. In this chapter, the techniques of fluorescence anisotropy (FA) and 
enzyme-linked immunosorbant asssay (ELISA) are used to develop several assays 
for identification and validation of inhibitors of the NEMO/IKKβ PPI. These two 
assays are widely used for inhibitor identification as they are relatively simple to 
set up and can be miniaturized to accommodate the screening of a large number of 
compounds fairly easily.147 The theory and application of these assays is described 
below. 
FA assays are ideal for primary screening assays as they are easy to design 
and execute. The anisotropy signal is robust and reproducible and is not prone to 
many sources of error. Additionally, the assay is homogeneous – all components 
are added at the same time, with no requirement for washing or other physical 
separation of bound from unbound ligand – and is easily adapted from a binding 
assay to an inhibition assay. FA is a method that takes advantage of the difference 
in molecular motion between molecules of differing size. This technique is repre-
sented in Figure 3.1, which illustrates the situation when a small fluorescently-la-
beled peptide binds to a larger protein binding partner. If a sample containing a 
67
fluorescent molecule is irradiated with plane polarized light, those molecules in 
which the fluor is aligned with the polarized light vector will become excited. Spe-
cifically, molecules that have their fluorescent dipole aligned with the electric field 
vector of the incident light will become excited. The excited molecules can diffuse 
during the excited state lifetime of the fluorophore. The emission light thus loses 
polarization based on the degree of motion during the fluorescent lifetime, as the 
orientation of the fluorophore randomizes in the brief period between excitation 
and emission of the fluorophore. This phenomenon is referred to as depolariza-
A) B)
Excitation Emission EmissionExcitation
Polarization
Vector
I║
I┴
I║
I┴
Polarization
Vector
Figure 3.1: The principle of fluorescence anisotropy. (A) Top – A small fluorophore is irradiated 
with plane polarized light, but due to its rapid tumbling in solution it partially loses the polariza-
tion in the emission wave. Bottom – The ratio of emission light in the vector parallel to the polariza-
tion vector is not very different from the emission light in the perpendicular vector. (B) Top – If the 
fluorophore binds to a high molecular weight partner causing it to tumble slower, more emission 
light retains polarization. Bottom – the emission light is highly centered around the polarization 
vector and the magnitude of the intensity in this vector is greater than in the perpendicular vector. 
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tion, and the degree of depolarization is dependent primarily on the rotational 
correlation time of the molecule (Equation 3.1). Thus, by measuring the degree to 
which the initial polarization is retained in the emitted light, it is possible to mon-
itor the binding of a small fluorescently labeled ligand to a larger unlabeled recep-
tor, provided that the increase in the correlation time of the ligand upon binding 
is sufficiently large, and that a fluorophore with an excited state of appropriate 
lifetime is chosen. 
The rotational correlation time of a molecule is a measure of the rotation of 
a protein in solution (θ), and depends on the viscosity of the solution (η), the vol-
ume of the molecule (V), the gas constant (R), and the temperature of the system 
(T). Anisotropy is a measure of the degree of depolarization. It is a function of the 
fluorescence lifetime of the fluorophore, which describes the amount of time that 
the fluorophore remains in an excited state, and the rotational correlation time of 
the protein (Equation 3.2). In this equation,  is the anisotropy value if the fluoro-
phore were static in solution and thus retained the maximum possible degree of 
polarization,  is the measured anisotropy of the fluorescently-labeled ligand under 
the conditions of the experiment,  is the fluorescence lifetime, and  is the rotational 
Equation 3.1
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correlation time of the molecule to which the fluorophore is attached. 
 To study a ligand-receptor interaction, the bound and free states should 
have correlation times that can be resolved during the lifetime of the fluorophore 
– that is, the fluorescence lifetime should ideally be long compared to the correla-
tion time of the small unbound ligand, but short compared to that of the large 
and slower-tumbling bound complex. The figure of merit (Φ) is a function derived 
from Equation 3.1 that quantifies the degree to which a fluorophore with a given 
fluorescence lifetime adequately resolves the anisotropy of the bound and free 
states of an interaction between a ligand and receptor of defined size (Equation 
3.3). This function essentially compares the difference in anisotropy of the bound 
and free states of the fluorophore. To determine whether a fluorophore can max-
imally resolve the two states of a ligand-protein interaction, one must know the 
correlation time of each state. The correlation time of a protein can be estimated 
using Equation 3.4, which is a derivation of Equation 3.2 for spherical or globular 
proteins. In this equation, v is the specific volume of the protein, and h is the de-
gree of hydration. The specific volume for globular proteins can be approximated 
to 0.73 ml/cm, and the hydration is typically 0.23 grams H2O per gram of protein.
139 
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However, this equation only works well for globular proteins, where the shape is 
roughly spherical. For non-globular proteins, the correlation time can be calculat-
ed if the frictional ratio and axial ratio are known (see Appendix I). The frictional 
ratio describes the forces of a fluid on the rotation of a macromolecule, and can be 
calculated by a sedimentation-based method such as analytical ultracentrifuga-
tion.148 If the shape of a protein is simplified to a sphere or ellipsoid, the axial ratio 
is calculated from the length and width of the sphere or ellipse, and thus can be 
calculated from the frictional ratio (Appendix Equation 2).148 
In practical terms, anisotropy is measured by irradiating a fluorophore with 
plane polarized light and comparing the degree of polarized emission light detect-
ed in planes parallel and perpendicular to the original polarization plane (Figure 
3.1, Equation 3.5). In the literature there is sometimes confusion over the use of flu-
orescence anisotropy versus fluorescence polarization (FP) as a measure of the ex-
tent of depolarization. The term fluorescence polarization refers to the same type 
of assay, and is often used for high-throughput screening assays. FP is performed 
identically to the FA assay we have used in this study; however, the signal is cal-
culated differently. Specifically, FA is calculated from Equation 3.5, whereas FP is 
Equation 3.5
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r
I I
I I
=
+
−
1000
2
*
*
Parallel Perpendicular
Parallel Perpendicular
P
I I
I I
=
+
−
1000*
Parallel Perpendicular
Parallel Perpendicular
71
calculated using the slightly different equation shown in Equation 3.6.
In these equations, IParallel refers to the intensity of emitted light that is polar-
ized in the same plane as the original polarization vector, while IPerpendicular refers to 
the intensity of light polarized at 90° to the polarization vector (Figure 3.1). Anisot-
ropy, is normalized to the fluorescence contribution of the light wave in all three 
dimensions (Equation 3.5), whereas the polarization signal (P) is only normalized 
in two dimensions (Equation 3.6). The practical consequence of this difference is 
that the total FA signal is simply the weighted average of the FA signals of the 
different unbound and bound forms of the ligand in the reaction, whereas for FP 
the relationship between total FP signal and the concentrations of the species that 
Figure 3.2: NEMO binding and inhibition scheme. The IKKβ 45-mer peptide is conjugated to a 
fluorescein-derived fluorophore (IKKβ-fluorescein). (A) Direct binding of IKKβ-fluorescein as 
measured in the anisotropy assay. IKKβ-fluorescein in the unbound state has a faster tumbling 
rate than in the bound state, causing a higher degree of depolarization and resulting in a lower 
anisotropy value. (B) Competitive inhibition is measured by displacement of the IKKβ-fluorescein 
peptide with unlabeled IKKβ. 
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contribute is more complicated. Consequently, FA is more straightforward for the 
performance of quantitative biochemical binding and inhibition assays.138,149 
In this study, FA is used to measure the interaction of NEMO with a peptide 
derived from the NEMO binding domain of IKKβ (residues 701-745, Figure 3.2). 
The interaction of NEMO with IKKβ has been studied extensively and is known 
to be a high affinity interaction.86,110,113 Additionally, the frictional ratio of a NEMO 
construct containing residues 1-355 has been measured by sedimentation velocity 
analytical ultracentrifugation to be 2.3.114 If we can assume that the 45-mer IKKβ 
peptide is unstructured in solution, there is enough information to guide the de-
sign of a fluorescence anisotropy screening assay. Furthermore, because this assay 
is homogeneous, all assay components can be incubated with inhibitors allowing 
for easy adaptation of this assay to an inhibitor screening assay. 
Enzyme-linked immunosorbent assays (ELISA) are widely used assays for 
detecting and quantifying biomolecules, and for identifying and validating inhib-
itors.150 The type of ELISA used for this project is called a sandwich ELISA, as the 
interacting proteins are captured and detected using secondary proteins that aren’t 
directly involved with the interaction. These secondary proteins instead bind to a 
recognition tag on either protein (Figure 3.3). In contrast to the FA assay, ELISAs 
are heterogeneous and thus require that each protein reagent is captured on the 
assay plate separately, with a wash in between each step to remove any unbound 
reagent. Formation of the PPI complex is quantified by detecting one binding part-
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ner with a horseradish peroxidase (HRP)- conjugated antibody or streptavidin. 
HRP then enzymatically oxidizes colorless 3,3’,5,5’-Tetramethylbenzidine (TMB) 
into a colored product. The measured color intensity is proportional to the con-
centration of captured HRP, and thus to the amount of captured binding partner, 
assuming that the absorbance values conform to Beer’s law. The assay this gives a 
simple colorimetric signal, which differs from the fluorescence-based anisotropy 
signal in the FA assay. 
Inhibition ELISAs can be performed in two different formats. The first is 
by simply incubating the inhibitor with the immobilized target protein and letting 
the reaction come to equilibrium before adding the binding partner. This method 
Figure 3.3: NEMO-capture (left) and IKKβ-biotin-capture (right) ELISAs. (A) In the NEMO-capture 
format, an antibody that recognizes a 6xHis tag is used to capture NEMO on an assay plate. Forma-
tion of the NEMO/IKKβ PPI is detected by binding streptavidin-HRP to biotinylated IKKβ-biotin, 
and TMB oxidation by HRP results in a colored readout. (B) The IKKβ-capture format is an inverted 
version of the NEMO-capture assay. IKKβ-biotin is captured on an assay plate with streptavidin. 
Bound NEMO is detected via the 6xHis tag using nickel chelated by the HisProbe-HRP reagent. 
Formation of this complex is similarly detected by the oxidation of TMB. 
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is useful only if the inhibitor is expected to bind to the immobilized protein rather 
than to the other binding partner that is added subsequently, as is the case in the 
NEMO-capture ELISA (Figure 3.3).150 Conversely, if the inhibitor is expected to 
bind to the soluble binding partner rather than to the immobilized ligand, as with 
the IKKβ-biotin capture ELISA (Figure 3.3b), the inhibitor can be pre-incubated 
with the soluble binding partner prior to adding this reagent to the assay plate.151 
There are several considerations when adapting a binding assay to measure 
inhibition by screening chemical libraries. The assay must be sensitive to inhibition 
and must give a robust and reliable signal. The concentration of the labeled ligand 
(tracer probe) must be chosen such that the assay sensitivity is high. If the tracer 
probe concentration is too low, the assay signal will either be undetectable by the 
detection instrument or the error propagated from the instrument will be large 
compared to the signal or signal range. The concentration of inhibitor that gives a 
50% signal decrease in the assay is termed the IC50. The IC50 is related to the true 
binding affinity of the inhibitor for its target by the Cheng-Prusoff Relationship:152
This formula (Equation 3.7), which reflects the competition between inhib-
itor and tracer probe for binding to the target, relates the measured IC50 with the 
concentration and affinity of the tracer probe ([L] and KD, respectively), allowing 
Equation 3.7
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the true binding constant for the inhibitor to be calculated from a measured IC50. 
This relationship shows that, for a competitive inhibitor measured under equilib-
rium conditions, the observed IC50 exceeds the inhibitor’s KD by a factor of the de-
nominator in Equation 3.7. Consequently, the assay “ceiling” – the lower limit of 
inhibitor potency that the assay can detect – is a factor of this denominator larger 
than the inhibitor’s actual binding constant. The assay ceiling, which corresponds 
to the sensitivity of the assay to weak inhibitors, can be increased by decreasing 
the tracer probe concentration and thus minimizing the factor relating IC50 and KD. 
Conversely, the assay “floor” is a measure of the highest IC50 the assay can detect. 
The expected IC50 for an inhibitor of a given binding affinity for the target 
can be determined by Equation 3.8. This equation is derived from the mass-bal-
ance equations relating the distribution of total protein and inhibitor concentra-
tion among bound and free states. For infinitely potent inhibitors, Equation 3.8 
is dominated by the value of half of the protein concentration, which is the assay 
floor.
The type of curve fit used to interpret binding data is dependent on the 
concentration of the tracer probe relative to the binding affinity. When the tracer 
probe concentration is much smaller than the KD value, depletion of the tracer 
probe due the formation of the protein-ligand complex is negligible. Under this 
Equation 3.8IC K ProteinI T50
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assumption, the data can be fitted to a simple hyperbola. The KD is equal to the 
concentration of the titrated component that gives 50% signal. However, when the 
tracer probe is close to or above its KD, the effect of ligand depletion due to binding 
must be accounted for in the binding model. A more complex quadratic binding 
model must be used in this situation. Consequently, this relationship between the 
KD and tracer probe affects the fitting of inhibition data as well. When the protein 
concentration is low compared to the KI of the inhibitor, the data can be fitted to 
a four-parameter curve fit. The IC50 from this curve fit is related to the KI from the 
Cheng-Prusoff shift. If the protein is present in the assay close to or above its KI, 
fitting the inhibition data becomes non-trivial, and may not be modeled easily 
by a four-parameter fit. In cases where a four-parameter fit does fit the data well, 
the Cheng-Prusoff relationship can be used to determine KI. However, when a 
four-parameter fit does not adequately model the data, the IC50 is not relatable to 
the KI by a simple derivation such as the Cheng-Prusoff relationship, and more 
complex models need to be applied.153 One way to determine the KI of the inhibi-
tor, which is used in this study, is by using a numerical fitting algorithm to fit the 
inhibition curve.153,154
 Assay robustness is related to the precision of the assay signal. Robustness 
is measured by the coefficient of variation (%CV) and the Z’-factor. The %CV is 
a measure of how the standard deviation (σ) compares to the mean assay signal 
measured for a positive control sample, expressed as a percentage (Equation 3.9). 
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A low %CV – under 5-10% – represents good precision and reproducibility of the 
assay signals. 
The Z’-factor (Equation 3.10) is another measure of robustness that is cal-
culated using the variation of the positive and negative controls compared to the 
range between the controls.155 The Z’-factor is a measure of the distribution of error 
around the positive and negative controls and whether the range between these 
values allows for the experimental values to be statistically distinct from them. 
This value is normalized to 1, which would describe an assay that had no devia-
tion in the assay controls and thus could perfectly discriminate between a positive 
and a negative result. Lower Z’-factors correspond to lower degrees of fidelity of 
the assay measurements. Adequate assay precision corresponds to a Z’-factor of 
0.5 or above.153,155  A low Z’-factor can be due to either high deviation in the assay 
signal, or a working range (i.e. a difference between positive and negative assay 
signal) that is too small. The Z’-factor can be improved by reducing the error, or 
increasing the range of the assay signals by increasing the protein or tracer probe 
concentration. However, increasing the range will likely reduce the assay sensitiv-
ity. 
In this chapter, I have developed assays to detect and quantify inhibition 
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of the interaction between NEMO and IKKβ, and validated that they are robust 
under the conditions used for screening compounds. All NEMO assays used the 
5xAla construct because, as shown in the previous chapter, this construct behaves 
well in solution, can be purified to the highest yield among the set of mutants, and 
retains full wild-type activity with respect to IKKβ binding. A fluorescein-labeled 
45-mer peptide derived from the NEMO binding domain of IKKβ was used in the 
FA assay as the tracer probe. As we show, fluorescein has a fluorescence lifetime 
that is appropriate to resolve the bound and free states when this labeled peptide 
binds to full-length NEMO. The ELISA an IKKβ peptide with the same sequence, 
but that is biotinylated rather than fluorescein-labeled, to allow detection using 
HRP-labeled streptavidin. Additionally, I describe the development of another FA 
assay using the Bcl-xL/BAK interaction, for use as a counter screen to identify 
non-specific inhibitors. This assay uses Bcl-xL protein and a fluorescein labeled 
peptide derived from the BH3 domain of Bcl-xL’s binding partner BAK. 
3.2 Materials and Methods
3.2.1 Materials
The 5xAla construct was used as the NEMO reagent for all assays, and was 
prepared as described in section 2.2.2. All IKKβ peptides used in this chapter were 
based on the 45-mer sequence that has been highly characterized.86,113,123,124 The se-
quences of the IKKβ peptides are listed in Table 3.1. IKKβ-fluorescein was used for 
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fluorescence anisotropy assays and contains fluorescein conjugated to the N-ter-
minus via a flexible aminohexanoic acid (Genscript, Piscataway, NJ). The unla-
beled IKKβ-(45-mer) peptide was donated by Biogen. IKKβ-click was synthesized 
by 21st Century Biochemicals (Marlboro, MA) with an N-terminal propargyl gly-
cine residue. The α-His antibody, streptavidin, streptavidin-HRP, HisProbe-HRP, 
and TMB were purchased from Pierce. For the ELISA blocking buffers, non-fat dry 
milk was purchased from Bio-Rad, and BSA was purchased from Fisher. The gene 
for Bcl-xL was obtained from Addgene (#8790), and the BAK-fluorescein peptide 
was synthesized by Genscript (sequence in table 3.1)
3.2.2 NEMO/IKKβ	Fluorescence	Anisotropy	Assays
Several variations on the FA assay were used for this chapter. Each NEMO/
IKKβ FA assay was performed in 96-well or 384-well polypropylene black plates 
(Corning, Corning, NY) using a total volume of 200 μL. Each individual concen-
tration tested was performed in triplicate, and each assay was done at least three 
Table 3.1: Amino acid sequence of peptides used for binding to and inhibiting NEMO and Bcl-xL. 
Each peptide was synthesized with an amino-group at the N-terminus and a carboxy group at the 
C-terminus, except for the fluorescent peptides. FITC stands for fluorescein isothiocyanate, Ahx 
is an aminohexanoic acid linker between FITC and the peptide, Pra is a click-reactive propargyl 
glycine residue, and Peg is polyethylene glycol.
IKKβ-(45-mer) H3N-PAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWS-
WLQTE-OH
IKKβ-fluorescein FITC-Ahx-PAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWS-
WLQTE-OH
IKKβ-click H3N-Pra-PAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWS-
WLQTE-OH
IKKβ-biotin H3N-Pra(PEG3-Biotin)-PAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFT-
ALDWSWLQTE-OH
BAK-fluorescein FITC-GQVGRQLAIIGDDINR-OH
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times. The assay buffer contained 50 mM Tris pH 7.4, 200 mM sodium chloride, 
0.01% v/v Triton X-100, and 1 mM dithothreitol (DTT). Assays were incubated for 
1 h at 25 °C unless otherwise noted. The parallel and perpendicular fluorescence 
readings were measured using a SpectraMax M5 plate reader (Molecular Devices, 
Sunnvyale, CA) at 488 nm excitation wavelength and a 520 nm emission wave-
length. The anisotropy values were calculated first by subtracting the fluorescence 
contribution of the buffer and then using Equation 3.5. 
A direct binding experiment was performed to measure the affinity of IK-
Kβ-fluorescein for NEMO. In this format, NEMO was serially diluted by half in 
an assay plate and IKKβ-fluorescein was added at a fixed, final concentration of 
15 nM. This format was also used to validate whether equilibrium was reached by 
incubating for 30 min, 1, 2, 4, 6, and 24 h prior to reading. Direct binding titrations 
were fit to a quadratic binding equation (Equation 3.11). Instead of seeing satu-
rating signal corresponding to complete binding of IKKβ-fluorescein to NEMO, 
there is an increase in the anisotropy signal at high NEMO concentrations. For the 
purposes of this chapter, this extra signal was incorporated into the direct binding 
fitting equation as an extra background term, denoted by m[R]T. 
To adapt the assay for inhibition measurements, NEMO was fixed at 15 
nM. Inhibition of the NEMO/IKKβ-fluorescein complex was measured by serially 
Equation 3.11
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diluting an unlabeled IKKβ peptide (Table 3.1) two-fold, followed by the addition 
of NEMO, assay buffer, and IKKβ-fluorescein. Wells containing only NEMO and 
IKKβ-fluorescein or only IKKβ-fluorescein were included as positive and nega-
tive controls, respectively. Individual inhibition curves were fit using a numerical 
model in DynaFit (Appendix IV) that includes separate terms for NEMO binding 
to labeled IKKβ-fluorescein and to IKKβ-(45-mer). The KD values for each replicate 
were averaged. 
The assay floor was modeled using DynaFit and the script in Appendix 
IV.156 This script incorporated the binding of IKKβ and an inhibitor to NEMO. The 
KD for IKKβ binding was fixed at the experimentally determined value of 5.4 nM. 
The inhibition curve was modeled for inhibitors with KIs ranging from 0.0001-100 
nM. 
The assay statistics were measured using replicates of the inhibition assay 
controls in both 96-well and 384-well plates. Half of the plate was devoted to the 
positive control replicates and the other half for the negative controls. The positive 
control wells contained 15 nM NEMO and 15 nM IKKβ-fluorescein, whereas the 
negative control wells contained 15 nM IKKβ-fluorescein only. The assay was per-
formed identically to the standard FA assay protocol. The CV was calculated for 
the positive and negative controls separately using Equation 3.9. The Z’-factor was 
calculated using Equation 3.10. 
Any compounds tested in this assay will likely need to be assayed in the 
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presence of DMSO to retain solubility. To test the degree with which DMSO per-
turbs the assay signals, DMSO was serially diluted two-fold from a concentration 
of 20% v/v. Three controls were measured at each concentration of DMSO repre-
senting complete binding of IKKβ-fluorescein to NEMO (high value), IKKβ-flu-
orescein in the absence of NEMO (low value), and partial inhibition with 20 nM 
of unlabeled IKKβ. The DMSO limit was determined qualitatively from the point 
where the assay signal degraded to a level that would hinder the assay robustness. 
A set of miscellaneous organic macrocyclic compounds was provided by 
the Boston University Center for Library and Methodology Development and was 
tested in the NEMO FA assay to gauge whether the assay is perturbed by the in-
clusion of small, organic compounds. These compounds were screened at 10 μM 
in the assay in the presence of 2.5% v/v DMSO. A sub set of these compounds 
was re-tested in a dose-response format to further gauge any effects of organic 
compounds on the assay fidelity. Four compounds were tested in this way, and 
they include the three compounds that initially gave the lowest anisotropy signal 
(MC2, MC10, and MC11) and one with the highest (MC19). These compounds 
were serially diluted by half in an assay plate starting at 50 μM in the presence of 
2.5% DMSO. 
3.2.3 Preparation	of	IKKβ-biotin
The IKKβ-click peptide (Table 3.1) was biotinylated with Biotin-(PEG)3-Azide 
using copper catalyzed click chemistry.  A 200 μM sample of the peptide was in-
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cubated with 1% SDS for 5 min and then a 10-fold excess of Biotin-(PEG)3-Azide 
was added. The Click-iT Protein Reaction Buffer kit (Invitrogen, C10276) was used 
to label the peptide, following the associated protocol. The reaction was purified 
on a Superdex Peptide 10/300 column (GE Healthcare) using 30% acetonitrile/70% 
water, 0.125% ammonium hydroxide and a flow rate of 0.4 mL min-1. The fractions 
corresponding to labeled peptide were pooled and concentrated using a 3K molec-
ular weight cutoff Amicon Ultra-4 Centrifugal Filter (EMD Millipore). The peptide 
was further purified on a RESOURCE RPC 3 mL column (GE Healthcare) using a 
buffer system of 0.125% ammonium hydroxide in water and 80% acetonitrile/20% 
water, 0.125% ammonium hydroxide and a flow rate of 3 mL min-1. The labeled 
peptide fractions were concentrated using Amicon Ultra-4 Centrifugal Filter and 
the mass was confirmed using ESI –MS. 
3.2.4 Development	of	an	ELISA	for	Detection	of	NEMO/IKKβ	Binding
The ELISA was developed in two ways, denoted either “NEMO-capture” 
or “IKKβ-biotin capture” (Figure 3.3). All ELISAs were performed using Nunc 
Maxisorp 96-well plates and each component was added at 100 μL except for the 
blocking buffer, which was 300 μL. A series of controls was run on each plate in 
duplicate to ensure that all steps were performed properly. These controls were 
treated in the same way as the non-control wells except that the capture mole-
cule (anti-6xHis antibody or streptavidin), NEMO, IKKβ-biotin, or the detection 
reagent (streptavidin-HRP or HisProbe-HRP) was omitted. The wash buffer and 
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assay diluent used was 100 mM phosphate, 200 mM sodium chloride, 0.05% v/v 
Tween-20. For the NEMO and IKKβ-biotin capture steps, 1 mM DTT was added 
to the assay diluent to keep cysteine-mediated aggregation minimal, as with the 
NEMO FA assay. All concentrations were tested in triplicate. 
In the NEMO-capture ELISA, a plate was coated with 1 mg/mL anti-6x-His 
antibody (Thermo Scientific) diluted in 50 mM bicarbonate, pH 9.6 overnight at 4 
°C. The plate was washed using a Nunc Plate Washer (Thermo Scientific) by re-
peated filling and aspiration of the wells with wash buffer). The washing step was 
performed three times in between capturing steps. The plate was blocked with 300 
μL of either 1% w/v BSA, 3% w/v BSA, or 3% non-fat dry milk for 2 h. This and all 
subsequent steps were performed at 25 °C. NEMO was then captured on the plate 
followed by the addition of IKKβ-biotin. Formation of the NEMO/IKKβ complex 
was detected using streptavidin-HRP, which was incubated for 30 min. Strepta-
vidin-HRP was visualized by the enzymatic oxidation of the 1-Step Ultra TMB 
reagent. TMB oxidation was allowed to proceed from 5-15 min until a sufficiently 
blue color developed. The reagent was then quenched with 2 N H2SO4 and read at 
450 nm.  
The IKKβ-biotin capture ELISA format was run identically except for the 
following differences. The assay plate was coated with 1 mg/mL streptavidin 
(Thermo Scientific) overnight at 4 °C. IKKβ-biotin was captured first, and then 
NEMO was incubated with the captured IKKβ-biotin. The HisProbe-HRP reagent 
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was incubated for 15 min to detect the IKKβ-biotin/NEMO complex. The plate was 
washed six times after HisProbe-HRP incubation. 
To determine the optimal coating concentration of NEMO for the NE-
MO-capture format, an ELISA was performed in which NEMO was titrated two-
fold along the columns and IKKβ-biotin was titrated two-fold along the rows. The 
optimal streptavidin-HRP dilution was determined concurrently using four di-
lutions of the streptavidin-HRP reagent. For the IKKβ-biotin capture ELISA, IK-
Kβ-biotin was coated at 25 nM. The HisProbe-HRP reagent performed sufficiently 
at the manufacturer’s recommended dilution of 1 μg mL-1.
A titration of the detected analyte was measured to determine the apparent 
KD. The resulting binding curves were fit to a quadratic equation (Equation 3.12)
in which A450 nm represents the absorbance at 450 nm, P is a proportion constant re-
lating the max signal to the molar units, and Min is the baseline absorbance value. 
To adapt the NEMO-capture assay for inhibition, the assay was performed 
with 25 nM of NEMO and 0.5 nM IKKβ-biotin. To validate that inhibition can be 
measured in this format, the unlabeled IKKβ-click peptide was measured as the 
inhibitor. IKKβ-click was serially diluted two-fold starting at 10 μM in a volume 
of 100 μL and incubated for 30 min. IKKβ-biotin was then added at 1 nM directly 
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to the plate in 100 μL and incubated for 30 min. Because the plate was not washed 
in between these two steps, the final concentration of IKKβ-biotin was 0.5 nM. The 
remainder of the assay was performed as previously discussed. 
Measurement of inhibition using the IKKβ-biotin capture assay was per-
formed as a “Friguet”-ELISA.151 The unlabeled IKKβ-click peptide was serially di-
luted two-fold in a separate plate and incubated with NEMO for 1 h. The NEMO/
IKKβ-click mixture was transferred to the ELISA plate for the NEMO incubation 
step. Only NEMO that was not bound to the unlabeled peptide would be able to 
bind to immobilized IKKβ-biotin. Both inhibition curves were fit using a four-pa-
rameter curve fit (Equation 3.13). 
The assay statistics were measured for both of these ELISA formats. The 
assay buffer was used in place of an inhibitor. One column of the ELISA plate was 
reserved for the assay controls where one component of the assay was omitted to 
ensure the assay was functioning normally.  The rest of the wells were divided in 
half to serve as replicates for the positive controls (NEMO and IKKβ-biotin) or the 
negative control (only NEMO or IKKβ-biotin). The assay signals were averaged 
and the CV and Z’-factor were calculated as with the NEMO FA assay. 
The tolerance of the NEMO capture ELISA to DMSO was measured. The 
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assay was run in the inhibition format, where first DMSO was incubated in the 
assay plate for 30 mins and IKKβ-biotin was added and incubated for a further 
30 min. DMSO was serially diluted two-fold starting from 25% v/v and added in 
place of an inhibitor. 
3.2.5 Development of Bcl-xL FA Assay
The gene for Bcl-xL was synthesized with codon optimization and inserted 
into the pET24b(+) plasmid by Genscript (Appendix II). The C-terminal region, 
which contains a transmembrane domain, was excised from the plasmid using the 
QuickChange method.53 Primers were developed to connect the 1-209 region of 
Bcl-xL to the plasmid 6xHis-tag to effectively ‘pinch’ out the C-terminal portion of 
the protein (Appendix IV). The truncated Bcl-xL(1-209) plasmid was transformed 
into NEB T7 Express IQ competent cells for protein expression. To produce recom-
binant Bcl-xL(1-209), a culture of the transformed cells was inoculated in of LB 
with kanamycin and grown overnight at 37 °C. A larger culture was inoculated 
with a 1:200 dilution of the overnight culture and allowed to grow at 37 °C until 
the absorbance at 600 nm reached 0.4-0.6. The culture was induced for protein ex-
pression with 1 mM IPTG and was grown for three more hours. 
Cells were lysed by adding Bacterial Permeabilization Reagent (B-PER, 
Pierce) at 4 mL/g of cell pellet along with 2.5 mg/mL lysozyme (Pierce), 5 mg/mL 
streptomycin sulfate (Gold Bio), 10 μL/mL Halt Protease Inhibitor Cocktail (Ther-
mo Scientific), and 0.2% v/v DNase I (Pierce). The lysate was incubated for 30 min 
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at 4 °C, clarified by centrifugation at 38,000 RPM for 30 min, and filtered through a 
0.8 μm filter. The prepared lysate was applied to a 5 mL HisTrap FF crude column 
(GE Healthcare), followed by 5 column volumes of 20 mM phosphate, 500 mM 
NaCl, 40 mM imidazole, at pH 7.4. The bound protein was eluted from the column 
using a step gradient of increasing concentration of 20 mM phosphate, 500 mM 
NaCl, 500 mM imidazole, at pH 7.4. The protein was concentrated and applied 
to a HiPrep 26/60 Sephacryl, S-300 HR column (GE Healthcare) equilibrated with 
20 mM phosphate, 500 mM NaCl, at pH 7.4. Purified protein was concentrated 
using 10K molecular weight cutoff Amicon Ultra-4 Centrifugal Filter, aliquoted, 
and stored at -80 °C. The concentration of the protein was calculated from the ab-
sorbance at 280 nm (NanoDrop) using an extinction coefficient of 41,940 M-1cm-1 
calculated from the protein sequence. 
A fluorescence anisotropy assay was designed using the recombinant Bcl-
xL(1-209) and synthetic BAK-fluorescein peptide (Table 3.1). FA assays were per-
formed identically to the NEMO/IKKβ assays, except that the assay buffer did not 
contain DTT. 
Direct binding of Bcl-xL(1-209) to the BAK-fluorescein peptide was mea-
sured by serially diluting Bcl-xL(1-209) from 500 nM and holding the BAK-fluo-
rescein concentration constant at 30 nM. The data was fit using a quadratic curve 
fit (Graphpad Prism 6.0, Equation 3.12). 
As with the NEMO/IKKβ assays, the assay tolerance to DMSO was tested 
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by diluting the DMSO concentration from 25% v/v by half eight times and measur-
ing either the anisotropy of BAK-fluorescein alone or with 120 nM Bcl-xL(1-209). 
3.3 Results and Discussion
3.3.1 Development	of	a	NEMO/IKKβ	Fluorescence	Anisotropy	Assay
In these studies, a FA assay was developed to measure NEMO/IKKβ bind-
ing and to detect inhibition of the NEMO-IKKβ PPI. This interaction has widely 
characterized using a variety of NEMO and IKKβ constructs, therefore there are 
good estimates for the affinity of this interaction.86,110,113 Furthermore, as noted in 
section 2.3.3, the affinity as measured by the NEMO FA assay agrees well with 
these prior measurements. The figure of merit was derived to determine if a flu-
orescein-based fluorophore can resolve the free IKKβ-fluorescein peptide in the 
bound and free states. Roehrl et al. has outlined formulas derived from the Perrin 
equation (Equation 3.1) that can approximate the correlation time of a protein and 
thus determine an optimal fluorophore (Appendix I).139,149 These formulas only 
require knowledge of the molecular weight of a protein and an estimate of its 
shape. The frictional ratio of a 1-355 NEMO construct has been measured to be 2.3 
by sedimentation velocity.114 If it is assumed that NEMO adopts a prolate spheroid 
shape, the frictional ratio can be correlated with the axial ratio by the Appendix 
Equation 2. As discussed, this equation is complex  but estimates for the axial ratio 
can be determined from the frictional ratio.148 A frictional ratio of 2.3 gives an axial 
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ratio of 30. With these parameters, the correlation time of NEMO can be estimated. 
Figure 3.4 shows the figure of merit for NEMO/IKKβ-fluorescein with the lifetimes 
of commercially available fluorophores indicated by the open circles. The figure 
of merit plot indicates that a fluorophore with a fluorescence lifetime of ~10 ns can 
resolve the bound and free states to the greatest extent. We chose to use a fluores-
cein-based dye as it was close to the figure of merit maximum and was generally 
cost-effective. Fluorescein-based fluorophores generally have lifetimes around 4 
ns and while they may not give the maximum anisotropy difference, they are ap-
propriate for this assay.
Direct binding of NEMO to IKKβ has been discussed in the previous chap-
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Figure 3.4: Figure of merit function for NEMO binding to IKKβ-(45-mer). The figure of merit was 
calculated based on a globular IKKβ peptide binding to a rod-like NEMO dimer. The optimal flu-
orophore for this interaction has a fluorescence lifetime of ~10 ns. Two commercial fluorophores, 
indicated by the open circles,  with a lifetime of 4 or 20 ns should be adequate in resolving these 
two states. 
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ter (section 2.3.3). The data presented here agree well with the previous assessment 
(Figure 3.5).  The data were fit to a quadratic curve fit accounting for the sloping 
effect at high concentrations of NEMO (Equation 3.11). The affinity of NEMO for 
IKKβ-fluorescein was measured to be 5.4 ± 1.5 nM (n = 3). Based on these data, a 
concentration of 15 nM NEMO was chosen for the inhibition assays, as it gave a 
large enough signal to background ratio and is close to the KD of the interaction. 
For the assay condition of 15 nM NEMO and a NEMO/IKKβ interaction affinity 
of 5.4 nM, any inhibitors will appear to be 3.8-fold weaker than their true KI val-
ue. For screening purposes, the assay will likely be performed with up to 500 μM 
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Figure 3.5: Direct binding measurement of NEMO and IKKβ as measured in the fluorescence an-
isotropy assay. Varying concentrations of NEMO were incubated for 1 h with a fixed concentration 
of IKKβ-fluorescein (15 nM). The error bars represent the standard deviation of three replicate 
measurements. The data were fit to a quadratic binding model (Equation 3.11) that includes terms 
accounting for the non-zero background at no NEMO and the increase in signal at high NEMO 
concentrations.
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inhibitor. Thus, the weakest inhibitor that can be detected in this assay can have a 
KI of 131 μM. Using Equation 3.8, the assay floor for this concentration of NEMO 
is 7.5 nM, so the lower limit of potency that can be measured is 7.5 nM in terms of 
IC50, or 2.0 by KI.  
To determine if the interaction between NEMO and IKKβ-fluorescein had 
reached equilibrium after 1 h, the KD,app was measured using the direct binding 
assay incubated for either 30 min, 1, 2, 4, 6, or 24 h. The values of KD,app tend to 
level off after 1 h (Table 3.2), indicating that the system comes to equilibrium fairly 
quickly. However, the KD,app value after 24 h is slightly higher than at earlier times. 
This may imply that the assay components are not stable for long incubation times 
at 25°C, and that denaturation or aggregation of the components can lead to a 
percentage of inactive protein. Furthermore, the range of the anisotropy values 
increased at this later time point. The anisotropy signal is based on the size or 
molecular motion of the fluorescent complex, in this case the NEMO/IKKβ-fluo-
rescein complex. The most likely explanation for the increased signal range at later 
Table 3.2: Equilibrium assessment of NEMO-IKKβ binding via FA. Varying concentrations of 
NEMO were incubated with a fixed concentration of IKKβ for various times. The apparent KD was 
calculated from the curve fit in order to assess the extent by which the interaction had come to 
completion. 
Length of Incubation KD,app
30 Minutes 7.1
1 Hour 8.7
2 Hours 9.9
4 Hours 10.2
6 Hours 9.7
24 Hours 12.5
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incubation times is that the complex adopts a different size, probably as a result of 
time-dependent aggregation. 
An unlabeled version of the 45-mer IKKβ peptide was used as a positive 
control inhibitor of the interaction of NEMO with IKKβ-fluorescein (Figure 3.6). 
Ideally, inhibition measurements would be performed holding the concentration 
of NEMO low compared to the KI. The curves could then be fit using hyperbolic 
fits, and the IC50 derived from the fit would be related to the KI constant by the 
Cheng-Prusoff relationship.152,157 However, the KD of NEMO for IKKβ-fluorescein 
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Figure 3.6: Inhibition of NEMO/IKKβ-fluorescein by an unlabeled IKKβ peptide. Various concen-
tration of an unlabeled IKKβ peptide were incubated with 15 nM of NEMO and IKKβ-fluorescein. 
The interaction between NEMO and IKKβ-fluorescein was inhibited by this peptide to the baseline 
anisotropy level of unbound IKKβ-fluorescein. The error bars in the data points and the high and 
low controls represent the standard deviation of triplicate measurements. The KD for the unlabeled 
peptide was determined by fitting the individual replicates to a dual-site binding model in DynaFit 
(Appendix IV). 
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is quite low, and concentrations below this value would be below the detection 
sensitivity of the fluorescence plate reader used. Therefore, it was necessary to 
use concentrations of NEMO and IKKβ of 15 nM each, significantly above their 
KD. To fit the inhibition data obtained under these conditions, where an exact an-
alytical binding equation cannot be derived, we used numerical methods using 
the program DynaFit, as described in the Methods.156 The binding constant of the 
unlabeled IKKβ-(45-mer) peptide was determined to be 2.2 ± 0.8 nM (n = 4). This 
affinity is similar to the affinity for the IKKβ-fluorescein peptide, indicating that 
the presence of a fluorophore on the N-terminus of the peptide does not affect the 
interaction. 
3.3.2 The NEMO FA Assay is Suitable for Use as a Screening Assay
To determine the assay floor – that is, the lower limit to the inhibitor KI 
values that can be effectively discriminated by the assay – DynaFit was used to 
simulate the inhibition curves expected for inhibitors with KI values ranging from 
0.0001-100 nM (Figure 3.7). As the KI of the inhibitors decreases, the curves con-
verge. When the model is fit to a four-parameter equation (Equation 3.13), the 
IC50 values deviate from the predictable Cheng-Prusoff relationship in the range 
of 7.5-15 nM KI, which corresponds to concentration of NEMO in the simulation. 
The results of this simulation suggest that  inhibitors with affinities stronger than 
15 nM will look equally potent in the assay, and will give IC50 values of ~7.5 nM. 
These values therefore represent the assay floor. 
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The assay robustness was evaluated by calculating the coefficient of varia-
tion and the Z’-factor in a 96-well and 384-well format (Table 3.3). The %CV rep-
resents the relative standard deviation of the assay controls, and a %CV under 10% 
is acceptable for a screening assay. The %CV was 2.5% for the 96-well format and 
4.8% for the 384-well format. This parameter should be as low as possible to reflect 
a low magnitude of error, and the <5% deviation is that was observed indicates 
that both plate formats perform adequately by this measure. The Z’-factor is a 
comparison of the precision of the positive and negative controls of an assay com-
pared to the range between them, normalized to a maximum value of 1.153,155 
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Figure 3.7: Simulation of the NEMO FA assay floor. Inhibition curves for various KI values were 
simulated using the conditions for the NEMO FA assay programmed into a DynaFit script (Ap-
pendix IV). (Inset) The simulated curves were fit to a four-parameter curve fit and the calculated 
IC50 was compared to the simulated KI. The curve deviates from linearity at ½ of the NEMO con-
centration (dotted line). This value represents the assay floor, and the potency of any inhibitors that 
approach this value cannot be accurately determined from this assay format.
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The Z’-value value for the 96-well format was 0.61, which is above the threshold 
of Z’ > 0.5 that is considered to reflect an acceptable performance for a screening 
assay.153 However, in the 384-well format, the assay gave a value of Z’ = 0.35, 
suggesting that this format is not accurate enough for use as a screening assay. 
The low Z’-factor is most likely due to the human error associated with pipetting 
into a very small well with simlarly small volumes, and therefore could perhaps be 
overcome by using an automated pipetting system. The 384-well format could also 
potentially be improved by increasing the concentration of NEMO to increase the 
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Figure 3.8: Tolerance of the fluorescence anisotropy assay to DMSO. DMSO was titrated in the 
NEMO FA inhibition assay to measure the point at which the signals degrade due to interference 
from the solvent. DMSO appears to have two effects on the assay signal. The low signal (open 
circles), which represents unbound IKKβ-fluorescein in solution, increases at high DMSO con-
centrations, suggesting the increased viscosity slows down the rotational correlation time of the 
fluorophore and thus increases the anisotropy. The high signal (black circles), representing IK-
Kβ-fluorescein bound to NEMO, decreases at high DMSO concentrations. This is likely due to 
disruption of the PPI rather than decreasing the rotational correlation time of the complex, which 
would instead increase the anisotropy. 
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denominator of Equation 3.8, although this would likely increase the assay floor 
and complicate fitting of the inhibition curves.  
Any compounds tested in the assays will require some amount of DMSO 
to remain soluble at the high screening concentration. To measure the robustness 
of the assay with respect to the inclusion of this solvent, the assay signal was mea-
sured in various DMSO concentrations (Figure 3.8). The results show that the as-
say can tolerate up to 5% DMSO before the anisotropy signals are greatly com-
promised. However, at 5% DMSO, the assay signal range is reduced to ~80% of 
that seen without DMSO. The inclusion of DMSO at high concentrations has a 
negative impact on the Z’-factor and may make the assay less sensitive at detecting 
inhibition. Interestingly, the assay signals seen for the high and low controls are 
perturbed by DMSO in different ways. DMSO has a higher viscosity than water 
(1.996 cP and 1.0 cP, respectively, at 20 °C). Increasing amounts of DMSO will 
Table 3.3: Assay statistics of the NEMO fluorescence anisotropy assay and NEMO-capture ELISA. 
The coefficient of variation and Z’-score were calculated for the NEMO FA assay in a 96-well and 
384-well formats and the NEMO-capture ELISA. The 96-well FA assay had the lowest %CV out 
of the three assays, indicating that well-to-well variation is low. However, both ELISAs showed 
similar Z’-scores to the FA assay, suggesting that they are equally reliable assays for identifying 
inhibitors.
Protein with Tracer Peptide Tracer Peptide Alone
Assay Average Standard 
Deviation
CV Average Standard 
Deviation
CV Z' Score
Anisotropy:
96-well Format
92.2 2.3 2.5% 54.4 2.6 4.8% 0.61
Anisotropy: 
384-well Format
100.1 4.8 4.8% 64.7 2.9 4.4% 0.35
ELISA: 
NEMO-capture
0.384 0.032 8.4% 0.056 0.007 12% 0.64
ELISA: 
IKKβ-biotin Capture
1.774 0.177 10% 0.066 0.026 39% 0.64
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therefore increase the anisotropy signal, since the rotational correlation time is 
dependent on viscosity (Equation 3.1).139 It is likely that the increased anisotropy 
of the IKKβ-fluorescein control is due to the effect of higher viscosity. Conversely, 
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Figure 3.9: Tolerance of the NEMO FA assay to a panel of small macrocyclic compounds. A set of 
macrocycles were tested in the NEMO FA assay to simulate a compound screen. (A) The macro-
cycles were screened at a single concentration of 10 μM in the NEMO FA inhibition assay. Com-
pounds MC2, MC10, and MC11 appeared to reduce the assay signal by more than 20%, suggesting 
that they may be inhibiting the interaction. The assay otherwise appeared to tolerate the macro-
cycles well, as there was no great trend toward spurious inhibition. (B) Compounds MC2, MC10, 
and MC11 were titrated in the NEMO FA inhibition assay in a dose-response format starting at 50 
μM. None of the compounds showed any dose-dependent inhibition, suggesting that a threshold 
of 20% inhibition will likely result in a large number of false hits.
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the high concentrations of DMSO may also have an effect on the integrity of the 
PPI, effectively disrupting the interaction and thereby decreasing the anisotropy 
of the high control.
Finally, a set of 35 small macrocyclic molecules was tested to assess the vari-
ance and robustness of the assay in the presence of compounds similar to those 
that will be screened in the assay (Figure 3.9). Generally, the 35 compounds tested 
did not cause a large non-specific effect in the assay. However, three compounds 
inhibited to a value greater than 20%. These three compounds and compound 
19, which gave the highest anisotropy signal, were re-tested in a dose-dependent 
manner to determine whether these compounds represent the normal variation 
in the assay or if they are true inhibitors (Figure 3.9b). None of these compounds 
inhibited the interaction over the range tested, suggesting that the threshold of 
20% inhibition for classifying a hit will identify false positives but should also be 
adequate for identifying true inhibitors. 
3.3.3 Development of an ELISA screening assay
Two ELISAs were developed as secondary screening assays to validate in-
hibitors identified in the FA assay. In this assay format, the NEMO/IKKβ inter-
action is quantified using a colorimetric readout. The ELISA offers a second way 
to measure the NEMO/IKKβ interaction allowing us to identify and rule out any 
compounds that appear to inhibit in the FA assay but are acting through an as-
say-dependent artifact such as through interference with the fluorescence signal. 
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The first ELISA developed was termed the NEMO-capture ELISA (Figure 3.3a). In 
this assay, NEMO is captured on a plate using an anti-6xHis tag antibody that rec-
ognizes the 6x-His tag on recombinant NEMO. The binding of IKKβ-biotin to the 
NEMO on the assay plate is detected by subsequent addition of HRP-conjugated 
streptavidin. The second ELISA has the reverse format, and thus is called the IK-
Kβ-biotin capture assay (Figure 3.3b). IKKβ-biotin is captured on the assay plate 
via streptavidin and then NEMO binding is quantified using an HRP-conjugated 
antibody that binds to the NEMO protein’s C-terminal 6xHis tag. 
Heterogeneous assays such as ELISAs require that the assay plate is 
“blocked” to reduce nonspecific binding. This is done by incubating the assay 
plate with a solution containing an inert protein that can non-specifically adsorb 
to the plate surface to block any non-specific interaction of assay components with 
the plate. Choosing the right blocking buffer is important, however, as the assay 
components may interact non-specifically with the protein used to block the plate. 
To determine the optimal blocking buffer, tests were performed for both ELISAs 
Table 3.4: Effect of blocking buffer on the NEMO-capture ELISA controls. The ELISAs were run 
with controls lacking one of the components listed in Figure 3.3 and averaged together. The con-
trol wells should give a very low absorbance value since the complex should not be able to form. 
Non-fat dry milk gave the lowest absorbance for the NEMO-capture assay, whereas the BSA buf-
fers gave higher signals, indicating that one or more of the assay components interacts with BSA. 
Conversely, 1% BSA was optimal for the IKKβ-biotin capture format.
NEMO-Capture IKKβ-Capture
Blocking Buffer Average Standard 
Deviation
Average Standard 
Deviation
Non-fat Dry Milk 0.062 0.011 0.089 0.027
1% Bovine Serum Albumin 0.205 0.243 0.056 0.010
3% Bovine Serum Albumin 0.144 0.080 NT NT
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using as blocking buffer either 1% bovine serum albumin (BSA), 3% BSA, or 3% 
non-fat dry milk (NFDM). Assay controls in which each assay component was 
left out in turn were used to identify any non-specific binding (Table 3.4). The 
controls in the NEMO-capture ELISA had baseline background signals only when 
using 3% NFDM as the blocking buffer. The BSA blocking buffers gave much 
higher absorbances in the negative control wells, suggesting that there is non-spe-
cific binding occurring involving one of the assay components. Conversely, the 
IKKβ-biotin-capture ELISA performed better in 1% BSA. These blocking buffers 
were therefore used for subsequent experiments using these ELISAs. 
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Figure 3.10: Testing various dilution of streptavidin-HRP on the evolution of the NEMO-capture 
ELISA signal. NEMO and IKKβ-biotin were captured at various concentrations on a NEMO-cap-
ture ELISA. The dilution of streptavidin-HRP was varied to identify a concentration that allows 
for slow signal evolution to under 1.0 absorbance, allowing the assay data to be fit quantitatively 
via the Beer-Lambert law. The highest dilution factor tested, 1:20,000, yielded adequate absorbance 
values under 1.0, and was chosen for future ELISAs
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In order to fit the ELISA data to quantitative models, the colorimetric signal 
must conform to Beer’s law. The ELISA signal is based on the continuous color 
evolution of the TMB detection reagent. The reaction must be stopped before the 
absorbance reaches 1.0. To that end, the streptavidin-HRP reagent was tested at 
1:10,000, 1:15,000. 1:17,500, and 1:20,000 dilutions to find an optimal concentration 
that allows for slow color development. A NEMO-capture ELISA was performed 
with varying concentrations of NEMO and IKKβ. The amount of the streptavi-
din-HRP was varied (Figure 3.10). The two higher streptavidin-HRP concentra-
tions oxidized TMB very quickly. However, the 1:20,000 dilution allowed for more 
manageable control of the signal and thus was chosen for future assays. Further-
more, the 25 nM concentration of NEMO and IKKβ gave an absorbance of <1.0. 
This concentration was chosen for the coating concentration of NEMO or IKKβ-for 
their respective assays. The signal for the IKKβ-biotin-capture ELISA evolved in a 
more manageable time using the manufacturer’s recommended dilution of 1 μg/
mL of HisProbe-HRP, therefore no optimization was needed. 
To validate that each assay format shows the expected affinity for NEMO/
IKKβ binding, dose-response experiments were performed in which either the 
concentration of NEMO (for the IKKβ-capture assay) or of IKKβ-biotin (for the 
NEMO capture assay) was varied. Surprisingly, the two assays gave different ap-
parent affinities for NEMO/IKKβ binding. The IKKβ-biotin capture assay gave an 
apparent affinity of 6.1 nM (n = 3), consistent with the affinity for this interaction 
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that was measured in the FA assay (Figure 3.11). However, the NEMO-capture as-
say gave a much higher affinity binding, with KD(App) = 0.4 nM (n = 3). One possible 
explanation for the higher affinity observed in the NEMO-capture assay is that the 
apparent affinity is increased due to avidity effects from capturing two NEMO 
dimers in close proximity. Alternatively, the ELISA involves capturing the compo-
nent out of solution into the solid phase. The KD values measured, therefore, may 
not accurately represent the solution-phase affinity.  
The assays were run in an inhibition format using a variant of the IKKβ-
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Figure 3.11: Direct binding ELISA of both NEMO capture and IKKβ-biotin capture formats. Di-
rect binding between NEMO and IKKβ-biotin was measured by incubating the captured analyte 
at 25 nM and then incubating the detected analyte at various concentrations. The data were fit 
to a quadratic binding model (Equation 3.12). The error bars represent the standard deviation of 
three replicate values. The apparent KD for the NEMO capture format was approximately 10-fold 
stronger than that measured by in the NEMO FA assay, while the apparent KD measured in the 
IKKβ-capture ELISA was comparable.
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(45-mer) peptide. This peptide contains a click-reactive propargyl glycine at the 
N-terminus and was used to label the peptide with biotin to support the develop-
ment of the ELISAs. This IKKβ-click peptide was titrated in both ELISA assays to 
show that the interaction between NEMO and IKKβ can be inhibited in this ELISA 
format (Figure 3.12). The IC50 measured in the NEMO-capture assay was 1.1 ± 0.1 
(n = 3), and the IKKβ-capture assay was 97.4 ± (n = 3). The two ELISA formats re-
quire different methods of incubating the inhibitor with NEMO. The NEMO-cap-
ture assay involves incubating the inhibitor with the assay plate captured protein, 
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Figure 3.12: Titration of unlabeled IKKβ-click peptide in the NEMO-capture and IKKβ-biotin 
capture ELISAs. The Cheng-Prusoff relationship for both assay formats was measured from an 
inhibition assay format in order to determine which assay is better suited as a screening assay. 
Furthermore, the mode of inhibition differs between the two formats. In the NEMO-capture assay, 
the inhibitor is first incubated with captured NEMO and the tracer prober (IKKβ-biotin) is added 
to the assay plate without washing away the inhibitor.  In the IKKβ-capture assay, the inhibitor is 
incubated with NEMO in a separate plate. This mixture is then added to the plate to capture any 
unbound NEMO. 
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whereas the IKKβ-capture assay requires that soluble NEMO is incubated with 
the inhibitor separately, before the mixture is added to the assay plate display-
ing the IKKβ. The IKKβ-capture format allows NEMO to come to equilibrium in 
the solution phase and avoids the possibility that the structure or properties of 
NEMO are altered if it is first captured on the plate surface. This format is ideal 
only for binding mechanisms in which the inhibitor dissociation rate is negligible 
compared to the length of the subsequent capture step.151 If the dissociation rate is 
not negligible, however, the pre-established equilibrium will be disrupted and the 
signal will represent competition between the ligand and inhibitor, rather than the 
degree of free protein.   
The assay statistics were measured for both assays (Table 3.3). Both formats 
had rather high coefficients of variation of 8%-10%. Since ELISAs are heteroge-
neous assays, they require multiple incubation and wash steps. The numerous 
steps introduces many opportunities for variability and is likely the source for the 
high %CV values. However, this assay also differs from the FA assay in that the 
signal is not an intrinsic property of the system under study. The oxidation of TMB 
gives rise to the ELISA signal and can be allowed to react long enough to allow for 
a large signal. Furthermore, if a given concentration of detected binding partner 
causes a large signal increase quickly, that concentration can be reduced and the 
TMB reaction can be lengthened to give a sufficiently high signal. Therefore, the 
ELISA robustness is dependent on the length of time of TMB oxidation to increase 
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the signal to background range. This is seen in the Z’-factors, which are 0.64 for 
both ELISA formats, similar to the value seen for the NEMO FA assay. Thus, de-
spite their rather large %CVs, both ELISAs are sufficiently robust to be used in 
characterizing inhibitors. 
Comparison of the IC50 values observed in Figure 3.12 for the unlabeled 
IKKβ peptide in the two assays shows that the Cheng-Prusoff shift observed for 
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Figure 3.13: Tolerance of the NEMO-capture ELISA to DMSO. DMSO was incubated at varying 
concentrations in the NEMO-capture inhibition ELISA. NEMO was incubated at 25 nM, followed 
by the addition of DMSO and then IKKβ-biotin at 0.5 nM. The assay tolerated DMSO up to approxi-
mately 10% v/v. This value is comparable to the tolerance NEMO FA assay tolerance to DMSO (Fig-
ure 3.8: Tolerance of the fluorescence anisotropy assay to DMSO. DMSO was titrated in the NEMO 
FA inhibition assay to measure the point at which the signals degrade due to interference from 
the solvent. DMSO appears to have two effects on the assay signal. The low signal (open circles), 
which represents unbound IKKβ-fluorescein in solution, increases at high DMSO concentrations, 
suggesting the increased viscosity slows down the rotational correlation time of the fluorophore 
and thus increases the anisotropy. The high signal (black circles), representing IKKβ-fluorescein 
bound to NEMO, decreases at high DMSO concentrations. This is likely due to disruption of the 
PPI rather than decreasing the rotational correlation time of the complex, which would instead 
increase the anisotropy.).
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the IKKβ-biotin assay is substantially higher than that seen in the NEMO-capture 
ELISA. Inhibitors tested in the NEMO capture assay will have an IC50 that is calcu-
lated 5-fold higher than the KI whereas in the IKKβ-biotin capture format, the IC50 
values are calculated 63.5-fold higher than the true KI. Thus the sensitivity of the 
IKKβ-biotin format assay for detecting weak inhibitors is somewhat less than that 
of the NEMO-capture format. 
Finally, the effect of DMSO on the assay robustness was measured. The NE-
MO-capture ELISA was performed with 25 nM of NEMO and 0.5 nM of IKKβ-bio-
tin, in buffers containing various levels of DMSO (Figure 3.13). The assay tolerated 
DMSO up to approximately 10% v/v. This value is comparable to the tolerance 
NEMO FA assay tolerance to DMSO (Figure 3.8). The assay appeared to tolerate 
up to ~5% v/v DMSO without causing any substantial decrease in dynamic range, 
similar to the DMSO sensitivity observed for the NEMO FA assay. 
3.3.4 Design of a Counter Screen FA Assay Based on the Bcl-xL-BAK Interaction
Protein-protein interfaces typically contain some amount of hydrophobic 
surface, and these hydrophobic regions tend to be responsible for most of the 
binding interaction energy.13,46 One way in which a positive hit in a screening as-
say could inhibit is through a non-specific interaction targeting these hydrophobic 
sites at the PPI interface. To provide a method to identify compounds that inhibit 
in this non-specific manner, we developed an assay for use as a counter screen, 
using the well-characterized interaction between Bcl-xL and a BAK peptide. The 
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BAK peptide is derived from a domain that is present in many binding partners 
of Bcl-xL, and binds to Bcl-xL with a reported affinity of 340 nM.158 the topology of 
the Bcl-xL/BAK interaction is similar to that of NEMO/IKKβ, in that both NEMO 
and Bcl-xL accommodate their helical peptide ligands within a relatively deep 
groove (Figure 1.4).53,86,158 Furthermore, both assays use the same fluorophore and 
assay methodology. Therefore, any putative NEMO inhibitors that also inhibit the 
Bcl-xL/BAK interaction are likely working through a nonspecific mechanism or by 
interfering with the fluorescence assay readout, and therefore are of low interest. 
Full-length Bcl-xL protein contains a transmembrane domain which ren-
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Figure 3.14: Bcl-xL binding curve. Direct binding of Bcl-xL to a BAK-fluorescein peptide was mea-
sured in a fluorescence anisotropy. Various concentrations of Bcl-xL were incubated with a fixed 
concentration of BAK-fluorescein (30 nM). The data were fit to a quadratic curve fit (Equation 3.12). 
The affinity of this interaction was 46.7 nM, which is stronger than the literature reported value. 
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ders the protein insoluble in vitro. However, a deletion mutant lacking this do-
main has been engineered and has the same binding affinity for the BAK domain 
as wild-type protein.158 A recombinant form of Bcl-xL – Bcl-xL(1-209) – lacking 
this transmembrane region was cloned, expressed, and purified to a yield of 16.1 
mg per liter of cells. A FA assay was developed to measure direct binding of Bcl-
xL(1-209) and BAK-fluorescein (Figure 3.14). Varying the concentration of Bcl-xL 
resulted in a dose-dependent increase in the observed FA signal (Figure 3.14). The 
data were fit using a quadratic binding equation (Equation 3.12), as described in 
the Methods, and gave a binding affinity of 46.7 ± 7.4 nM (n = 2). This value rep-
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Figure 3.15: Bcl-xL FA assay tolerance to DMSO. The tolerance of the Bcl-xL assay signal to DMSO 
was measured as in the NEMO FA assay. DMSO was titrated against the assay controls of the 
BAK-fluorescein peptide alone and the Bcl-xL/BAK-fluorescein complex. The signals in this assay 
all show an upward trend, suggesting that DMSO has only a primary effect on the anisotropy me-
diated by the slower rotational correlation time due to the high viscosity of DMSO.
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resents three-fold stronger binding than the literature reported value for this in-
teraction, due to differences in calculating the protein concentration or due to a 
different assay design. The assay was tolerant to DMSO at concentrations up to 5% 
v/v, similar to the NEMO FA assay (Figure 3.15). Having established that the assay 
gives a binding affinity for the Bcl-xL/BAK interaction that is similar to reported 
values, and it was tolerant to moderate amounts of DMSO, it was deemed validat-
ed for use as a counter-screen for hits of the NEMO-IKKβ interaction. 
3.4 Conclusions and Future Directions
Overall, three assays have been developed by which inhibitors of the NE-
MO-IKKβ protein-protein interactions can be identified and validated. The NEMO 
FA assay can serve as an initial screening and validation assay due its simplicity in 
execution. The NEMO-capture ELISA performed well and had a low Cheng-Pru-
soff shift and could serve as a follow-up assay to hits validated through the FA 
assay. The Bcl-xL FA assay can be used to identify any non-specific NEMO/IKKβ 
inhibitors or general PPI inhibitors. Furthermore, while the primary focus of the 
project is on finding NEMO inhibitors, if desired the Bcl-xL assay could be used to 
identify inhibitors specific for this PPI.
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Chapter 4: Screening for Inhibitors of the NEMO/IKKβ Interaction
4.1 Introduction
This chapter describes the screening of macrocyclic and small-molecule li-
braries, and the further characterization of the screening assay “hits” to eliminate 
false positives and identify lead inhibitors of genuine interest. The work present-
ed in this chapter follows the flow-chart shown in Figure 4.1 up to the point of 
Primary Screen
• Fluorescence Anisotropy Assay
• 10 or 100 μM
Dose Response Validation
• Fluorescence Anisotropy Assay
Elimination of False Positives
• Shoichet
• Alternative binding assay
Controls
Dose Response Re-Validation
• ELISA
Measurement of Direct Binding
• STD-NMR
• Biacore
Cellular Activity
• Ability to inhibit cellularNF-κB function
Figure 4.1: Inhibitor discovery and validation flow chart. This flow chart describes the process of 
inhibitor discovery from initial screening and validation of hits through confirmation of direct 
binding to the protein target and biological activity. This chapter focuses on the first four steps up 
to confirmation of direct binding of inhibitors to NEMO. 
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determining direct binding. As Figure 4.1 shows, the initial steps in lead identifi-
cation involves (1) identification of compounds that show inhibition in a primary 
screening assay (described in section 3.3.1), (2) confirmation of these intial hits by 
measuring their concentration-dependent inhibitory properties, (3) weeding out 
false inhibitors that arise from insolubility or other non-specific interference, and 
(4) confirmation of the inhibitors’ activity by testing in a second inhibition assay. 
The interaction of NEMO with IKKβ has been studied using experimental 
and computational methods. As discussed (Section 1.3), alanine scanning muta-
genesis and computational mapping of this interaction has revealed that there is a 
major hot-spot of binding energy centered on residues W739 and W741 with two 
minor hot-spots centered on L708 and L719.111,123,159 Furthermore, computational 
mapping predicts that these areas will likely bind drug-like molecules. The iden-
tification of these hotspots was used to guide the development of a library of mac-
rocyclic inhibitors. This library was created by docking synthetically accessible 
macrocycles into the major hot spot (Figure 1.7), analyzing those macrocycles that 
dock with the best conformations, and then synthesizing these best-fit molecules. 
The theory and development of the FA screening assay is described in Chap-
ter 3. Even though fluorescence anisotropy is used frequently as a high-fidelity as-
say for identifying inhibitors, there are several ways in which the method is prone 
to false inhibition. The assay signal is a ratiometric function of the fluorescence in-
tensity in the planes parallel and perpendicular to the original polarization vector, 
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as shown in Equation 3.5. Thus factors that affect the overall fluorescence intensity 
likely will not affect the final anisotropy value. However, fluorescent compounds 
that have excitation and emission maxima near the corresponding tracer probe 
values may skew the calculated ratio toward apparent inhibition.147 This is be-
cause, in the NEMO FA assay, the compounds tested are generally much smaller 
than the IKKβ-fluorescein tracer probe. Thus, any compounds that are excited by 
the wavelength used will have a smaller anisotropy signal than either the free or 
bound peptide. The contribution of the anisotropy signaling arising from such 
compounds to the overall FA assay signal might therefore result in reduction of 
the measured anisotropy that could be mistaken for inhibition.  The inner-filter ef-
fect is a phenomenon by which absorbance of the emitted fluorescence light reduc-
es the overall fluorescence. Any compounds that cause the inner-filter effect may 
also artificially appear as false hits simply by absorbing the emitted light.139 The 
NEMO FA assay is performed with a low concentration of IKKβ-fluorescein. This 
concentration is close to the limit of detection of the instrument used. Thus, the 
inner-filter effect may reduce the assay signal to below the assay sensitivity and 
appear as false inhibition. It is therefore important to have one or more secondary 
assays that use a different detection method, to help distinguish valid from false 
inhibitors.
ELISA technology, as discussed in section 3.2.4, is quite prevalent as a means 
to detect binding of two biomolecules. This type of assay is especially useful when 
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used as a complementary screening assay to FA, as it can be designed to use a 
non-fluorescent readout. Instead the ELISA can be read out through a colorimet-
ric signal resulting from oxidation of the TMB reagent from a colorless to colored 
product. Additionally, development of the signal is not coupled to the compound 
incubation step, so there is a low likelihood that the presence of a small molecule 
or macrocycle could interfere directly and alter the signal. Like any assay, howev-
er, ELISAs can be prone to false positive and false negative results through other 
types of experimental artifacts
One major cause of false inhibition arises when compounds are screened 
at or around their solubility limit. It has been shown that compounds that are 
screened above this level can appear active as inhibitors simply due to interference 
from microaggregates of the compound, which can nonspecifically sequester and 
inactive the protein.160 One of the critical steps in a screening paradigm is to deter-
mine whether hits are inhibiting via this common mechanism. There are several 
ways to parse out this mechanism. First, if the compound is tested in a dose-re-
sponse format, the steepness of the resulting curve may indicate compound in-
solubility. A true inhibitor should go from low to high inhibition (~10-90%) over 
roughly two concentration orders of magnitude, whereas inhibition curves result-
ing from compound microaggregates will typically have much steeper slopes, cor-
responding with the solubility limit of the compound.160 Additionally, the mode 
of inhibition may not be competitive, suggesting that these microaggregates are 
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non-specifically inhibiting rather than competing for binding to the same site as 
the natural ligand.160 There are a few ways to experimentally test for this type 
of non-specific inhibition. The effect of compound aggregation on activity can be 
alleviated by increasing the protein concentration, by adding in a non-ionic deter-
gent to solubilize the aggregates, or by centrifuging the assay mixture to pellet out 
the aggregate.160
In this chapter, the screening data for designed macrocycles and for a sepa-
rate small-molecule library are presented. In the macrocycle compound set several 
potential hits were observed but none passed all of the validation steps. However, 
one compound from the small-molecule library was validated as a hit and is being 
pursued as a potential inhibitor of the NEMO/IKKβ PPI. 
4.2 Materials and Methods 
4.2.1 Materials 
All macrocycles and small-molecule compounds were provided by the Bos-
ton University Center for Methodology and Library Development (BU-CMLD). 
The macrocycles were designed using computational docking algorithms devel-
oped by the Vajda laboratory (Boston University, Department of Biomedical En-
gineering) and were synthesized by the BU-CMLD. The small-molecule library 
was provided by the BU-CMLD from their library of compounds. The remaining 
reagents were identical to those used in chapter 3 (Section 3.2.1). A list of the com-
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pound sets tested is in Table 4.1. 
4.2.2 Initial Screen in the NEMO Fluorescence Anisotropy Assay
Macrocyclic and small-molecule compounds were provided as a stock solu-
tion in 100% DMSO at 20 mM. For initial screening, the compounds were tested 
at a single concentration of either 10 μM or 100 μM, by diluting the compound to 
either 40 μM or 400 μM in 50 μL water and DMSO for a final DMSO concentration 
of 10% v/v, so that the addition of 50 μL into a final assay volume of 200 μL results 
in the desired final concentration in 2.5% v/v DMSO. Prior to screening, the UV 
spectra from 220-750 nm of the compounds was measured in a 96-well UV-trans-
parent 96-well microtiter plate. The absorbance at 700 nm was used as a simple 
method for determining solubility by measuring the degree of optical interference 
by insoluble particles. 
After the UV spectra were taken to assess solubility, the compounds were 
transferred to a black 96-well plate. The FA assay was performed as described in 
Table 4.1: Sets of compounds tested. The compounds tested in this study are grouped into sets 
determined by when they were screened. Listed in this table is the hit rate and the number of com-
pounds re-screened in a dose-response format. (*) Some compounds from the initial screen that did 
not approach 20% inhibition were re-tested in the dose-response assay. (†) The one hit from Set 3 
was purified and re-screened along with the separated contaminant. 
Type of Com-
pound
Number of 
Compounds 
Screened
Number 
of Hits
Number 
Retested
Set 1 Macrocycles 166 13 16*
Set 2 Macrocycles 37 0 (FA)
1 (ELISA) 2*
Set 3 CMLD Library 2130 1 2†
Set 4 CMLD Library 17 17
Set 5 CMLD Library 19 14 11
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the previous chapter (Section 3.2.2). Briefly, 50 μL assay buffer (200 mM Tris, pH 
7.4, 800 mM NaCl, 0.04% v/v Triton X-100, 4 mM DTT, stock concentration) was 
added to each well. Both NEMO and IKKβ-fluorescein were diluted from a con-
centrated stock to 60 nM in water and then added to the wells at 50 μL each. One 
row of wells was reserved in the assay plate for the negative control (NEMO and 
IKKβ-fluorescein), a second row was reserved for the positive control (IKKβ-fluo-
rescein alone), and a third was reserved for the buffer only control. In some assays 
in which a large number of compounds was screened, the controls were restricted 
to half of a row to conserve space. Finally, the assay was incubated for 1 h at 25 °C 
before the plate was read. 
 The anisotropy signals were calculated based on the method used in sec-
tion 3.2.2 and converted to percent NEMO/IKKβ binding activity using Equation 
4.1. Essentially, the assay signal (S) was normalized to the assay range (SHigh to SLow) 
and multiplied by 100 to give the percentage of tracer probe binding observed at 
that inhibitor concentration. This allows for a direct comparison of the potency of 
compound screened at different concentrations.
4.2.3 Follow-Up Dose-response Assay
Any compound that gave less than 80% activity (representing >20% inhi-
bition) in the initial single-concentration screen was classified as a hit. Hits were 
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retested in the anisotropy assay in a dose response format. The assay was identical 
to the initial screen with the following changes: The hit compounds were diluted 
to either 400 μM or 2 mM (normalizing DMSO to 10% v/v) and then serially dilut-
ed two-fold in 10% v/v DMSO down one column of wells in a UV-transparent 96-
well microtiter plate. The UV-Vis spectra were taken as in the initial screen. After 
this measurement, the compounds were transferred to a black 96-well plate. From 
here, the assay was performed as in section 4.2.2. The FA data were normalized to 
percent NEMO/IKKβ binding activity as before (Equation 4.1). If the compound 
showed dose-dependent inhibition, the data were fit to a four-parameter curve fit 
(Equation 4.2) to determine the IC50. 
For some of the compounds screened, the total fluorescence intensity was 
also examined to determine if the compounds were fluorescent at the wavelengths 
used for the FA measurement. The fluorescence was calculated from the intensities 
measured for the anisotropy signal using Equation 4.3. 
4.2.4 Hit Validation
Compounds that showed dose-dependent inhibition were subjected to sev-
eral additional tests to confirm that the inhibition derived from specific binding to 
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NEMO rather than being a false positive arising from an assay artifact. The first 
test involved measuring inhibition at a single concentration in the Bcl-xL count-
er-screen FA assay described in Chapter 3 (Section 3.3.4). Compounds were tested 
at the same concentration as in the initial NEMO/IKKβ screening assay (either 10 
μM or 100 μM) using the same protocol, with a few exceptions. Namely, the Bcl-xL 
fluorescence anisotropy assay buffer did not contain DTT, Bcl-xL was added at a 
final concentration of 120 nM, and the BAK-fluorescein peptide was present at 30 
nM. 
Next, to determine if the compounds mediate inhibition through inactiva-
tion of NEMO by the formation of compound microaggregates due to insolubility, 
the hit compounds were re-screened at a single concentration in one of two vari-
ant assays. In the first test, the amount of NEMO was increased five-fold to a final 
concentration of 75 nM. In the second test, the assay was run with Tween-20 at 
0.05 %v/v instead of Triton X-100, to determine if an alternate non-ionic detergent 
could solubilize any insoluble aggregates. Both of these tests  have been shown to 
be diagnostic for inhibition arising from the formation of compound microaggre-
gates.160
4.2.5	 ELISA	Dose-Response	Assay
Compounds that show dose-dependent inhibitory activity in the NEMO FA 
assay and passed the validation tests described above were further tested in the 
NEMO-capture ELISA, in a dose-response format. The design and execution of 
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this assay is described in sections 3.2.4 and 3.3.3. Briefly, a 96-well assay plate was 
coated with 1 μg/mL of an anti-6xHis antibody overnight at 4 °C. The plate was 
washed four times in assay buffer, and was washed again after every step except 
for the compound incubation step. NEMO was captured at a concentration of 25 
nM for 1 h at 25 °C. Compounds were diluted to 500 μM in assay buffer with a final 
DMSO concentration of 2.5% v/v, and were serially diluted 2-fold in this buffer in 
a second 96-well plate. The contents of the second plate were then transferred to 
the assay plate. One column of 8 wells, representing the positive (high-signal) con-
trol, was incubated with assay buffer containing 2.5% v/v DMSO but with no com-
pound. The compounds were incubated for 30 min, IKKβ-biotin was added to the 
wells at a final concentration of 0.5 nM, and the plate was incubated for 30 more 
min. Additionally, one column of wells was reserved for the negative (low sig-
nal) control, in which no IKKβ-biotin was added. Finally, the plate was incubated 
with a 1:20,000 dilution of streptavidin-HRP for 30 min, and the TMB reagent was 
added to develop the signal. The absorbance of the positive control (NEMO and 
IKKβ-biotin without compound) was monitored at 650 nm until it approached 0.3 
absorbance units, and the reaction was stopped with 2 N H2SO4. The absorbance at 
450 nm was measured and used as the assay signal. 
As with the NEMO FA assay, the data were normalized to the assay con-
trols using Equation 4.1, and data showing inhibition were fit using a four-param-
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eter curve fit (Equation 4.2). 
4.2.6 Assay Cosolvent Tolerance
A subset of the macrocyclic compounds proved to be insoluble in the NEMO 
FA assay buffer. The NEMO FA assay and NEMO-capture ELISA were modified 
in order to find a way to solubilize the compounds. 
The tolerance of the NEMO FA assay to a variety of organic cosolvents was 
measured. The assay was performed in the inhibition format, with both IKKβ-flu-
orescein and NEMO at 15 nM. An additional set of measurements was run that 
contained 75 nM NEMO, to see whether the high signal observed at this higher 
NEMO concentration would increase the tolerance of the assay to cosolvents. The 
cosolvents tested were DMSO, ethanol, isopropanol, acetonitrile, β-cyclodextrin, 
and polyethylene glycol 400 (PEG-400).  These cosolvents were serially diluted 
two-fold eight times starting from the following concentrations: DMSO was titrat-
ed from 20% v/v; ethanol, acetonitrile, and isopropanol were titrated from 25% 
v/v; β-cyclodextrin was titrated from 8 mM; and PEG-400 was titrated from 5% 
v/v. 
A second iteration of the cosolvent screen was performed in order to test 
the limit of DMSO tolerance in the presence of 5% and 10% ethanol or isopropanol. 
In this format, DMSO was titrated starting at 12.5% v/v. 
The tolerance to ethanol and DMSO was also measured for the NEMO-cap-
122
ture inhibition ELISA. The cosolvent conditions tested were 10% v/v ethanol with 
5% v/v DMSO, 20% v/v ethanol with 10% v/v DMSO, 30% v/v ethanol with 15% 
v/v DMSO and 40% v/v ethanol with 20% v/v DMSO. 
4.2.7	 Rescreen	of	the	Poorly	Soluble	Macrocycles
The set of macrocyclic compounds that in the initial screen were found to 
be poorly soluble were re-tested in the NEMO FA assay using both cosolvents 
10% v/v ethanol and 5% v/v DMSO. These compounds were also tested in the NE-
MO-capture ELISA at 100 μM using 20% v/v ethanol with 10% v/v DMSO as cosol-
vents. Two of these compounds were subsequently retested in the NEMO-capture 
ELISA in a dose-response format. 
4.3 Results and Discussion 
4.3.1 Macrocyclic Compound Screening and Validation
A set of 166 macrocycles (Set 1) was synthesized and tested in the NEMO 
FA assay. These macrocycles were designed, using a computational docking al-
gorithm, to bind in the region of the IKKβ binding site on NEMO that accommo-
dates IKKβ residues W739 and W741 on IKKβ (Figure 1.7). Set 1 compounds were 
screened at a fixed concentration of 10 μM. However, in order to identify weaker 
inhibitors of the NEMO/IKKβ interaction, later sets of macrocycles were screened 
at 100 μM. The resulting anisotropy values for each inhibitor were normalized to 
the controls to give percent NEMO/IKKβ binding activity using Equation 4.1. An 
123
activity of ≤80% was chosen as the threshold to classify a compound as a hit in this 
initial screen. The data from the initial screening of Set 1 are presented in Figure 4.2. 
Out of this set of 166 macrocycles, 13 compounds appeared to inhibit with ≥20% 
inhibition. These compounds were re-screened in a dose-response format to deter-
mine their inhibitory activity (Figure 4.3). Additionally, three compounds, 8558, 
8559, and 8560, did not approach the 80% threshold in the initial screen but were 
re-screened in the dose-response format as controls. Most hits were re-screened 
starting at 100 μM (Figure 4.3a). At this concentration, no inhibition was detected. 
The fact that the compounds initially appeared to inhibit at the ~20% level in the 
FA assay is therefore likely due to random variance. Furthermore, the threshold 
for classification as a hit is set relatively low, with the expectation that some false 
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Figure 4.2: Initial screen of 166 macrocycles (Set 1). The macrocycles from Set 1 were screened ei-
ther at 10 μM or 100 μM in the NEMO FA assay. The threshold for classification as a hit was set at 
≤80% activity (indicated by the dotted line). In this screen, 13 compounds passed this threshold and 
were re-tested in a dose-response assay (red circles). 
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inhibitors will be identified, to make sure even weak real hits are not missed. In 
this early stage of compound design, even weak inhibitors may be informative. 
For this same reason later macrocycle sets were initially screened at 100 μM, and 
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Figure 4.3: Dose-response titration of hits from Set 1 (Figure 4.2: Initial screen of 166 macrocycles 
(Set 1). The macrocycles from Set 1 were screened either at 10 μM or 100 μM in the NEMO FA as-
say. The threshold for classification as a hit was set at ≤80% activity (indicated by the dotted line). 
In this screen, 13 compounds passed this threshold and were re-tested in a dose-response assay 
(red circles).). (A) Many of the macrocycles in Set 1 that gave >20% inhibition in the primary screen 
were retested in the NEMO FA dose-response assay. The macrocycles were tested at varying con-
centrations up to 100 μM. (B) Compounds 9175, 9176, and 9469 in Set 1 were tested at varying con-
centrations up to concentrations of 500 μM. None of these macrocycles inhibited up to the highest 
concentration tested. 
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the confirmatory dose-response experiments were tested at 500 μM (Figure 4.3b). 
Unfortunately, even at this higher concentration, no hits were found for which 
activity could be confirmed in the dose-response retest. 
A major difficulty that emerged in screening the initial sets of synthetic 
macrocycles was the poor solubility of the compounds. It is likely that even com-
pounds that are fractionally insoluble at the tested concentrations will have a det-
rimental effect on the assay signal. To that end, as part of our screening protocol 
we assessed the solubility of all of the tested macrocycles by measuring the degree 
of optical interference of compound solutions at 700 nm as an indication of the 
presence of insoluble particles (Table 4.2). Each of the hits from Set 1 showed an 
increased absorbance at 700 nm compared to the buffer value (10% DMSO). The 
three compounds that had the highest absorbance also gave anomalous high FA 
signals (i.e., above the 100% signal that corresponds to the uninhibited NEMO/
Table 4.2: Solubility measurements of macrocycles in Set 1. The solubility of the hits from Set 1 were 
assessed to determine whether insolubility has an effect on the inhibition curve. Solubility was 
measured through the absorbance at 700 nm. Many of the compounds showed increased absor-
bance at 700 nm, suggesting that there is a degree of optical interference from insoluble particles. 
Compound Absorbance 
(700 nm)
Compound Absorbance 
(700 nm)
8558 0.052 8591 Not Tested
8559 0.056 8549 Not Tested
8560 0.067 8524 Not Tested
8517 Not Tested 8961 Not Tested
8518 Not Tested 9175 0.121
8544 Not Tested 9176 0.120
8366 Not Tested 9469 0.214
8546 Not Tested Buffer 0.038
8590 Not Tested
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IKKβ-fluorescein complex). According to the work by Shoichet, insoluble com-
pound microaggregates can sequester or denature proteins in biochemical assays 
thereby causing inhibition by non-specific means.160 In our case, the formation of 
compound microaggregates does not cause inhibition. Instead, since anisotropy 
is a size-based measurement, it is likely that any insoluble particles are instead 
adsorbing the fluorescent peptide. In this case, the signal will exceed the 100% lev-
el associated with the uninhibited NEMO/IKKβ complex because the fluorescent 
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Figure 4.4: Initial screen of the compounds in Set 2. Set 2 contains 19 macrocycles and their acyclic 
precursors. (A) Screening results from compounds screened at 100 μM in the NEMO FA assay. 
The data are scattered, and in most cases give assay signals >100%, suggesting that the compounds 
interfere with the assay signal due to their insolubility. (B) The absorbance at 700 nm of each of the 
compounds in Set 2 is much higher than the baseline, confirming that these compounds are not 
fully soluble at this concentration even in 10% DMSO.
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molecule is bound to a large compound aggregate. This phenomenon explains the 
increase in NEMO/IKKβ binding activity seen for compounds 8590, 8961 in Figure 
4.3a, and 9175, 1976, and 9469 in Figure 4.3b. 
4.3.2	 Modification	of	the	Assay	to	Screen	Insoluble	Macrocycles	(Set	2)
An additional set of macrocycles was designed through additional itera-
tions through the design process with the knowledge that Set 1 macrocycles were 
not inhibitors. Set 2 included these 19 macrocycles (compounds 8134-8153) and 
their acyclic precursors (compound 8114-8133). These compounds were screened 
in the NEMO FA assay at 100 μM (Figure 4.4). No compound inhibited the interac-
tion of NEMO with IKKβ to the threshold of 80% activity. Instead, like some of the 
compounds referred to above at high concentrations these compounds generally 
gave anomalous signals that were greater than 100%, suggesting that they are not 
soluble at the highest concentrations tested (Figure 4.4a). In agreement with the 
activity data, the measured absorbance at 700 nm for these compounds also indi-
cated that they were poorly soluble in the buffer tested (Figure 4.4b).
Due to the amount of synthetic design that went into the development of 
the Set 2 macrocycles, and because docking of these compounds looked promis-
ing, we sought a way to modify the assay that would allow the compounds to be 
tested in a soluble format. In an effort to solubilize and thus accurately test these 
compounds, the assay tolerance to additional solvents was measured and plotted 
(Figure 4.5). Six cosolvents were tested in the NEMO anisotropy assay to assess 
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the level of interference on the assay signal of the fluorescent peptide and the 
binding of NEMO to IKKβ. An additional set of measurements were included in 
which NEMO was present at five times the normal assay concentration (75 nM). 
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Figure 4.5: Tolerance of the NEMO FA assay to various cosolvents. The NEMO FA assay was per-
formed in the presence of six organic solvents in order to assess the tolerance to each solvent. 
The level of tolerance is indicated by the gray line in each assay. Three controls were assessed 
– IKKβ-fluorescein alone (blue circles), 15 nM NEMO with IKKβ-fluorescein (red circles), 75 nM 
NEMO with IKKβ-fluorescein (green circles). (A) DMSO, (B), ethanol, (C), isopropanol, and (D) 
acetonitrile are all tolerated well by the assay. (E) PEG-400 and (F) β-cyclodextrin both perform 
poorly in the assay. 
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Having a higher amount of NEMO in the screening assay would likely reduce 
the assay sensitivity (section 3.1). However, we hoped that the expected increase 
in the assay signal that accompanies use of a higher NEMO concentration would 
make the assay more robust to the presence of organic cosolvents. The level at 
which the cosolvent reduced the fidelity of the assay signal was determined qual-
itatively by looking for a substantial reduction in the positive control assay signal 
(i.e. IKKβ-fluorescein with NEMO) compared to the IKKβ-fluorescein only neg-
ative control. The threshold for what we considered to be an unacceptable loss 
of dynamic range is indicated by a gray line on each graph. The effect of DMSO 
was previously measured for this assay (Figure 3.8), and inclusion of DMSO as 
a potential cosolvent in this new experiment confirmed that 10% v/v DMSO is 
the tolerance limit of the assay (Figure 4.5a). Ethanol and isopropanol showed 
similar effects on the assay (Figure 4.5b, c), being tolerated up to 10% v/v and 5% 
v/v, respectively. Acetonitrile was tolerated to approximately 5% v/v (Figure 4.5d). 
Acetonitrile may not be ideal for binding experiments, as it is frequently used for 
HPLC separation of biomolecules and may inhibit binding of the macrocycles and 
IKKβ. The cosolvent β-cyclodextrin is used as an excipient in some drug formu-
lations, and the increase in FA signal observed at concentrations of this substance 
suggests that above 0.1 mM it binds to the IKKβ-fluorescein peptide, rendering it 
unsuitable for use as a cosolvent in our assay (Figure 4.5f).161 Any macrocycles that 
are solubilized by β-cyclodextrin will not be released to bind to NEMO, consistent 
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with its use as way to encapsulate drugs to increase oral bioavailability.161 A small 
PEG molecule, PEG-400, is often used to increase the solubility of drugs.162 How-
ever, PEG-400 seems to have a drastic effect on the assay fidelity at above 1% v/v, 
causing an extreme increase in the measured anisotropy values for all controls 
(Figure 4.5e), perhaps because it is so much more viscous than the assay buffer. As 
discussed (section 3.1), anisotropy is heavily influenced by the solution viscosity 
(Equation 3.2), and any increases in macrocycle solubility caused by PEG-400 will 
be obscured by the cosolvent rendering the anisotropy signal unusable.
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Figure 4.6: NEMO FA Assay tolerance to DMSO combined with ethanol or isopropanol. The 
NEMO FA assay tolerance to DMSO in the presence 10% or 5% ethanol (a, b) or isopropanol (c, d) 
was assessed. Three controls were assessed – IKKβ-fluorescein alone (blue circles), 15 nM NEMO 
with IKKβ-fluorescein (red circles), 75 nM NEMO with IKKβ-fluorescein (green circles). The assay 
tolerates DMSO up to ~2.5-5% v/v in all assay conditions.  
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From the above results, we concluded that ethanol or isopropanol were the 
best choices for assay cosolvents to increase the solubility of the macrocycles from 
Set 2. Next, the tolerance of the assay to varying DMSO concentrations was tested 
in the presence of 5% and 10% ethanol or isopropanol, to gauge the limit of assay 
robustness with these combined cosolvents (Figure 4.6). The results suggest that 
in the presence of either of the alcohol cosolvents the assay is tolerant to 5-10% v/v 
DMSO, indicating as expected that the assay can tolerate somewhat less DMSO 
when another organic cosolvent is present. It appeared that isopropanol combined 
with DMSO was slightly more detrimental to the assay that DMSO with ethanol 
(Figure 4.6d). Therefore, cosolvent conditions of 10% ethanol with 5% DMSO was 
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Figure 4.7: Screening of Set 2 macrocycles and acyclic precursors in the NEMO FA assay with 10% 
ethanol and 5% DMSO. The compounds were re-screened at 100 μM in the presence of 10% v/v eth-
anol and 5% v/v DMSO. The data are plotted as anisotropy rather than percent activity to show the 
increased error in the controls. The black dashed line represents the averaged positive and negative 
controls and the gray dashed lines are one standard deviation from those values.
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chosen to re-test the macrocycles. 
The 37 macrocycles from Set 2 were re-screened at 100 μM using an assay 
buffer containing 10% v/v ethanol with 5% v/v DMSO (Figure 4.7). Nearly all of 
the macrocycles appeared to show some degree of inhibition under these assay 
conditions. However, under these conditions the standard deviation for the con-
trol wells was substantially increased (Figure 4.7). Furthermore, the FA observed 
for the low signal control wells (representing the anisotropy of the free IKKβ-fluo-
rescein peptide) was approximately 10-15 anisotropy units higher in the presence 
of the cosolvents. This result indicates that the presence of the cosolvents increases 
the error and decreases the assay working range, which together reduce the assay 
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Figure 4.8: Tolerance of the NEMO-capture ELISA to ethanol and DMSO. The NEMO-capture ELI-
SA assay tolerance to various cosolvents was assessed by performing the assay in the presence of 
increasing concentrations of DMSO and ethanol. The signal arising from NEMO/IKKβ binding 
(blue) and the baseline signal (red) were tested in triplicate at each concentration of cosolvent. The 
assay performs well in the presence of up to 20% v/v ethanol with 10% v/v DMSO. 
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robustness. Due to this increased assay variation, it was difficult to distinguish ac-
tual inhibition from intrinsic assay error. We therefore decided to instead test the 
compounds in the NEMO-capture ELISA, to determine whether this assay would 
be more robust to the presence of the cosolvents required to render the macrocy-
cles from Set 2 soluble and therefore testable. 
 In preparation for testing the macrocycles from Set 2 in the NEMO-capture 
ELISA, we first tested the tolerance of this assay to ethanol and DMSO (Figure 4.8). 
The assay showed a greater tolerance to ethanol and DMSO than was seen for the 
NEMO FA assay. However, there was a degree of phase separation between the 
assay buffer and the cosolvents at high ethanol and DMSO concentrations. Thus, 
20% ethanol with 10% DMSO was chosen as the cosolvent for the macrocycle re-
screen, as this concentration was the highest that avoided phase separation. While 
the assay signal was depressed at higher cosolvent concentrations, this did not 
necessarily rule out their use in the assay. One advantage of the ELISA is that the 
strength of the signal is not an intrinsic property of the interacting binding part-
ners. Instead, the signal can be developed for a length of time sufficient to reach a 
good signal to background ratio.
The compounds were diluted in the ELISA assay buffer with cosolvent and 
were tested to measure their activity and solubility (Figure 4.9). Another advan-
tage to the ELISA is that the compounds can be dissolved directly in the final as-
say buffer, allowing the solubility as measured by the absorbance at 700 nm to be 
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determined under the final assay conditions. It is notable that the cosolvent was 
able to solubilize nearly all compounds (Figure 4.9b). It is surprising, however, 
that the macrocycles, compounds 8133-8153, seemed to be less soluble than their 
acyclic precursors. This is not in agreement with their calculated solubility though 
the cLogP values (data not shown), nor with that of the solubility measured in the 
NEMO assay format (Figure 4.4b). One explanation for this discrepancy is that 
the acyclic molecules may have better solubility in a buffered solution with phos-
phate, salt, ethanol, and DMSO whereas the cyclized molecules may behave better 
in DMSO alone. 
Only one compound, 8126, appeared to inhibit at a level greater than the 
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Figure 4.9: NEMO-capture ELISA screen of compounds in Set 2 in the presence of 20% ethanol with 
10% DMSO. (A) Only one compound showed inhibition in the ELISA screen, compound 8126. (B) 
Nearly all of the compounds show an absorbance at 700 nm close to the buffer baseline, indicating 
that they are soluble in this assay buffer with ethanol and DMSO. 
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threshold of <80% signal (Figure 4.9a). To validate that 8126 was a true hit, the 
compound was re-tested in the ELISA in a dose-response format. Since this is an 
acyclic molecule, the corresponding macrocycle, 8147, was tested as well (Figure 
4.10).  To ensure that the compounds retained solubility, the ethanol and DMSO 
were included at the same concentration as in the initial screen. Neither cyclic nor 
acyclic variant appeared to inhibit in this dose-response retest, suggesting that the 
inhibition seen in the initial ELISA screen was an artifact. A high-prevalence of 
false-inhibition is a likely occurrence in the ELISA, as there are numerous separa-
tion steps compared to the FA assay. Thus, the ELISA has a higher probability of 
both human and systematic error. 
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Figure 4.10: Dose-response titration of the acyclic hit and its cyclic variant from Set 2 in the NE-
MO-capture ELISA. The compoudns were incubated at varying concentrations in the NEMO-cap-
ture ELISA up to 500 μM. Neither cyclic nor acyclic compound inhibits the interaction up to the 
highest concentration tested. 
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4.3.3 Small-Molecule Library Screen and Validation
In addition to the macrocyclic compound sets described above, a large set of 
2130 non-macrocyclic small molecules from the CMLD compound collection was 
screened in the NEMO FA assay, both to identify hits and to potentially further 
guide the development of macrocyclic inhibitors by identifying chemotypes that 
allow for NEMO/IKKβ inhibition (Set 3 and 4). The compounds in Set 3 were ini-
tially screened at 10 μM whereas the compounds in set 4 were assayed at 100 μM. 
Because of the relatively large size of the set, the compounds were plated directly 
into the assay plate by the CMLD staff using their automated equipment. Thus, the 
solubility of these compounds was not measured in the initial screen. Out of this 
set of 2130 compounds, 47 hits were identified (Appendix V), corresponding to a 
hit rate of 2.2% (Figure 4.11).
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Figure 4.11: Initial screen of 2130 compounds from the CMLD collection in the NEMO FA assay. 
2130 compounds from the CMLD library were tested in the NEMO FA assay at 100 μM. In total, 
47 hits inhibited to ≤80% activity (red dots).
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Due to challenges in re-synthesizing some of these compounds, only 27 of 
the 47 primary hits were available for re-testing in a dose-response format. Com-
pounds in Set 3 were screened at 10 μM in the primary assay and were titrated 
starting from 100 μM in the dose-response assay (Figure 4.12). Nearly all of these 
compounds showed no measureable inhibition up to 100 μM. In these cases the 
activity seen in the initial screen represents the results of random assay variance. 
However, one compound from this set, 8664, showed dose-dependent inhibition 
with an IC50 of 26 μM. However, the total fluorescence measured for the wells con-
taining this compound was significantly higher than the fluorescence in control 
wells (Table 4.3), suggesting that the compound is itself fluorescent and that the 
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Figure 4.12: Dose-response titration of Set 3 hits identified from the initial screen of the CMLD 
compound collection (Figure 4.11: Initial screen of 2130 compounds from the CMLD collection in 
the NEMO FA assay. 2130 compounds from the CMLD library were tested in the NEMO FA assay 
at 100 μM. In total, 47 hits inhibited to ≤80% activity (red dots).). The Set 3 hits were titrated in the 
NEMO FA assay up to 100 μM. Out of this set of compounds, only compound 8664 shows dose-de-
pendent inhibition, with an IC50 of 26 μM. 
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apparent inhibition is likely due to assay interference rather than to inhibition of 
NEMO/IKKβ binding. 
To further probe the nature of inhibition by 8664, the preparation of this 
compound was analyzed by HPLC. Impurities were discovered in this chromato-
gram, suggesting that the apparent inhibition that was observed could be due to a 
fluorescent contaminant (data not shown). To that end, the compound preparation 
was re-purified by HLPC by CMLD personnel. Two of the major species were sep-
arated and re-tested in a dose-response format in the FA assay (Figure 4.13). Nei-
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Figure 4.13: Dose-response titration of purified 8664, the fluorescent impurity, and the original 
inhibition curve from Figure 4.12: Dose-response titration of Set 3 hits identified from the initial 
screen of the CMLD compound collection (Figure 4.11). The Set 3 hits were titrated in the NEMO 
FA assay up to 100 μM. Out of this set of compounds, only compound 8664 shows dose-dependent 
inhibition, with an IC50 of 26 μM. Compared with the initial titration, neither compound shows the 
same amount of inhibition, suggesting that they are not the cause of false-inhibition. 
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ther purified 8664 nor the impurity showed dose-response inhibition. Most likely 
the fluorescent contaminant was not one of the two tested. Overall, these results 
showed that compound 8664 did not inhibit the NEMO/IKKβ interaction and thus 
is not a validated hit. 
Table 4.3: Potency, solubility, and spectral parameters for the re-screened small-molecule inhib-
itors. Inhibitors from the CMLD collection that were re-screened in the NEMO FA assay were 
analyzed for assay artifacts stemming from compound insolubility, fluorescence, or absorbance. 
The solubility limit is estimated based on the concentration that causes the absorbance at 700 nm 
to increase above the baseline signal. The fluorescence is calculated from the raw parallel and per-
pendicular fluorescence values (Equation 4.3) and is also expressed as a factor of the fluorescence 
of the IKKβ-fluorescein peptide. The absorbance was measured at the approximate wavelengths 
used for excitation and emission of the IKKβ-fluorescein peptide, and is expressed as a factor of the 
control absorbance. Values highlighted in yellow represent a threshold that could have a moderate 
effect on the reliability of the data, and values highlighted in red could have a large effect on the 
reliability (NT: not tested, ND: not detected). 
Compound IC50 Solubility Limit
Fluorescence Absorbance
490 nm 520 nm 490 nm 520 nm
Measured Normalized Measured Normalized
8664 26 μM NT 84.2 4.2 NT NT NT NT
3097 21 μM Good 15.0 0.7 0.040 0.038 1.2 1.2
6343 38 μM <500 μM 14.5 0.7 0.320 0.250 9.8 7.7
7493 120 μM <125 μM 88.0 4.1 0.210 0.180 6.4 5.5
7494 30 μM <500 μM 13.6 0.6 0.280 0.210 8.6 6.5
7546 >500 μM Good 19.7 0.9 0.040 0.039 1.2 1.2
7548 215 μM <125 μM 21.4 1.0 0.170 0.170 5.2 5.2
8829 30 μM Good 51.1 2.4 0.100 0.100 3.1 3.1
9637 >500 μM Good 23.74 0.8 0.036 0.035 1.1 1.1
9639 >500 μM <125 μM 28.49 1.0 0.178 0.166 5.3 5.0
9640 ND <125 μM 27.25 0.9 0.078 0.077 2.3 2.3
9641 39 μM <250 μM 79.05 2.8 0.215 0.204 6.4 6.1
9643 ND Good 26.65 0.9 0.035 0.035 1.0 1.0
9645 ND <250 μM 27.81 1.0 0.058 0.059 1.7 1.8
9646 ND <125 μM 26.02 0.9 0.339 0.306 10.1 9.2
9649 31 μM <62.5 μM 25.39 0.9 0.076 0.068 2.3 2.0
9650 ND Good 27.93 1.0 0.036 0.035 1.1 1.0
9651 51 μM <62.5 μM 27.29 1.0 0.049 0.046 1.5 1.4
Reserpine 50 μM <125 μM 65.25 2.3 0.049 0.043 1.5 1.3
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The hits in Set 4 were re-screened in the FA assay. These compounds were 
initially screened at 100 μM, and they were re-tested starting at 500 μM (Figure 
4.14). Many of these compounds did not inhibit NEMO binding to IKKβ, as seen 
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Figure 4.14: Dose response titration of the hits identified in Set 4 from Figure 4.11: Initial screen 
of 2130 compounds from the CMLD collection in the NEMO FA assay. 2130 compounds from the 
CMLD library were tested in the NEMO FA assay at 100 μM. In total, 47 hits inhibited to ≤80% ac-
tivity (red dots).. Hits from Set 4 were re-tested in the NEMO FA assay starting at a concentration 
of 500 μM. (A) Many of the compounds showed no inhibitory activity up to 500 μM. (B) Seven 
compounds showed inhibition with IC50s ranging from 21 μM to > 500 μM. 
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in Figure 4.14a. However, seven compounds gave a measurable IC50 in this assay 
(Figure 4.14b). The solubility of these compounds was generally good (Table 4.3). 
Compounds 7493 and 7548 were the least soluble, with a solubility limit of around 
125 μM. This limit also corresponds approximately to their IC50s (120 μM and 215 
μM, respectively), suggesting that inhibition is an artifact of poor solubility. The 
rest of the compounds were soluble up to at least 500 μM.  
A set of 19 additional compounds (Set 5) was identified with structures re-
lated to the seven validated hits from Figure 4.14, and were screened to elucidate 
the structure-activity relationships of hits identified. These compounds were test-
ed at 100 μM in the NEMO FA assay (Figure 4.15). As expected, many (14 out of 
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Figure 4.15: Initial screen of structurally analogous compounds to the hits identified in Figure 
4.14: Dose response titration of the hits identified in Set 4 from Figure 4.11: Initial screen of 2130 
compounds from the CMLD collection in the NEMO FA assay. 2130 compounds from the CMLD 
library were tested in the NEMO FA assay at 100 μM. In total, 47 hits inhibited to ≤80% activity (red 
dots).. Hits from Set 4 were re-tested in the NEMO FA assay starting at a concentration of 500 μM. 
(A) Many of the compounds showed no inhibitory activity up to 500 μM. (B) Seven compounds 
showed inhibition with IC50s ranging from 21 μM to > 500 μM. (Set 5). The Set 5 compounds were 
screened in the NEMO FA assay at 100 μM. almost all of these compounds appeared to inhibit the 
interaction. 
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Figure 4.16: Dose response titration of the hits identified in Set 5 (Figure 4.15: Initial screen of struc-
turally analogous compounds to the hits identified in Figure 4.14: Dose response titration of the 
hits identified in Set 4 from Figure 4.11: Initial screen of 2130 compounds from the CMLD collec-
tion in the NEMO FA assay. 2130 compounds from the CMLD library were tested in the NEMO FA 
assay at 100 μM. In total, 47 hits inhibited to ≤80% activity (red dots).. Hits from Set 4 were re-tested 
in the NEMO FA assay starting at a concentration of 500 μM. (A) Many of the compounds showed 
no inhibitory activity up to 500 μM. (B) Seven compounds showed inhibition with IC50s ranging 
from 21 μM to > 500 μM. (Set 5). The Set 5 compounds were screened in the NEMO FA assay at 100 
μM. almost all of these compounds appeared to inhibit the interaction.) re-tested starting at 500 
μM. (A) Some compounds showed no activity up to 500 μM. (B) Six of the re-tested compounds 
showed inhibition with IC50s ranging from 21 μM to > 500 μM.
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19) of these compounds show some degree of inhibition in the assay. Eleven out of 
the 14 compounds that appeared active in Figure 4.15 were available for resupply, 
and these 11 were re-tested in the FA assay to assess their potency (Figure 4.16). 
Five of these compounds were inactive as inhibitors up to 500 μM (Figure 4.16a). 
However, the remaining six did show a degree of inhibition, with potencies simi-
lar to those seen with the analogous compounds (Figure 4.16b).  
4.3.4 Secondary Validation of Small-Molecule Hits 
Many of the putative inhibitors identified in Sets 4 and 5 (Figure 4.14 and 
Figure 4.16) showed some degree of insolubility, increased fluorescence, or in-
creased absorbance in the FA assay at 500 μM (Table 4.3). Any of these properties 
could be indicative of false inhibition by modulation of the fluorescence signal of 
10 100
0
50
100
150
10 100 0.0001 0.01 1
3097 6343 IKKβ-click
Pe
rc
en
t B
in
di
ng
Compound (µM)
Figure 4.17: NEMO-capture ELISA titration of the two compounds that showed dose-response in-
hibition. Each compound was titrated in the ELISA and the resulting binding curve was fit to a four 
parameter fit. Only compounds 3097 and 6343 showed dose-response inhibition in the ELISA. The 
unlabeled IKKβ-click peptide was used as a positive control to show that the assay was functioning 
normally when the compounds were screened.  
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the IKKβ-fluorescein peptide. However, it is not clear from these properties alone 
whether any of the hits are causing aberrant inhibition. To that end, the NEMO 
ELISA was used as a secondary screening assay to see whether compounds re-
tain their activity in an assay with a completely different format and based on a 
non-fluorescent signal read-out (section 3.1). Thus, any false positive signal mod-
ulation in the FA screening assay that results from increased fluorescence or from 
the inner-filter effect cannot occur in the ELISA. The compounds were tested in 
the ELISA at the same concentrations as used in the NEMO FA assay (Figure 4.17). 
Only two compounds, 3097 and 6343, showed some degree of inhibition in this 
format, suggesting that all other hits in Table 4.3 were assay-dependent false pos-
itives and were not bona fide inhibitors of NEMO/IKKβ binding. The IC50 value 
obtained for 3097 in the ELISA, 41 μM, was quite similar to the value of 21 μM 
seen for this compound in the FA assay. Conversely, 6343 appeared nearly 12-fold 
weaker in the ELISA (38 μM compared to 460 μM), making it less likely that this 
compound is a true inhibitor. Partly for this reason, and partly because of difficul-
ties in obtaining additional quantities of 6343, currently only compound 3097 is 
being advanced as an inhibitor of NEMO. 
4.3.5 Properties of Compound 3097 
To further assess the likelihood of compound 3097 being a true NEMO in-
hibitor, drug-like properties were assessed. It is well known that compounds that 
are insoluble can cause false inhibition in screening assays due to the formation of 
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insoluble particles that denature or otherwise alter the assay components.160 One 
hallmark of this property is an especially steep inhibition curve, corresponding 
not to inhibition but to the solubility limit of the compound.160 An inhibition curve 
modeling true inhibition should show the data going from no to full inhibition 
over 1-2 orders of magnitude of the titrated compound. From the titration of com-
pound 3097 in the NEMO FA assay (Figure 4.14:) and the NEMO ELISA (Figure 
4.17), it appears that inhibition is achieved over a range of 1-1.5 orders of magni-
tude. This, along with the good solubility measurement (Table 4.3) implies that 
compound 3097 is not inhibiting through an insolubility mechanism.
4.4 Conclusions and Future Directions
None of the macrocyclic compounds tested showed activity as an inhibitor 
of NEMO/IKKβ binding. This is not surprising, as the computational and synthet-
ic methods used for the rational design of macrocycles are still being developed by 
the NEMO project team, and the compounds available for testing thus far repre-
sent the results of only the first few rounds of compound design and synthesis. It is 
likely that several more rounds of model refinement and better elaboration of the 
synthetic methods will be needed before a macrocyclic inhibitor can be identified. 
A single active compound (non-macrocyclic) was identified from the CMLD 
collection, and its activity was confirmed by eliminating the possibility of solubili-
ty-dependent and other assay artifacts, as shown in Table 4.3, and by showing that 
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the compound retained activity when tested in a different assay (ELISA) with an 
unrelated format and detection method.  For this inhibitor, 3097, one next step of 
validation involves obtaining proof of direct binding to NEMO. This step can be 
accomplished using a few different methods. One approach would be to use sur-
face-plasmon resonance, by immobilizing NEMO to a BIAcore chip surface and 
measuring binding of the small-molecule. Another approach would be to use one 
of several NMR methods that can report on protein-ligand binding. A preliminary 
saturation-transfer difference (STD) NMR experiment was performed to measure 
direct binding, by Dr. Stefan Jehle in the Allen group, though this experiment did 
not detect binding. The technical aspects of the method may need to be refined in 
order to accurately measure direct binding of 3097 to NEMO. Other members of 
the NEMO project team, in this case Prof. Thomas Gilmore and his co-workers, 
are additionally testing 3097 to evaluate its activity in cellular assays on NEMO 
function. 
At this point in the validation of 3097, none of the control tests rule out 
3097 inhibition due to a non-specific mechanism. Furthermore, it is possible that 
3097 interacts with NEMO by a covalent mechanism, labeling some key site on 
the protein in the region of IKKβ binding, biding directly to IKKβ, or by forming 
some reactive dimeric form that itself is covalently active. Once the mechanism of 
inhibition is determined, using direct biding measurements and determination of 
biological activity, 3097 may become a good lead for the development of drug-like 
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inhibitors of the NEMO/IKKβ interaction or will at least provide greater evidence 
for the tractability of this therapeutic mechanism. 
It is clear from this limited initial success that targeting the NEMO/IKKβ 
interaction with small-molecule inhibitors is a tractable. This is in agreement with 
the success of a separate research group in which a HTS was perfomed that yield-
ed seven unique small-molecule inhibitors of this interaction.127 Thus the ease by 
which our two research groups have identified inhibitors suggests that any pre-
vious limitations in NEMO inhibition have been due to the inherent difficulties in 
working with the protein and the previous lack of detailed information as to how 
NEMO interacts with IKKβ. I expect that the future will yield many more interest-
ing inhibitors. 
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Chapter 5: Biophysical Analysis of NEMO Interactions: Cooperativity 
of IKKβ Binding, and NEMO Oligomerization State 
5.1 Introduction
The oligomerization state of NEMO within and outside of the IKK com-
plex has been a topic of debate since the protein was discovered. Table 5.1 lists 
the oligomeric states that have been reported for NEMO, using different protein 
constructs, and the methods used in each case. A variety of oligomeric states have 
been observed for NEMO ranging from a monomer to pentamer. In an attempt to 
capture biologically relevant NEMO oligomers, several researchers used chemical 
crosslinking to “freeze” the proteins in their active forms and assessed oligomer-
ization by SDS-PAGE separation and Western blotting.84,87–89 This analysis yielded 
the observation of 1, 2, 3, and 4-mer NEMO species. Recent work has suggested 
that multiple copies of the IKK complex associate on chains of linear ubiquitin.97 
Depending on the chemical crosslinker used, there is a chance that two adjacent 
but non-interacting IKK complexes could become crosslinked, resulting in appar-
ent detection of a higher oligomeric state that would not represent a biologically 
relevant form of NEMO.  Researchers have therefore additionally characterized 
the association state of NEMO using in vitro biophysical techniques.86,87,113–119 In 
each studies, monomeric NEMO has been seen only in a few cases. Specifically, 
appreciable amounts of monomer were reported for full-length a murine NEMO87 
and for a 38-196 fragment of human NEMO113. Similarly, trimeric and pentam-
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NEMO Construct Method Reference
Monomer Full-length Cross-linking with SDS-PAGE Rothwarf 1998
134-419 Cross-linking with SDS-PAGE Rothwarf 1998
1-300 Cross-linking with SDS-PAGE Rothwarf 1998
Full-length (Murine) SEC, SV-AUC, SE-AUC Agou 2002
Full-length (In Vivo) Cross-linking with SDS-PAGE Agou 2002
Full-length Cross-linking with SDS-PAGE Huang 2002
38-196 SEC-MALS Lo 2008
Dimer Full-length Cross-linking with SDS-PAGE Rothwarf 1998
134-419 Cross-linking with SDS-PAGE Rothwarf 1998
1-300 Cross-linking with SDS-PAGE Rothwarf 1998
Full-length (Murine) SEC, SV-AUC, SE-AUC Agou 2002
Full-length (In Vivo) Cross-linking with SDS-PAGE Agou 2002
Full-length Cross-linking with SDS-PAGE Huang 2002
288-337 SEC Agou 2004
294-336 SEC Agou 2004
44-111 X-ray crystallography, SEC-MALS, SV-AUC Rushe 2008
38-196 SEC-MALS Lo 2008
150-272 X-ray crystallography Bagneris 2008
1-355 (C54S, K285N) SEC-MALS, SV-AUC Ivins 2009
254-337 X-ray crystallography Rahighi 2009
251-350 SEC-MALS Lo 2009
246-419 SEC-MALS Lo 2009
246-337 SEC-MALS, X-ray crys Lo 2009
249-343 - murine X-ray crystallography Yoshikawa 2009
251-337 - murine X-ray crystallography, SEC-MALS Grubisha 2010
Trimer Full-length Cross-linking with SDS-PAGE Rothwarf 1998
134-419 Cross-linking with SDS-PAGE Rothwarf 1998
1-300 Cross-linking with SDS-PAGE Rothwarf 1998
Full-length (Murine) SEC, SV-AUC, SE-AUC Agou 2002
Full-length (In Vivo) Cross-linking with SDS-PAGE Agou 2002
Full-length Cross-linking with SDS-PAGE Huang 2002
241-387 SEC, SE-AUC Agou 2004
251-337 SEC Agou 2004
248-287 SEC, SE-AUC Agou 2004
38-196 SEC-MALS Lo 2008
Tetramer Full-length Cross-linking with SDS-PAGE Teghethoff 2003
1-355 (C54S, K285N) SEC-MALS, SV-AUC Ivins 2009
Pentamer 38-196 SEC-MALS Lo 2008
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eric forms of NEMO were only seen with murine NEMO87 or with fragments of 
human NEMO encompassing the CC2 region of the protein90,113. It is clear that 
the oligomeric state that is observed depends on the NEMO construct generated, 
and also on the experimental method that is used. In general, most of the stud-
ies that reported NEMO monomers, trimers, or 5-mer complexes have significant 
complications, while the most recent and direct studies have tended to suggest 
that NEMO exists as a dimer and/or tetramer.84,86,87,89,90,113–119 Additionally, multiple 
crystal structures that have been reported for fragments of NEMO show a dimeric 
form.86,115–119 With the exception of the zinc finger domain, which exists in a mo-
nomeric state (Figure 1.6), all six NEMO structures, encompassing three distinct 
domains of NEMO,86,117–119 show the protein as a dimer. However, essentially all of 
these prior biophysical and structural studies done with human NEMO used ei-
ther truncations86,90,113–119 or alternate homologs of NEMO (Table 5.1),87 which raises 
the question of the biological relevance of the results. 
One of the best previous study investigating NEMO’s oligomeric state used 
analytical ultracentrifugation (AUC) and size-exclusion chromatography cou-
pled with multi-angle light scattering (SEC-MALS) to show that a recombinant 
NEMO(1-355) construct exists in equilibrium between a dimer and tetramer.114 
Like other previous studies, a NEMO truncation was used instead of full-length 
NEMO. However, the 1-355 form of NEMO used in this particular study encom-
Table 5.1: NEMO oligomerization. A variety of methods have been used to determine the oligomer-
ic state of recombinant and natively-expressed NEMO. Nearly all studies measure a NEMO dimer, 
including those that incorporated structural studies.
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passed residues 1-355, comprising ~85% of the NEMO sequence and longer than 
any other form of human NEMO analyzed by biophysical methods. Moreover, 
the study used a variety of direct biophysical methods to evaluate the size of the 
recombinant NEMO protein in solution. The results from this study are therefore 
the most likely to provide good information on the oligomeric state of full-length 
NEMO. The tetramer they observed was suspected to be an artifact of the high con-
centration used in the experiment, as it was inhibited by the addition of an IKKβ 
peptide, which suggested to the authors that tetramerization was a non-specific 
interaction involving the relatively hydrophobic IKKβ-binding region of NEMO. 
Despite the rigorous methods used in this report to characterize oligomerization, 
there is still the question of how the remaining one-sixth of NEMO (amino ac-
ids 356-419) that was absent from their construct might affect the oligomerization 
state. It is known that the C-terminus of NEMO is responsible for binding IκB and 
allowing it to interact with N-terminally bound IKKβ.122 Additionally, there are 
several disease-causing mutations in this region of NEMO that affect the proper 
functioning of the protein.105 Thus, this region of NEMO, which includes the zinc 
finger domain, which is missing in the 1-355 construct, holds importance in prop-
er NF-κB function, and it is not clear what the effect of the absence of this region 
might have on the oligomerization of NEMO. Due to the limitations in these prior 
studies, we sought to investigate the oligomeric state of NEMO using our full-
length constructs. 
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Many of the studies listed in Table 5.1 used a form of analytical ultracentrif-
ugation to study NEMO oligomerization. AUC is well-suited to the determination 
of the size and shape of proteins and the determination of the number of differ-
ent proteins in solution.163 In AUC, a protein sample is centrifuged at a constant 
speed in transparent cells contained within a centrifugation rotor, and the distri-
bution of the protein as a function of radial distance from the center of the rotor 
is measured by UV absorbance or interferometry. There are two different types of 
AUC that can be used to solve these properties, and they differ by how the data is 
collected. In a sedimentation velocity AUC (SV-AUC) experiment, sedimentation 
is monitored over time at one rotor speed. Sedimentation is dependent upon the 
forces on the protein during the experiment. These forces involve the centripetal 
force, which is a function of the mass of the protein, the rotor speed (ω), and the 
distance from the center of the rotor (r). There is also a counterforce from the mass 
of the solvent as the protein is subjected to the gravitational field. The counterforce 
reduces the centripetal force on the protein, such that the effective mass of the 
protein is described as its “buoyant mass” (Mb). Finally, the frictional force on the 
protein as it moves through the solvent is described by the frictional coeffeicent 
(f) and the velocity of motion. The effect of these parameters on the sedimentation 
properties of a protein are expressed in terms of a “sedimentation coefficient,” as 
shown in Equation 5.1.148,163,164 The Lamm equation combines the sedimentation 
and diffusion properties of a protein to describe its migration in an AUC cell , in 
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terms of how the distribution of the concentration of a protein at any point in the 
cell (c) will vary over time (t) (Equation 5.2).148,163
A different type of AUC experiment is called “sedimentation equilibrium” 
AUC (SE-AUC). This method involves sedimenting a protein at multiple rotor 
speeds such that the protein reaches an equilibrium distribution across the cell. 
The description of protein sedimentation at equilibrium is much simpler, and is 
described by variations of a simple exponential equation (Equation 5.3).163,164 In 
terms of physical parameters, sedimentation at equilibrium is only affected by the 
buoyant molecular weight of the sedimenting protein. Thus, this method is the 
preferred method for determining the molecular weight, oligomerization state, or 
association state of proteins in solution. 
Apart from questions of the oligomerization state of NEMO, the degree 
by which IKKβ binds cooperatively has not yet been studied. IKKβ is a large pro-
tein that intrinsically forms a dimeric structure.135–137 None of the three crystal 
structures of IKKβ reveal the structure of the NBD region. It is likely that this 
region of IKKβ is intrinsically unstructured when not bound to NEMO. Similarly, 
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it has been shown that the N-terminus of NEMO is unstructured in the absence 
of IKKβ.86 One way that the interaction between NEMO and IKKβ achieves high 
affinity despite the region of interaction on both proteins being disordered could 
be through a cooperative process. To date, there have been no studies measuring 
the phenomenon for NEMO. 
In this chapter, I describe the characterization of the oligomeric state of 
NEMO using analytical ultracentrifugation and fluorescence anisotropy. A meth-
od to achieve site-specific fluorescent labeling of full-length NEMO was devel-
oped to support these studies. Furthermore, the degree of cooperativity of IKKβ 
binding to NEMO was measured by FRET. 
5.2 Materials and Methods
5.2.1 Materials
The 5xAla NEMO construct was expressed and purified as described in 
Section 2.2.2. The IKKβ-fluorescein peptide was prepared as discussed in Section 
2.2.5.
5.2.2 Analytical Ultracentrifugation of 5xAla NEMO
A sample of 5xAla was dialyzed overnight against 20 mM sodium phos-
phate pH 7.4, 150 mM NaCl, and 2.5 mM TCEP. A two-sector sedimentation ve-
locity cell was filled with 430 μL of buffer in one sector and 420 μL of the dialyzed 
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protein at 40 μM, 20 μM, or 7 μM in the other sector. A sedimentation velocity ex-
periment was performed at 4 °C at 40,000 rpm in a Beckman XL-I AUC instrument. 
The cell absorbance at 280 nm was monitored over 24 h.  
To determine the distribution of species, a g(s*) distribution was modeled 
in SedAnal.165–167 Scans 25-34 from each cell were analyzed to generate a time-inde-
pendent plot of the distribution of species. The plots were normalized by dividing 
all values by the sedimentation coefficient of the major peak in cell 1. The SV-AUC 
data were also analyzed by a continuous sedimentation (c(s)) distribution in Sed-
Fit.168 
5.2.3	 Labeling	of	10xAla(396C)	NEMO
The 10xAla(396C) NEMO construct was developed using the mega-primer 
quick change protocol (Section 2.2.1) using 11xAla NEMO-pET24b(+) as the base 
construct and the primers listed in Appendix I. The mutated sequence was con-
firmed by sequencing. The protein was expressed and purified using the standard 
protocol described in Section 2.2.2.
To prepare the protein for labeling, a 40 μM sample of the protein was buf-
fer exchanged into 20 mM phosphate pH 7.4, 500 mM NaCl, and 10 mM TCEP. 
TCEP was not removed prior to labeling as the protocol indicated that maleimide 
does not readily react with this reducing agent. The fluorophore – DyLight 594 
Maleimide (Pierce) or BODIPY® FL N-(2-Aminoethyl))Maleimide (Life Technolo-
gies) – was dissolved in anhydrous DMSO to 10 mM, and was added dropwise to 
156
the protein sample  up to a final volume of 400 μM fluorophore, giving a 10-molar 
excess over 10xAla(396C) NEMO monomer. The DyLight labeling reaction was 
incubated for 1 h at room temperature, and the labeled NEMO (NEMO-594) was 
purified using a standard nickel affinity purification protocol, as follows: The la-
beling reaction mixture was loaded onto a 5 mL HisTrap FF crude column (GE 
Healthcare, Piscataway, NJ) and washed with 5 column volumes of 20 mM sodi-
um phosphate, 500 mM NaCl, 40 mM imidazole, at pH 7.4. The bound and labeled 
protein was eluted using a step gradient of 8, 17, 40, 60, and 100% elution buffer 
(20 mM sodium phosphate at pH 7.4, 500 mM NaCl, and 500 mM imidazole). 
The BODIPY labeled protein (NEMO-BODIPY) precipitated upon mixing 
of the protein and fluorophore, indicating that the labeled protein was insoluble in 
20 mM phosphate with 500 mM NaCl at pH 7.4. The precipitated labeled protein 
was pelleted and washed with 20 mM phosphate with 500 mM NaCl at pH 7.4 to 
remove the excess labeling reaction components. The labeled protein was solu-
bilized in a denaturing buffer (20 mM phosphate pH 7.4, 500 mM NaCl and 6 M 
urea) and was used in this form. 
5.2.4 Fluorescence Anisotropy Studies of Labeled NEMO
To measure NEMO higher-order oligomerization, both of the labeled 
NEMO proteins were analyzed using a fluorescence anisotropy assay. The con-
centration of the tracer probe (either NEMO-594 or NEMO-BODIPY) was fixed at 
100 μM. The concentration of unlabeled 5xAla NEMO was varied. The NEMO-594 
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and NEMO-BODIPY (hereby referred to as NEMO-fluor) FA assays were other-
wise performed identically to other FA binding assays (Sections 2.2.5 and 3.2.2). 
The resulting binding data were fit using a hyperbolic curve fit (Equation 5.4).
The effect of viscosity on the anisotropy of IKKβ-fluorescein was measured 
in the standard NEMO FA assay (Section 3.2.2), with the exception that one of three 
different proteins or glycerol was added in place of the NEMO. Bcl-xL prepared 
as in Section 3.2.5, BSA (Thermo Scientific), thyroglobulin (Sigma Aldrich), and 
glycerol were varied in the anisotropy assay in the presence of 15 nM IKKβ-fluo-
rescein. The assay was performed identically to that in Section 3.2.2. 
Equation 5.5 was used to fit the viscosity data. This equation is a modifi-
cation of Equation 3.1 to allow for the fitting of a viscosity coefficient (ηc) rather 
than an empirical measurement of the viscosity. In this equation, τ was set at 4 
ns for the fluorescein or DyLight 594 dye and 5 ns for the BODIPY FL dye. R was 
fixed at 8.14x107, T at 293 K. The values for molecular weight (M), partial specific 
volume (v), and hydration (h) were calculated from the protein sequence entered 
in Sednterp. 
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5.2.5	 FRET-Based	Cooperativity	Measurements
To measure cooperativity of IKKβ(45-mer) peptide binding to the two 
binding sites on the opposite faces of the NEMO dimer, a FRET assay was devel-
oped. Fluorescein-based fluorophores have a significant degree of spectral over-
lap between the excitation and emission light,139 and FRET can be achieved when 
two fluorescein-based fluorophores are in close proximity (termed self-FRET 
or self-quenching). FRET between two IKKβ-fluorescein peptides bound to the 
NEMO dimer was measured by calculating the total IKKβ-fluorescein fluorescence 
intensity (excitation: 488 nm; emission: 520 nm) measured in the NEMO binding 
site titration assay (Section 2.2.5). Anisotropy is calculated using the fluorescence 
intensity of the emission light parallel and perpendicular to the original polariza-
tion plane. The total fluorescence can be calculated by the parallel and perpen-
dicular fluorescence intensities using Equation 4.3, which is equivalent to the de-
nominator in anisotropy calculation.139 Because the data in these experiments were 
taken at five different IKKβ-fluorescein concentrations, the data were normalized 
by dividing the fluorescence intensities at each NEMO concentration by the fluo-
rescence intensity of IKKβ-fluorescein in the absence of NEMO. The data were fit 
using a linear curve for the association of NEMO and IKKβ up to the equivalence 
point, and Equation 5.6 was used to model an uncooperative binding process as 
doubly IKKβ-fluorescein distributes among an excess of NEMO. The full deriva-
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tion of this equation is in Appendix VI. In this equation, the fluorescence signal is 
correlated to the total concentration of IKKβ and NEMO by the fluorescent coef-
ficients for free IKKβ (CIKKβ) and the homoquenched signal for the doubly-bound 
NEMO dimer (C(NEMO/IKKβ)2). The value for CIKKβ, was fixed as a constant value that 
was determined by dividing the IKKβ-fluorescein fluorescence by the concentra-
tion of IKKβ-fluorescein. Similarly, C(NEMO/IKKβ)2 was fixed at the fluorescence signal 
at the equivalence point divided by the concentration of IKKβ-fluorescein.
5.3 Results and Discussion
5.3.1	 Sedimentation	Velocity	AUC	Shows	that	Recombinant	5xAla	NEMO	Exists	as	a	
Mixture	of	Two	Different	Dimeric	Species
To directly determine the oligomeric state of NEMO, we performed a sed-
imentation velocity experiment using 5xAla NEMO. NEMO forms an extended 
rod-like structure,113,114 therefore determining the molecular weight by comparing 
to globular protein standards run on a gel-filtration column gives an overestimate 
of the true molecular weight. This deviation from globularity complicates not only 
the determination of the molecular weight of recombinantly produced NEMO, but 
the extent of oligomerization as well. 
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A previous study using a truncated NEMO construct encompassing resi-
dues 1-355, using the method of SV-AUC, showed concentration-dependent te-
tramerization of the protein.114 In our own experiments, the FA binding curves 
shown in previous chapters (Figure 2.8, 2.10, and 2.19), suggested the possible 
existence of higher-order NEMO oligomers. As discussed in Chapter 3, the signal 
from an FA assay is dependent on the diffusional motions – and therefore the size 
– of the fluorescently labeled species. In the case of NEMO binding to IKKβ, the 
signal arises from the difference in size between the IKKβ-fluorescein molecule 
and the NEMO/IKKβ-fluorescein complex. Given that NEMO is titrated to excess 
over the IKKβ peptide, the anisotropy signal should saturate at a constant amount, 
representing complete binding of the IKKβ-fluorescein molecule. However, there 
is additional signal at high NEMO concentration. One explanation for this signal 
is an additional binding event that occurs at high NEMO concentration. It is likely 
to assume that a NEMO tetramer bound to IKKβ-fluorescein could give a higher 
signal than a NEMO dimeric complex. An SV-AUC experiment using full-length 
5xAla NEMO should enable us to determine whether NEMO does tetramerize, 
and whether a NEMO tetramer is responsible for the increasing anisotropy signals 
that we see at high NEMO concentrations.
We performed an SV-AUC experiment using three concentrations of NEMO 
(40 μM, 20 μM, and 7 μM). We chose a rotor speed of 40,000 RPM to mirror the 
analysis performed on the NEMO(1-355) construct.114 The raw data for each cell 
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Figure 5.1: Sedimentation velocity analytical ultracentrifugation data. The migration of NEMO was 
measured along the length of the cell over time. Each cell (cell 1, 40 μM; cell 2, 20 μM; cell 3, 7 μM; 
cell 5, 40 μM; cell 6, 20 μM; and cell 7, 7 μM) was monitored at 280 nm and a buffer subtraction 
was used to pre-process the data. The meniscus for the buffer sector in cell 6 was not aligned to the 
sample meniscus, causing an incorrect buffer subtraction.
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are shown in Figure 5.1. The data from cell 6 were discarded, as the buffer and 
sample menisci were not aligned properly, leading to improper buffer absorbance 
subtraction. This is seen in the break in the scans at ~6.28 cm (Figure 5.1). The data 
appear to show the presence of more than one species, as indicated the multiple 
boundaries in nearly every scan (Figure 5.2). To determine the number of species 
present in solution the data were analyzed using a g(s*) distribution.166,167 To fit the 
data to this distribution, a subset of the scans is selected and pairs of scans within 
this subset are subtracted. This yields a dc/dt plot, referred to as the time deriva-
tive plot. The x-axis for these subtracted scans is transformed from the radius of 
the cell to an apparent sedimentation coefficient (s*). Finally, the subtracted scans 
from the dc/dt plot are averaged together. This distribution is known as a “mod-
el-free” distribution as it makes no assumptions of the physical properties of the 
particles in solution and does not use the Lamm equation to solve for these proper-
ties.166,167 While it does not give any information on the properties of the particles, 
it is useful as an initial step toward fitting to more computationally-intensive mod-
els. The g(s*) distribution can give some insight into the number of species and 
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Figure 5.2: Scans 25-30 of cell 1. There appear to be multiple boundaries in the sedimentation 
curves, suggesting that the protein is a heterogeneous population of proteins or oligomers. 
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their approximate sedimentation coefficients by the number of peaks and where 
they fall on the x-axis. Furthermore, any concentration dependence of the presence 
and number of the peaks can indicate that there is reversible oligomerization. The 
g(s*) distribution method was used to determine these properties for each cell by 
using 10 scans (scans 25-34). The g(s*) distribution shows a major peak with a sed-
imentation coefficient maximum at 1.8 S (Figure 5.3). If it is assumed that this is the 
sedimentation coefficient of the full-length NEMO dimer, this value is significant-
ly lower than the 3.0 S quoted for the NEMO(1-355) construct.114 The g(s*) distribu-
tion also shows a smaller peak at 3.2 S. Similar to the analysis of the NEMO(1-355) 
construct,114 the presence of this peak appeared to be dependent on the concentra-
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Figure 5.3: G(s*) distribution of 5xAla NEMO. The g(s*) distributions were normalized using the 
major peak in Cell 1 as the maximum g(s*) value. The distribution modeled from each cell looks 
similar, showing a major peak at ~1.8 S and a minor peak at ~3.2 S. 
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tion of NEMO. However, given that the sedimentation coefficients measured in 
this study do not match the values determine in Ivins et al. 2009,114 it is likely that 
there is a significant difference between the proteins used in each study. 
The g(s*) distribution analysis for 5xAla NEMO does not preclude the pres-
ence of more than two species. To more accurately determine the distribution of 
the species and their physical properties, the data were analyzed using a continu-
ous c(s) distribution (Figure 5.4). The c(s) distribution solves the Lamm equation 
(Equation 5.2) with the assumptions that the species in solution are non-interact-
ing and they have the same weight-average frictional ratio – that is, they are all 
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Figure 5.4: c(s) distribution of 5xAla NEMO. The sedimentation traces for each cell were fitted to a 
continuous c(s) distribution to model the number of species, their sedimentation coefficients, and 
their frictional ratios. 
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the same shape and the frictional ratio scales with mass. The sedimentation coef-
ficient for the major component is at ~ 1.8 S, consistent with the g(s*) distribution. 
The results from Chapter 2 (Figure 2.11b) indicate that in the presence of 2.5 mM 
TCEP, 5xAla NEMO exists primarily as a non-covalent dimer with a small amount 
of covalently crosslinked dimer. If this cross-linked form is shaped differently, it 
should have a different sedimentation coefficient. The c(s) distribution indicates 
that there is one or two additional species with a high sedimentation coefficient 
(~2.8 to 4 S). The peaks in this area are obscured in the cell 3 and 7 traces, as that 
absorbance data from that condition was at the limit of detection. However, it 
is highly likely one of these peaks corresponds to the crosslinked NEMO dimer. 
Neither peak appears to be dependent on the concentration of NEMO, in contrast 
to the results from Ivins et al.114 The full-length form of NEMO used in this study 
does not show the same reversible tetramerization. 
5.3.2 Tetramerization of Full-Length NEMO is not Seen by Fluorescence Anisotropy
It was not clear by SV-AUC whether 5xAla NEMO tetramerizes. As an al-
ternative way to test for the formation of NEMO tetramers, a fluorescent variant of 
NEMO was created. In Section 2.3.6, the NEMO construct containing 11 Cys to Ala 
mutations was shown to be fully active for binding to IKKβ, and by CD spectros-
copy this construct looked structurally similar to other NEMO constructs tested. 
We therefore used this 11xAla NEMO as a base for the introduction of a single 
cysteine residue to allow site specific labeling of the protein with a thiol reactive 
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fluorophore. As discussed in Chapter 2, Cys396 is the only residue on NEMO that 
(1) does not come in contact with IKKβ, and (2) there is structural information that 
this residue is solvent exposed (Figure 2.17). Thus, the 10xAla(C396) construct was 
developed. Because there is only one Cys residue in this construct, thiol-reactive 
maleimide chemistry can be used to label that residue with a fluorophore. 
As described in Chapter 3, the selection of a fluorophore is critical in re-
solving the bound and free states under study by FA. Therefore, to choose a fluo-
rophore suitable for measuring the NEMO dimer-tetramer equilibrium by FA we 
calculated the figure of merit for measurement of a rod-like NEMO dimer tetram-
erizing into a similarly rod-like structure (Appendix II, Figure 5.5). Based on the 
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Figure 5.5: Figure of merit plot of a rod-like NEMO dimer forming into a tetramer. The optimal 
fluorescence lifetime to resolve these two states is 75 ns. The two commercial fluorophores used to 
label NEMO are indicated on the plot.
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results, two fluorophores were chosen to label the protein: DyLight 594 Maleim-
ide and BODIPY® FL N-(2-Aminoethyl))Maleimide. The DyLight 594 fluorophore 
is more water soluble and should have a minimal effect on the solubility of the 
labeled protein. However, the figure of merit for this fluorophore is lower than 
BODIPY FL and it may not be able to fully resolve the two states. Conversely, 
BODIPY FL should give more well-resolved anisotropy signals. This fluorophore, 
however, may hinder the aqueous solubility of NEMO. These two fluorophores 
were chosen despite their sub-optimal fluorescence lifetimes as there were no oth-
er commercial fluorophores with better lifetimes. 
The 10xAla(C396) NEMO construct was labeled with each of these two fluo-
rophores. The protein was readily labeled with DyLight 594, coming to near 100% 
labeling efficiency after 30 min as assessed by SDS-PAGE (Figure 5.6a). When the 
protein was labeled with BODIPY FL, the protein immediately precipitated. When 
the precipitate was analyzed by SDS-PAGE, a large, fluorescent band for NEMO 
was apparent (Figure 5.6b). Thus, the BODIPY FL-labeled protein was insoluble 
under normal buffer conditions. However, the protein could be solubilized when 
denatured (as seen by the normal migration after boiling in SDS sample buffer). 
Furthermore, the longer fluorescence lifetime of BODIPY FL means that it is the 
preferred label for this analysis. To increase the usefulness of this construct, the 
protein was concentrated in buffer containing 6 M urea. Since the protein sponta-
neously refolds in the absence of urea as determined by the standard purification 
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protocol (Section 2.2.2), dilution from this concentrated stock into buffer contain-
ing no urea should result in a dilute, folded solution of labeled protein. 
The labeled proteins were tested in an anisotropy assay designed similarly 
to the NEMO/IKKβ FA assay. In the current experiments, the concentration of the 
fluorescent NEMO protein was held constant, and unlabeled 5xAla NEMO was 
varied to measure the tendency of the unlabeled NEMO to bind to the labeled pro-
tein to form NEMO tetramers (Figure 5.7). To reduce the effect of the formation of 
homotypic NEMO dimers, 5xAla NEMO was used as the unlabeled protein. The 
data analysis could be complicated by the formation of a NEMO dimer composed 
of one molecule of labeled NEMO and one molecule of unlabeled NEMO. Binding 
of both labeled forms of NEMO is shown in Figure 5.8. It is clear that there is an in-
crease in the anisotropy signals at high concentrations of unlabeled 5xAla NEMO, 
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Figure 5.6: Labeling of 10xAla(C396) NEMO with (A) DyLight 594 and (B) BODIPY FL. The 
594-labeled protein was reasonably soluble and migrated normally by SDS-PAGE. Conversely, 
the BODIPY FL-labeled protein precipitated upon labeling. SDS-PAGE analysis of the precipitate 
shows that it is indeed the labeled protein that precipitated. 
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suggesting that the 5xAla NEMO is binding to the labeled protein. However, the 
binding curve does not plateau even when NEMO is added at 100 μM (Figure 
5.8b). If 5xAla NEMO tetramerizes with the same dissociation constant as in Ivins 
et al. (25.6 μM)114 the binding curve should reach approximately 80% of the max-
imum signal at 100 μM (as simulated by Equation 5.4). To reach full saturation, 
unlabeled NEMO should be present in excess of 250 μM. However, NEMO is not 
soluble at concentrations greater than 200 μM, and it may be impossible to fully 
define the binding curve due to this limitation.   
Furthermore, as NEMO is concentrated, the resulting solution tends to be 
more viscous than dilute NEMO solution. Anisotropy is dependent on the mo-
lecular motion of a fluorophore. Generally this method is exploited to measure 
binding of a protein to a fluorophore-labeled binding partner, as in our assay, de-
scribed in Chapter 3, for NEMO binding to IKKβ-fluorescein. However, molecular 
motion is not only slowed by binding. As discussed in Chapter 3, anisotropy is 
described by the Equation 5.7, in which r is anisotropy, ro is the maximum achiev-
Labeled NEMO NEMO Tetramer
Unlabeled
NEMO
Figure 5.7: NEMO tetramerization scheme.
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Figure 5.8: Labeled NEMO titration with unlabeled NEMO. Titration of 5xAla NEMO was mea-
sured with (A) NEMO-594 and (B) NEMO-BODIPY. Neither set of titration curves saturate at high 
NEMO concentration, suggesting that the curves are modeling a phenomenon other than tetram-
erization.
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able anisotropy, τ is the fluorescence lifetime, R is the molar gas constant, T is the 
temperature, M is the molecular weight, v is the specific volume of the fluorescent 
complex, h is the hydration of the fluorescent complex and η is the viscosity of the 
solution. It is clear from this relationship that anisotropy is equally dependent on 
the size of the complex and on viscosity. A concentrated protein solution tends to 
be more viscous than if the protein were dilute.169 It is likely that a rod-like protein 
will induce higher viscosity than a globular protein at a similar concentration. Due 
to the dependence of anisotropy on the solution viscosity, a set of experiments 
was performed to parse out the viscosity contribution from concentrated protein 
solutions. 
To explore the effect on the observed anisotropy of viscosity arising from 
high protein concentrations, we measured the anisotropy of the IKKβ-fluorescein 
peptide in the presence of varying concentrations of three proteins, Bcl-xL, BSA, 
and thyroglobulin. These three proteins represent small (Bcl-xL) and large (BSA) 
globular proteins and a large non-globular protein (thyroglobulin). The results 
show a clear trend toward increased anisotropy signals at high protein concentra-
tion for each of the proteins tested (Figure 5.9). Upon fitting the curves to a modi-
fied version of Equation 5.7, the viscosity coefficient can be determined (Table 5.2). 
Equation 5.7
r r RT
M v h
o=
+
+( )
1 τ
η
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The contribution of viscosity upon the anisotropy signal is more pronounced for 
the larger and non-globular thyroglobulin protein. In comparison, the coefficient 
for NEMO-594 shows a similar trend (Table 5.2). However, the NEMO-BODIPY 
coefficient, despite being a measured from a similar construct, is much lower 
than any other coefficient tested. The likely explanation for this discrepancy is 
due to the fact that the protein is denatured prior to incubating in the assay. The 
assay was performed under the assumption that by diluting the concentrated NE-
MO-BODIPY stock solution in the assay, the protein would spontaneously re-fold. 
It is clear that this is not the case for the protein, as the viscosity coefficient implies 
that the fluorescent complex is smaller or more globular than Bcl-xl. Overall, these 
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Figure 5.9: Titration of Bcl-xL, BSA, and thyroglobulin. The anisotropy of the IKKβ-fluorescein 
peptide was tested in the presence of three non-interacting proteins (blue, red, and green) and 
glycerol (black, inset) to assess the non-specific effects of viscosity on the signals. 
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data imply that indeed there may be a viscosity component to the binding curve 
seen for NEMO in Figure 5.8, and thus that the FA data for NEMO do not indicate 
formation of a NEMO tetramer. The data for the three control proteins do not de-
finitively preclude the possibility that the proteins are non-specifically binding the 
peptide. However, comparing the shape of the curves to that of when glycerol is 
present (Figure 5.9b), the data seem consistent with the effects of viscosity and do 
not show any hint of saturating binding. 
5.3.3	 Binding	of	IKKβ	to	the	NEMO	Dimer	is	not	Cooperative
The NEMO dimer has two binding sites for IKKβ. All studies in this work 
have used peptides derived from IKKβ rather than the full-length IKKβ protein. 
However, published X-ray crystal structures of IKKβ along with other biophysical 
evidence suggest that this protein is constitutively dimeric (see section 1.5 for a 
more detailed discussion).135–137 While none of these structures contains the NBD 
region of the IKKβ protein, since there are extensive contacts between IKKβ sub-
units, it is reasonable to assume that there may be a degree of cooperativity be-
tween the two domains binding to NEMO. To measure whether the IKKβ 45-mer 
peptide shows cooperativity in binding to NEMO, a FRET assay was developed. 
Protein Viscosity Coefficient
Bcl-xL 51,768
BSA 196,863
Thyroglobulin 2,126,000
NEMO-BODIPY 2720
NEMO-594 150,335
Table 5.2: Calculated viscosity coefficients for various proteins and fluorescent NEMO constructs. 
The viscosity coefficient increases for larger and more non-globular proteins. 
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Fluorescein-based fluorophores have a significant degree of overlap between the 
excitation and emission spectra. If two such fluorophores are brought in close 
proximity, they will exhibit self-quenching or self-FRET.139 This phenomenon can 
be exploited in the case of NEMO/IKKβ binding to distinguish NEMO to which a 
single IKKβ-fluorescein peptide has bound from NEMO bound by two IKKβ-flu-
orescein molecules. The Förster radius describes the distance at which the energy 
transfer between two fluorophores is 50% efficient.139 This value is 44 Å for two 
fluorescein fluorophores and the distance between the two IKKβ binding sites is 
~20.6 Å (Figure 5.10). Thus, when two IKKβ-fluorescein molecules bind to the same 
NEMO molecule, FRET between the two fluorophores should be >50% efficient, 
resulting in a significant reduction in fluorescence brightness per fluorophore. 
The affinity of the NEMO/IKKβ interaction measured in this study was 2.2 
± 0.8 nM. When IKKβ-fluorescein is added at a fixed concentration in excess of this 
value, binding to NEMO follows a quadratic model. If the IKKβ-fluorescein pep-
tide is in a great excess, the stoichiometric equivalence point of the reaction can be 
20.6 A°
Figure 5.10: Distance between bound IKKβ molecules. The attachment point for the fluorescein 
molecule is at the N-terminus of the peptide. The calculated distance between the N-terminal 
α-carbons is ~ 20.6 Å.
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defined with high precision. In the NEMO FA assay, this endpoint is represented 
by the maximum anisotropy signal (Figure 2.10). However, if the data are ana-
lyzed in terms of IKKβ-fluorescein homoquenching, the endpoint is determined 
by the lowest FRET signal. For the FRET assay, titration of NEMO to this equiva-
lence point represents full occupancy of the two binding sites on NEMO by IKKβ 
(Figure 5.11). After the equivalence point, the degree of cooperative binding can be 
assessed by the FRET response as NEMO is titrated to excess. 
If binding is highly cooperative, there would be no re-distribution among 
excess NEMO, and IKKβ will exist solely in 2:2 complexes. The FRET signal for 
this situation will remain fully quenched (Figure 5.11). However, if binding is not 
Figure 5.11: Cooperativity binding scheme. When NEMO is titrated against a fixed concentration 
of IKKβ, each site on NEMO becomes fully occupied at the equivalence point. When NEMO is 
titrated to excess, the system can exhibit strong cooperativity, in which IKKβ is not distributed 
across new NEMO molecules. In this case, the FRET signal will remain quenched. If there is no co-
operativity, IKKβ would then be fully distributed across excess NEMO to form a 2:1 NEMO:IKKβ 
complex. This complex would relieve any self-quenching. 
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cooperative, there would be a re-distribution of the IKKβ peptides among excess 
NEMO, and IKKβ will eventually exist only in 2:1 NEMO:IKKβ complexes. This 
complex should relieve homoquenching, and the signal should return to baseline 
values (Figure 5.11). Alternatively, the system may be less strongly cooperative – 
that is, quenching of fluorescence is relieved only to a partial extent in the presence 
of excess NEMO. 
 Self-quenching was measured in a binding experiment between NEMO 
and IKKβ (Figure 5.12). The fluorescence intensity data from Figure 2.10 were 
plotted as a function of NEMO dimer concentration. To determine the degree of 
cooperative binding, the data were analyzed by two functions. First, a linear curve 
fit was applied to the data to account first for the initial association of IKKβ up to 
the equivalence point, where both IKKβ-binding sites on NEMO are filled and the 
maximum homoquenching is achieved. After the equivalence point, Equation 5.6 
was used to plot the expected relief of homoquenching due to the distribution of 
IKKβ-fluorescein across excess NEMO. There were several assumptions used to 
model this region of the data. The fluorescence coefficient for free IKKβ-fluores-
cein was held at a fixed value that was determined by dividing the fluorescence 
value of free IKKβ-fluorescein by its concentration. For simplicity in modeling, 
the fluorescence of a NEMO dimer bound to one IKKβ-fluorescein molecule was 
assumed to be equivalent to free IKKβ. The fluorescence coefficient for the doubly 
bound NEMO/IKKβ complex was similarly constrained to the value of the fluo-
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rescence at the equivalence point divided by the IKKβ-fluorescein concentration. 
These assumptions worked well to model the data, as in all concentrations of IK-
Kβfluorescein tested the curve adequately returned to the baseline IKKβ-fluores-
cence value. Conversely, the highly-cooperative curve was modeled for each con-
centration tested simply by a straight line at the minimum fluorescence, defined 
by the equivalence point. 
For each concentration of IKKβ-fluorescein tested, binding appears to be co-
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Figure 5.12: Assessment of cooperative binding of IKKβ binding to NEMO. The fluorescence in-
tensity of IKKβ-fluorescein was measured as NEMO was titrated. IKKβ-fluorescein was tested at 
(A) 31.25 nM, (B) 62.5 nM, (C) 125 nM, and (D) 250 nM. The fluorescence of free IKKβ-fluorescein 
is indicated by the black dotted line on each curve. The data were fit with a linear curve fit up to 
the equivalence point to model initial formation of a NEMO/IKKβ tetramer. After the equivalence 
point, a simulation of the data was applied to show the expected trend in fluorescence when the 
IKKβ-fluorescein peptide is allowed to distribute among excess NEMO, indicating a non-cooper-
ative binding process (solid colored line) or a simple highly cooperative process (dotted colored 
line). 
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operative. However, there are a few limitations to the analysis of the data. At con-
centrations of NEMO greater than 625 nM, the data begin to decrease, rather than 
approaching the maximum fluorescence value. It is not clear why the data behave 
this way. One explanation for the anomalous data at high NEMO concentrations 
is that equilibrium had not yet been achieved in each case. Thus, IKKβ-fluorescein 
may not have had sufficient time to fully equilibrate across NEMO dimers. It is im-
portant to note that the experiment was performed by adding IKKβ-fluorescein to 
a solution of NEMO, rather than the other way around. This order of addition has 
the benefit of ensuring that a local concentration gradient is not formed by adding 
NEMO in second. In this case, NEMO could bind to molecules of IKKβ, and full 
equilibration of IKKβ would increase the overall equilibration time. Similar to the 
anomalous FA signals described in Chapter 2 and in this chapter, the high con-
centration of NEMO could affect the overall fluorescence by a non-specific solvent 
mechanism. Fluorescence is highly dependent on the solvent environment, and is 
affected by the solvent polarity and viscosity, both of which could be influenced 
by increasing concentrations of NEMO. 
Overall, it is clear that the binding of IKKβ to NEMO is cooperative, though 
the exact extent of cooperativity was unable to be measured. This is the first known 
study to show that this process is cooperative, and may have implications for un-
derstanding the biology of this interaction. For example. it may be interesting to 
measure the effect of the homologous IKKα protein in the same assay. This protein 
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shares ~50% sequence identity with IKKβ, but it is not suspected to play a large 
role within the IKK complex in normally functioning cells. 
5.4 Conclusions and Future Aims
Here, we have shown that under mildly reducing conditions 5xAla NEMO 
exists in a mixed state between differently oxidized dimers and a non-covalent 
dimer in vitro. It is likely that the oxidation is dependent on either one or both of 
the Cys residues. Furthermore, we have shown that the 5xAla construct, unlike 
the NEMO(1-355) construct, does not readily form tetramers. However, the AUC 
study was complicated by the heterogeneity of the 5xAla NEMO preparation. We 
have proposed a likely explanation for the anomalous FA signals observed at high 
NEMO concentrations and shown that this is not responsible for NEMO tetramer-
ization. Finally, we have shown that the binding of IKKβ to NEMO is cooperative. 
These studies should be supplemented by the use of a homogeneous NEMO con-
struct, i.e. one that is fully oxidized or reduced, to ensure that the analysis of these 
results is not complicated by the presence of multiple NEMO species.
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 Appendix I) Primers Used for Cloning
Construct Use Direction Sequence
WT NEMO Cloning Forward CTTTAAGAAGGAGATATACATATGAATAGGCACCTCTGGA
pET24b(+) Reverse GTGGTGGTGGTGGTGCTCGAGCTCAATGCACTCCATGACA
7xAla NEMO Cloning Forward CTTTAAGAAGGAGATATACATATGAATAGGCACCTCTGGA
 pET24b(+) Reverse GTGGTGGTGGTGGTGCTCGAGCTCAATGCACTCCATGACA
5xAla NEMO Cloning Forward GATATACATATGAACCGCCATCTGTGG
 pET24b(+) Reverse GTGCTCGAGTTCGATACATTC
6xAla(11) Mutation Forward ACCTCTGGAAGAGCCAACTGTGTGAGATGGTGCAGCCCAGTG
 A11C Reverse CACTGGGCTGCACCATCTCACACAGTTGGCTCTTCCAGAGGT
6xAla(54) Mutation Forward TCCAGCGCTGCCTGGAGGAGA
 A54C Reverse GTGGTGGTGGTGGTGCTCGAGCTCAATGCACTCCATGACA
6xAla(76) Mutation Forward ACCAGATTCTGCGGGAGCGCTGCGAGGAGCTTCTGCATTTCC
 A76C Reverse GGAAATGCAGAAGCTCCTCGCAGCGCTCCCGCAGAATCTGGT
6xAla(95) Mutation Forward AGGAGAAGGAGTTCCTCATGTGCAAGTTCCAGGAGGCCAGGA
 A95C Reverse TCCTGGCCTCCTGGAACTTGCACATGAGGAACTCCTTCTCCT
6xAla(131) Mutation Forward
AGGTGGAGCACCTGAAGAGATGCCAGCAGCAGATGGCT-
GAGG
 A131C Reverse CCTCAGCCATCTGCTGCTGGCATCTCTTCAGGTGCTCCACCT
6xAla(167) Mutation Forward
TGGAGGCTGCCACTAAGGAATGCCAGGCTCTGGAGGGTCG-
GG
 A167C Reverse CCCGACCCTCCAGAGCCTGGCATTCCTTAGTGGCAGCCTCCA
6xAla(347) Mutation Forward CTTTAAGAAGGAGATATACATATGAATAGGCACCTCTGGA
 A347C Reverse GACTCCTGAGCGCTGGCCTTC
8xAla Mutation Forward CGAGGAGCCACCTGACTTCGCCTGTCCCAAGTGCCAGTATC
 C396A Reverse GATACTGGCACTTGGGACAGGCGAAGTCAGGTGGCTCCTCG
10xAla(396C) Mutation Forward CTTTAAGAAGGAGATATACATATGAATAGGCACCTCTGGA
A396C Reverse CTTGGGAGCGCAGAAGTCAG
11xAla Mutation Forward CGAGGAGCCACCTGACTTCGCCTGTCCCAAGTGCCAGTATC
C396/397A Reverse GATACTGGCACTTGGGACAGGCGAAGTCAGGTGGCTCCTCG
Mutation Forward CTTTAAGAAGGAGATATACATATGAATAGGCACCTCTGGA
C400A Reverse CCTGATACTGGGCCTTGGGACAG
Mutation Forward CTTTAAGAAGGAGATATACATATGAATAGGCACCTCTGGA
C417A Reverse CTCGAGCTCAATGAACTCCATGAC
Bcl-xL Deletion Deletion Forward GTCGCAAGGGTCAGGAACGTCACCACCACCACCACCACTG
 (209-235) Reverse CAGTGGTGGTGGTGGTGGTGACGTTCCTGACCCTTGCGAC
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 Appendix II) DNA and Protein Sequences of NEMO and Bcl-xL
NEMO DNA Sequences
WILD-TYPE ATGAATAGGCACCTCTGGAAGAGCCAACTGTGTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
5xAla  ATGAACCGCCATCTGTGGAAAAGTCAGCTGGCAGAAATGGTGCAGCCGAGCGGCGGTCCG 60
7xAla  ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
6xAla(11C) ATGAATAGGCACCTCTGGAAGAGCCAACTGTGTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
6xAla(54C) ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
6xAla(76C) ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
6xAla(95C) ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
6xAla(131C) ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
6xAla(167C) ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
6xAla(347C) ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
11xAla  ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
10xAla(396C) ATGAATAGGCACCTCTGGAAGAGCCAACTGGCTGAGATGGTGCAGCCCAGTGGTGGCCCG 60
                                
WILD-TYPE GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
5xAla  GCAGCAGATCAGGATGTTCTGGGCGAAGAATCTCCGCTGGGTAAACCGGCAATGCTGCAC 120
7xAla  GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
6xAla(11C) GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
6xAla(54C) GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
6xAla(76C) GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
6xAla(95C) GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
6xAla(131C) GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
6xAla(167C) GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
6xAla(347C) GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
11xAla  GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
10xAla(396C) GCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCTCTGGGGAAGCCAGCCATGCTGCAC 120
 
WILD-TYPE CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCTGCCTGGAGGAGAATCAAGAG 180
5xAla  CTGCCGAGTGAACAGGGTGCACCGGAAACCCTGCAGCGTTGCCTGGAAGAAAACCAGGAA 180
7xAla  CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
6xAla(11C) CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
6xAla(54C) CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCTGCCTGGAGGAGAATCAAGAG 180
6xAla(76C) CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
6xAla(95C) CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
6xAla(131C) CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
6xAla(167C) CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
6xAla(347C) CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
11xAla  CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
10xAla(396C) CTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAGCGCGCCCTGGAGGAGAATCAAGAG 180
                                 
WILD-TYPE CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCTGCGAGGAGCTTCTG 240
5xAla  CTGCGTGATGCGATTCGCCAGAGTAATCAGATCCTGCGTGAACGCGCGGAAGAACTGCTG 240
7xAla  CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
6xAla(11C) CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
6xAla(54C) CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
6xAla(76C) CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCTGCGAGGAGCTTCTG 240
6xAla(95C) CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
182
6xAla(131C) CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
6xAla(167C) CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
6xAla(347C) CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
11xAla  CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
10xAla(396C) CTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTGCGGGAGCGCGCCGAGGAGCTTCTG 240
                                
WILD-TYPE CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGTGCAAGTTCCAGGAGGCC 300
5xAla  CATTTTCAGGCCAGCCAGCGTGAAGAAAAAGAATTTCTGATGGCCAAATTCCAGGAAGCA 300
7xAla  CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
6xAla(11C) CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
6xAla(54C) CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
6xAla(76C) CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
6xAla(95C) CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGTGCAAGTTCCAGGAGGCC 300
6xAla(131C) CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
6xAla(167C) CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
6xAla(347C) CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
11xAla  CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
10xAla(396C) CATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTCCTCATGGCCAAGTTCCAGGAGGCC 300
                               
WILD-TYPE AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
5xAla  CGTAAACTGGTGGAACGCCTGGGTCTGGAAAAACTGGATCTGAAACGTCAGAAAGAACAG 360
7xAla  AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
6xAla(11C) AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
6xAla(54C) AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
6xAla(76C) AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
6xAla(95C) AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
6xAla(131C) AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
6xAla(167C) AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
6xAla(347C) AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
11xAla  AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
10xAla(396C) AGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTCGATCTGAAGAGGCAGAAGGAGCAG 360
                               
WILD-TYPE GCTCTGCGGGAGGTGGAGCACCTGAAGAGATGCCAGCAGCAGATGGCTGAGGACAAGGCC 420
5xAla  GCCCTGCGCGAAGTTGAACACCTGAAACGTGCACAGCAGCAGATGGCCGAAGATAAAGCA 420
7xAla  GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
6xAla(11C) GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
6xAla(54C) GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
6xAla(76C) GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
6xAla(95C) GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
6xAla(131C) GCTCTGCGGGAGGTGGAGCACCTGAAGAGATGCCAGCAGCAGATGGCTGAGGACAAGGCC 420
6xAla(167C) GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
6xAla(347C) GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
11xAla  GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
10xAla(396C) GCTCTGCGGGAGGTGGAGCACCTGAAGAGAGCCCAGCAGCAGATGGCTGAGGACAAGGCC 420
                                
WILD-TYPE TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
5xAla  TCTGTGAAAGCGCAGGTTACCAGTCTGCTGGGCGAACTGCAGGAATCTCAGAGTCGTCTG 480
7xAla  TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
6xAla(11C) TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
6xAla(54C) TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
6xAla(76C) TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
183
6xAla(95C) TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
6xAla(131C) TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
6xAla(167C) TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
6xAla(347C) TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
11xAla  TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
10xAla(396C) TCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAGCTGCAGGAGAGCCAGAGTCGCTTG 480
                                
WILD-TYPE GAGGCTGCCACTAAGGAATGCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
5xAla  GAAGCAGCGACGAAAGAAGCCCAGGCACTGGAAGGTCGTGCGCGTGCGGCAAGCGAACAG 540
7xAla  GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
6xAla(11C) GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
6xAla(54C) GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
6xAla(76C) GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
6xAla(95C) GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
6xAla(131C) GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
6xAla(167C) GAGGCTGCCACTAAGGAATGCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
6xAla(347C) GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
11xAla  GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
10xAla(396C) GAGGCTGCCACTAAGGAAGCCCAGGCTCTGGAGGGTCGGGCCCGGGCGGCCAGCGAGCAG 540
                              
WILD-TYPE GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
5xAla  GCACGTCAGCTGGAATCTGAACGCGAAGCCCTGCAGCAGCAGCATAGCGTGCAGGTTGAT 600
7xAla  GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
6xAla(11C) GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
6xAla(54C) GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
6xAla(76C) GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
6xAla(95C) GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
6xAla(131C) GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
6xAla(167C) GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
6xAla(347C) GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
11xAla  GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
10xAla(396C) GCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAGCAGCAGCACAGCGTGCAGGTGGAC 600
                           
WILD-TYPE CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
5xAla  CAGCTGCGCATGCAGGGCCAGTCTGTGGAAGCAGCACTGCGTATGGAACGTCAGGCAGCA 660
7xAla  CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
6xAla(11C) CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
6xAla(54C) CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
6xAla(76C) CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
6xAla(95C) CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
6xAla(131C) CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
6xAla(167C) CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
6xAla(347C) CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
11xAla  CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
10xAla(396C) CAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCGCTCCGCATGGAGCGCCAGGCCGCC 660
                            
WILD-TYPE TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
5xAla  AGCGAAGAAAAACGTAAACTGGCGCAGCTGCAGGTTGCCTATCATCAGCTGTTCCAGGAA 720
7xAla  TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
6xAla(11C) TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
6xAla(54C) TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
184
6xAla(76C) TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
6xAla(95C) TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
6xAla(131C) TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
6xAla(167C) TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
6xAla(347C) TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
11xAla  TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
10xAla(396C) TCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAA 720
                               
WILD-TYPE TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
5xAla  TACGATAACCACATCAAAAGCTCTGTGGTTGGCAGCGAACGTAAACGCGGTATGCAGCTG 780
7xAla  TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
6xAla(11C) TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
6xAla(54C) TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
6xAla(76C) TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
6xAla(95C) TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
6xAla(131C) TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
6xAla(167C) TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
6xAla(347C) TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
11xAla  TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
10xAla(396C) TACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTGAGCGGAAGCGAGGAATGCAGCTG 780
                            
WILD-TYPE GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
5xAla  GAAGATCTGAAACAGCAGCTGCAGCAGGCCGAAGAAGCACTGGTGGCGAAACAGGAAGTT 840
7xAla  GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
6xAla(11C) GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
6xAla(54C) GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
6xAla(76C) GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
6xAla(95C) GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
6xAla(131C) GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
6xAla(167C) GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
6xAla(347C) GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
11xAla  GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
10xAla(396C) GAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAGGCCCTGGTGGCCAAACAGGAGGTG 840
                        
WILD-TYPE ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
5xAla  ATCGATAAACTGAAAGAAGAAGCAGAACAGCACAAAATCGTGATGGAAACCGTGCCGGTT 900
7xAla  ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
6xAla(11C) ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
6xAla(54C) ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
6xAla(76C) ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
6xAla(95C) ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
6xAla(131C) ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900 
6xAla(167C) ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
6xAla(347C) ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
11xAla  ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
10xAla(396C) ATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAGATTGTGATGGAGACCGTTCCGGTG 900
                           
WILD-TYPE CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
5xAla  CTGAAAGCGCAGGCCGATATTTATAAAGCCGATTTCCAGGCAGAACGTCAGGCGCGCGAA 960
7xAla  CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
6xAla(11C) CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
185
6xAla(54C) CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
6xAla(76C) CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
6xAla(95C) CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
6xAla(131C) CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
6xAla(167C) CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
6xAla(347C) CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
11xAla  CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
10xAla(396C) CTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTCCAGGCTGAGAGGCAGGCCCGGGAG 960
                               
WILD-TYPE AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
5xAla  AAACTGGCGGAGAAAAAAGAACTGCTGCAGGAACAGCTGGAACAGCTGCAGCGCGAATAC 1020
7xAla  AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
6xAla(11C) AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
6xAla(54C) AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
6xAla(76C) AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
6xAla(95C) AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
6xAla(131C) AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
6xAla(167C) AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
6xAla(347C) AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
11xAla  AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
10xAla(396C) AAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAGCTGGAGCAGCTGCAGAGGGAGTAC 1020
                           
WILD-TYPE AGCAAACTGAAGGCCAGCTGTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
5xAla  TCTAAACTGAAAGCAAGCTGTCAGGAATCTGCGCGTATCGAAGATATGCGTAAACGCCAT 1080
7xAla  AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
6xAla(11C) AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
6xAla(54C) AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
6xAla(76C) AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
6xAla(95C) AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
6xAla(131C) AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
6xAla(167C) AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
6xAla(347C) AGCAAACTGAAGGCCAGCTGTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
11xAla  AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
10xAla(396C) AGCAAACTGAAGGCCAGCGCTCAGGAGTCGGCCAGGATCGAGGACATGAGGAAGCGGCAT 1080
                                  
WILD-TYPE GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
5xAla  GTGGAAGTTAGCCAGGCACCGCTGCCGCCGGCACCGGCATATCTGAGTAGCCCGCTGGCA 1140
7xAla  GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
6xAla(11C) GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
6xAla(54C) GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
6xAla(76C) GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
6xAla(95C) GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
6xAla(131C) GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
6xAla(167C) GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
6xAla(347C) GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
11xAla  GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
10xAla(396C) GTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCTGCCTACCTCTCCTCTCCCCTGGCC 1140
                                       
WILD-TYPE CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
5xAla  CTGCCGAGTCAGCGTCGCAGCCCGCCGGAAGAACCGCCGGATTTCTGCTGTCCGAAATGC 1200
7xAla  CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
186
6xAla(11C) CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
6xAla(54C) CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
6xAla(76C) CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
6xAla(95C) CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
6xAla(131C) CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
6xAla(167C) CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
6xAla(347C) CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCTGTCCCAAGTGC 1200
11xAla  CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCGCCGCTCCCAAGGCC 1200
10xAla(396C) CTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCACCTGACTTCTGCGCTCCCAAGGCC 1200
                                    
WILD-TYPE CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
5xAla  CAGTACCAGGCGCCGGATATGGATACGCTGCAGATTCACGTGATGGAATGTATCGAACTC 1260
7xAla  CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
6xAla(11C) CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
6xAla(54C) CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
6xAla(76C) CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
6xAla(95C) CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
6xAla(131C) CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
6xAla(167C) CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
6xAla(347C) CAGTATCAGGCCCCTGATATGGACACCCTGCAGATACATGTCATGGAGTGCATTGAGCTC 1260
11xAla  CAGTATCAGGCCCCTGATATGGACACCCGCCAGATACATGTCATGGAGGCCATTGAGCTC 1260
10xAla(396C) CAGTATCAGGCCCCTGATATGGACACCCGCCAGATACATGTCATGGAGGCCATTGAGCTC 1260
                                
WILD-TYPE GAGCACCACCACCACCACCACCACCACTAA 1290
5xAla  GAGCACCACCACCACCACCACCACCACTAA 1290
7xAla  GAGCACCACCACCACCACCACCACCACTAA 1290
6xAla(11C) GAGCACCACCACCACCACCACCACCACTAA 1290
6xAla(54C) GAGCACCACCACCACCACCACCACCACTAA 1290
6xAla(76C) GAGCACCACCACCACCACCACCACCACTAA 1290
6xAla(95C) GAGCACCACCACCACCACCACCACCACTAA 1290
6xAla(131C) GAGCACCACCACCACCACCACCACCACTAA 1290
6xAla(167C) GAGCACCACCACCACCACCACCACCACTAA 1290
6xAla(347C) GAGCACCACCACCACCACCACCACCACTAA 1290
11xAla  GAGCACCACCACCACCACCACCACCACTAA 1290
10xAla(396C) GAGCACCACCACCACCACCACCACCACTAA 1290
NEMO Protein Sequences
WILD-TYPE MNRHLWKSQLCEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRCLEENQE 60
5xAla  MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRCLEENQE 60
7xAla  MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
6xAla(11C) MNRHLWKSQLCEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
6xAla(54C) MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRCLEENQE 60
6xAla(76C) MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
6xAla(95C) MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
6xAla(131C) MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
6xAla(167C) MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
6xAla(347C) MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
11xAla  MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
187
10xAla(396C) MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60
                 
WILD-TYPE LRDAIRQSNQILRERCEELLHFQASQREEKEFLMCKFQEARKLVERLGLEKLDLKRQKEQ 120
5xAla  LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
7xAla  LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
6xAla(11C) LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
6xAla(54C) LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
6xAla(76C) LRDAIRQSNQILRERCEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
6xAla(95C) LRDAIRQSNQILRERAEELLHFQASQREEKEFLMCKFQEARKLVERLGLEKLDLKRQKEQ 120
6xAla(131C) LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
6xAla(167C) LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
6xAla(347C) LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
11xAla  LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
10xAla(396C) LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120
                
WILD-TYPE ALREVEHLKRCQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKECQALEGRARAASEQ 180
5xAla  ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
7xAla  ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
6xAla(11C) ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
6xAla(54C) ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
6xAla(76C) ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
6xAla(95C) ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
6xAla(131C) ALREVEHLKRCQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
6xAla(167C) ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKECQALEGRARAASEQ 180
6xAla(347C) ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
11xAla  ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
10xAla(396C) ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180
                
WILD-TYPE ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
5xAla  ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
7xAla  ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
6xAla(11C) ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
6xAla(54C) ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
6xAla(76C) ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
6xAla(95C) ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
6xAla(131C) ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
6xAla(167C) ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
6xAla(347C) ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
11xAla  ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
10xAla(396C) ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240
                
WILD-TYPE YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
5xAla  YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
7xAla  YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
6xAla(11C) YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
6xAla(54C) YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
6xAla(76C) YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
6xAla(95C) YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
6xAla(131C) YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
6xAla(167C) YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
6xAla(347C) YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
188
11xAla  YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
10xAla(396C) YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300
              
WILD-TYPE LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASCQESARIEDMRKRH 360
5xAla  LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASCQESARIEDMRKRH 360
7xAla  LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
6xAla(11C) LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
6xAla(54C) LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
6xAla(76C) LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
6xAla(95C) LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
6xAla(131C) LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
6xAla(167C) LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
6xAla(347C) LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASCQESARIEDMRKRH 360
11xAla  LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
10xAla(396C) LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360
                
WILD-TYPE VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
5xAla  VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
7xAla  VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
6xAla(11C) VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
6xAla(54C) VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
6xAla(76C) VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
6xAla(95C) VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
6xAla(131C) VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
6xAla(167C) VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
6xAla(347C) VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIEL 420
11xAla  VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFAAPKAQYQAPDMDTRQIHVMEAIEL 420
10xAla(396C) VEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCAPKAQYQAPDMDTRQIHVMEAIEL 420
                 
WILD-TYPE EHHHHHHHH 429
5xAla  EHHHHHHHH 429
7xAla  EHHHHHHHH 429
6xAla(11C) EHHHHHHHH 429
6xAla(54C) EHHHHHHHH 429
6xAla(76C) EHHHHHHHH 429
6xAla(95C) EHHHHHHHH 429
6xAla(131C) EHHHHHHHH 429
6xAla(167C) EHHHHHHHH 429
6xAla(347C) EHHHHHHHH 429
11xAla EHHHHHHHH 429
10xAla(396C)EHHHHHHHH 429
Bcl-xL DNA Sequence
ATGTCTCAAAGCAATCGTGAACTGGTGGTGGACTTCCTGTCTTACAAACTGTCGCAAAAAGGTTATTCCT-
GGTCGCAATTCTCGGATGTTGAAGAAAACCGTACCGAAGCACCGGAAGGCACGGAATCGGAAATGGAAAC-
CCCGAGCGCTATTAACGGTAATCCGTCTTGGCATCTGGCTGATAGTCCGGCAGTCAATGGTGCAACGGGT-
CACAGCTCTAGTCTGGACGCGCGCGAAGTGATCCCGATGGCAGCCGTTAAACAGGCACTGCGTGAAGCTG-
GCGATGAATTTGAACTGCGCTATCGTCGCGCCTTCTCCGACCTGACCTCACAACTGCATATTACCCCGGG-
TACGGCATACCAGTCTTTTGAACAAGTGGTTAACGAACTGTTCCGTGATGGCGTCAATTGGGGTCGCATC-
189
GTGGCGTTTTTCTCCTTTGGCGGTGCCCTGTGCGTTGAATCAGTCGATAAAGAAATGCAGGTCCTGGT-
GTCGCGTATTGCAGCTTGGATGGCCACGTATCTGAACGATCACCTGGAACCGTGGATCCAAGAAAATGGC-
GGTTGGGACACCTTTGTGGAACTGTACGGCAACAATGCGGCCGCAGAAAGTCGCAAGGGTCAGGAACGT-
CACCACCACCACCACCACTGA
Bcl-xL Protein Sequence
MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGAT-
GHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNW-
GRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQ-
ERHHHHHH
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Appendix III) Derivation of the Rotational Correlation Rime of a Non-Globular 
Rod-like Protein (Prolate Spheroid)
Appendix Figure 1: The axes of a sphere (left) and an elliptical prolate spheroid (right). 
If the frictional ratio of a protein is known, the correlation time of the 
protein can be estimated. The frictional ratio is a measure of the shape of the 
protein with respect to a sphere. 
The axial ratio (Appendix Equation 1) is related to the frictional ratio 
of a protein by the formula:
This formula is quite complex, thus a list of frictional ratios and cor-
responding axial ratios is provided.148 The measured frictional ratio of the 
NEMO(1-355) construct is 2.3 and the corresponding axial ratio for is 1/30.114 
The axial ratio then can be used to determine the rotational correlation time 
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of a protein with a prolate spheroid shape with a length  of being 30 times 
larger than  (Appendix Figure 1). The parameter  is derived from the axial 
ratio (Appendix Equation 3), then the proportional frictional ratios for each 
axis are calculated (Appendix Equation 4, Appendix Equation 5). 
Next, the rotational correlation times about the individual axes are calculat-
ed (Appendix Equation 6, Appendix Equation 7).
Finally, the rotational correlation time of the entire protein is calculated 
(Appendix Equation 8). 
Appendix Equation 4
Appendix Equation 5
Appendix Equation 3
S
ln p
p
p
=
+ −







−
2
1 1
1
2
2
*
f
f
p
p S
a
Sphere
=
−( )
−( )
4 1
3 2
2
2
f
f
p
p S p
b
Sphere
=
−( )
−( ) − 
4 1
3 2 2
4
2 2
Appendix Equation 6
Appendix Equation 7
Appendix Equation 8
θ θa
b
Sphere
Sphere
f
f
=
θ θb
Sphere
a
Sphere
b
Sphere
f
f
f
f
= +






−
2
1
*
θ
θ θProtein a b
=
+− −
3
1 1
192
 Appendix IV) DynaFit Scripts
Inhibition Script:
[task]
 data = equilibria
	 task	=	fit
[mechanism]
 L + N <==> N.L : Kd1 dissoc
 N + C <==> N.C : Kd2 dissoc
[concentrations]
 L = 15
 N = 15
[constants]
 Kd1 = 5.7
 Kd2 = 10 ?
[responses]
 intensive
 N.L = 100 ?
 N.C = 50 ?
 L = 50 ?
[data]
 intensive
 variable C 
 error data
	 file	./NEMO/Inhibition/Averages.txt
	 plot	logarithmic
[output] 
	 directory	./NEMO/Inhibition/Avg
 [end]
Simulation of Assay Floor
[task]
 data = equilibria
 task = simulate
[mechanism]
 L + N <==> N.L : Kd1 dissoc
 N + C <==> N.C : Kd2 dissoc
[concentrations]
 L = 15
 N = 15
[constants]
 Kd1 = 5.7
 Kd2 = 0.0001 (Varied from 0.0001-100)
[responses]
 intensive
 N.L = 100 
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 N.C = 50 
 L = 50 
[data]
 intensive
 variable C 
	 mesh	logarithmic	from	0.01	to	10000	step	2
	 file	./NEMO/Inhibition/Averages.txt
	 plot	logarithmic
[output] 
	 directory	./NEMO/Simulate/0.0001
[settings]	
 WriteEPS = n
 WriteTeX = n
[end]
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 Appendix V) Structures of Compounds That Showed >20% Inhibition in 
the FA Assay
Macrocycles
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 Appendix VI) Derivation of the Homoquenching Function Describing 
IKKβ Cooperative Binding
To derive the formula for fitting the FRET homoquenching data, the probabili-
ty (P) of the sites on a NEMO dimer is determined.
From this relationship, the probability of the presence of each state can be 
determined:
These equations can be correlated with mass-balance equations for the var-
ious species:
These equations describe the distribution of IKKβ among NEMO at any 
concentration of NEMO, which is the varied component. Finally, the mass-balance 
Appendix Equation 9
Appendix Equation 13NEMO NEMO
IKK
NEMOT2 2
2
2
1
2
[ ] = [ ] − [ ][ ]






β
NEMO IKK NEMO
IKK
NEMO
IKK
NEMOT2 2
2 2
2
2
1
2
β
β β[ ] = [ ] [ ][ ]





 −
[ ]
*
[ ]






Appendix 
Equation 14
P
IKK
NEMOAny site is occupied   
=
[ ]
[ ]
β
2 2
Appendix Equation 10
Appendix 
Equation 11
Appendix Equation 12
P
IKK
NEMOBoth Sites are unoccupied   
= −
[ ]
[ ]





1 2
2
2
β
P P
IKK
NEMOSite is occupied Site is occupied      1 2
2
2
= =
[ ]
[ ]



β 

 −
[ ]
[ ]





1 2
2
IKK
NEMO
β
P
IKK
NEMOBoth sites are occupied   
=
[ ]
[ ]






β
2 2
2
207
equations can be applied to an equation describing the contribution of each spe-
cies to the fluorescence signal. For this equation, it is assumed that the fluorescence 
for a singly-bound IKKβ molecule is the same as if it were free in solution.
This final equation can be used to fit the portion of the data that describes 
the distribution of IKKβ among an excess of NEMO dimer. 
Appendix Equation 15
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